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Abstract 
The heat shock proteins represent an important class of pro-survival proteins that are 
intimately involved in cell survival, adaptation to cellular stress, and protein management. Heat 
shock protein 90 kDa (Hsp90) is a molecular chaperone responsible for the post-translational 
maturation of nascent polypeptides. Many of the Hsp90-dependent client proteins are involved in 
oncogenic processes, and accordingly, Hsp90 has emerged as a promising target for anti-cancer 
therapies. 
Unfortunately, the clinical evaluation of Hsp90 inhibitors has been met with dosing, 
scheduling, and toxicity issues. The Hsp90 inhibitors that have reached clinical trials bind to the 
Hsp90 N-terminal ATP-binding site and demonstrate pan-Hsp90 inhibition, as they bind to and 
inhibit all four human Hsp90 isoforms. This characteristic may rationalize the undesired 
toxicities related to Hsp90 inhibition. Interestingly, the identification and characterization of 
isoform specific client proteins has not been extensively explored. In addition, N-terminal Hsp90 
inhibition results in the induction of the heat shock response, whereby the expression of Hsp90 
and other heat shock proteins is induced. This attribute of N-terminal inhibitors results in the 
clinically observed dosing and scheduling detriments as levels of Hsp90 increase with 
administration of the drug. 
Described herein is the design, synthesis and biological evaluation of novel Hsp90 
inhibitors that avoid the above mentioned therapeutic liabilities of currently known Hsp90 
inhibitors. The identification and characterization of an Hsp90-isoform dependent client protein 
and an Hsp90-isoform selective inhibitor is also presented.  
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INVESTIGATION OF THE HSP90 C-TERMINAL BINDING SITE, NOVEL 
INHIBITORS AND ISOFORM-DEPENDENT CLIENT PROTEINS 
 
1 
Chapter I 
Introduction to Hsp90 Structure, Function, and Inhibition 
I. Introduction 
 Proteins are synthesized in the ribosome as linear polypeptides. These unfolded, nascent 
polypeptides in the dense, crowded environment of the cell are highly susceptible to improper 
folding and aggregation. Specifically, the hydrophobic amino acids that are normally found in 
the core of a three-dimensional protein tend to aggregate in the polar environment of the cell.  
The molecular chaperone family of proteins has evolved to prevent protein aggregation, to aid in 
the maturation and proper folding of proteins and to generally maintain protein homeostasis 
(proteostasis).
1-5
 Generally termed, molecular chaperones include any protein that interacts with 
a substrate or client protein to either stabilize or aid in its conformational maturation. 
 The heat shock proteins (Hsps), or stress proteins, are a family of molecular chaperones 
that are upregulated during cellular stress, a time at which protein denaturation and aggregation 
is prevalent. The Hsps are named by molecular weight and the various members of this family 
perform a vast array of cellular functions including protein folding, refolding of denatured 
proteins, protein trafficking, aggregate solubilization, and they also mediate protein degradation.
3
 
Hsps represent important therapeutic targets for the treatment of protein folding and aggregating 
diseases, such as Alzheimer’s disease, cystic fibrosis, or Parkinson’s disease. In addition, cancer 
cells have been shown to depend upon Hsps due to increased protein synthesis. These therapeutic 
avenues highlight the necessity to understand the molecular chaperone system as well as the need 
to identify modulators that can impact human disease.  
II. Heat Shock Protein 90 
2 
The 90 kDa heat shock proteins (Hsp90) are responsible for the post translational 
maturation of many proteins, as well as the solubilization of protein aggregates and the refolding 
of denatured proteins.
6-10
 Over 200 distinct proteins have been identified as Hsp90 client proteins 
that depend upon Hsp90 for their maturation.
11-12
 Hsp90 represents one of the most prevalent 
molecular chaperones in eukaryotic cells, comprising 1–2% of total cytosolic proteins in 
unstressed conditions and up to 4–6% during stress.
7,13-14
  Although there are 17 genes that 
encode for Hsp90 in the human genome, only 6 of these are responsible for encoding the four 
functional isoforms.
15-18
  The two predominant Hsp90 isoforms are Hsp90α and Hsp90β, which 
are found primarily in the cytosol. Hsp90α is induced upon exposure to stress, whereas Hsp90β 
is constitutively active and is considered a housekeeping chaperone. The genes for both α and β 
are located on chromosome 4, and are regulated through independent transcriptional events.
15
 
The Hsp75/tumor necrosis factor receptor associated protein 1 (Trap1) resides in the 
mitochondrial matrix and plays a role in oxidative cell death and maintaining mitochondrial 
integrity.
15,19
 The endoplasmic reticulum resident Hsp90 isoform, 94kDa gluclose-regulated 
protein (Grp94), chaperones both secreted and membrane proteins and participates in embryonic 
development, Ca
2+
 balance, immune 
response, and cell adhesion.
15,20-21
 
A. Hsp90 Structure 
Hsp90 functions as a 
homodimer while each monomer of 
the Hsp90 dimer is comprised of four 
domains: a highly conserved N and C-
terminal domain, a middle domain and 
 
Figure 1. The structure of Hsp90; PDB 2CG9. 
 
3 
a charged linker that connects the N-terminal and middle domains (Figure 1).
22-26
 The 25kDa N-
terminal domain (NTD) is responsible for binding ATP in a unique, bent conformation that is 
reminiscent of other members of the GHKL superfamily (gyrase, Hsp90, histidine kinase, and 
MutL).
27
 Proteins in this family share a common Bergerat ATP-binding fold, named 
appropriately after Agnes Bergerat who first identified this motif in 1997.
28
 This motif consists 
of four-interstranded β sheets and three α helices in a helix-sheet-helix orientation, wherein the 
ATP-binding site manifests interactions with residues in the loop region that connects the α 
helices and β sheets.
27
 This Hsp90 ATP binding site has been under intense pharmaceutical 
investigation, as the majority of known Hsp90 inhibitors bind competitively versus ATP to this 
domain.  
The 12 kDa C-terminal domain (CTD) is responsible for maintaining Hsp90s functional 
homodimeric state.
24,29-30
  The C-terminal domain is also responsible for coordinating 
interactions with several Hsp90 partner proteins and co-chaperones through its MEEVD 
sequence, which is recognized by proteins containing a tetratricopeptide repeat (TPR) motif.
31-34
 
The C-terminal domain also contains a putative nucleotide binding site, however, the C-terminal 
ATP binding site functions to facilitate nucleotide exchange at the N-terminus and does not 
manifest ATPase activity.
35-36
 The Hsp90 CTD also contains a small molecule binding site at 
which inhibitors bind and disrupt Hsp90 function. 
The 40 kDa middle domain (MD) that is connected to the N-terminus via a highly 
charged linker is responsible for binding the γ-phosphate of ATP, when bound to the N-terminal 
binding pocket. This region is also important for the recognition and binding of client proteins 
and co-chaperones. It is largely amphipathic in nature and can mediate interactions with various 
proteins.
6,37
  The middle domain also appears to play a key role in mediating Hsp90’s N-terminal 
4 
ATPase activity, as deletion of this region significantly retards Hsp90’s inherent ATPase 
activity, suggesting coordination of ATP-hydrolysis by the entire protein, which may be 
conformationally driven.
6
 
B. Hsp90 Function 
 Hsp90 not only aids in the conformational maturation of nascent polypeptides and 
activation of receptors under normal cellular conditions, but under stressful conditions, such as 
elevated temperature, abnormal pH, or nutrient deprivation, Hsp90 can be overexpressed to aid 
in the rematuration of denatured proteins in conjunction with Hsp70.
38-40
 Evidence suggests that 
expression of Hsp90 and other heat shock proteins is mediated by the transcription factor, heat 
shock factor 1 (HSF1). Under normal conditions, Hsp90 binds HSF1, preventing HSF1 release 
and transcriptional activation of the heat shock response. However, it has been postulated that 
under cellular stress, the HSF1/Hsp90 complex is disassembled and HSF1 trimerizes and 
ultimately translocates to the nucleus, wherein it binds to the heat shock binding elements and 
initiates transcription of the heat shock genes that encode for Hsp27, Hsp40, Hsp70, and 
Hsp90.
41-54
 
Table 1. Hsp90-associated proteins that comprise the Hsp90 protein folding machinery; From Ref. 55. 
Co-chaperone or 
Co-factor 
Description Reference 
Ahal Stimulates ATPase activity 56 
Cdc37 Mediates activation of protein kinase substrates 57 
CHIP Involved in degradation of unfolded client proteins 58-59 
CRN Ubiquitin Ligase (E3) involved in client protein degradation 60 
Cyclophilin-40 Peptidyl prolyl isomerase 61-62 
FKBP51 and 52 Peptidyl prolyl isomerase 62-63 
Hop Mediates interaction between Hsp90 and Hsp70 64-65 
Hsp40 Stabilizes and delivers client protein to Hsp90 folding machine 66-67 
Hsp70 Stabilizes and delivers client protein to Hsp90 folding machine 68-70 
NASP Stimulates ATPase activity 71 
p23 Stabilizes closed, clamped substrate bound conformation 22 
5 
PP5 Protein phosphatase 5 72-74 
Sgt1 Client adaptor, involved in client recruitment 75 
Tah1 Weak affect on ATPase activity 76 
Tom70 Facilitates translocation of pre-proteins into mitochondrial matrix 77-78 
Tpr2 Involved in ATP hydrolysis and substrate release 79 
WISp39 Regulates p21 stability 80-81 
  
 
The mechanism by which Hsp90 mediates the maturation of nascent polypeptides 
remains unresolved. There are a number of proteins that combine to form a competent 
heteroprotein complex, regarded as the Hsp90 protein folding machine. Numerous co-
chaperones, immunophillins and partner proteins bind the Hsp90 scaffold to form a competent 
protein folding machinery as denoted in Table 1.
55,82
  
 A polypeptide substrate can obtain conformational maturity by proceeding through 
various complexes and conformations that are mediated by the Hsp90 scaffold (Figure 2).
4
 
Succinctly, the nascent polypeptide exits the ribosome and is stabilized by an Hsp70-Hsp40-
 
Figure 2. The Hsp90-mediated protein folding cycle. NTD, N-terminal domain; CTD, C-terminal 
domain; MD, middle domain; PDBs 2CG9, 2O1U, 1UWH. 
6 
ADP complex that prevents side chain interactions that can otherwise lead to aggregation.
69
  This 
complex is often further stabilized by the Hsp70 interacting protein (Hip) or alternately, Bcl2-
associated athanogene (BAG) homologues that facilitate exchange of ADP for ATP, resulting in 
concomitant release of the polypeptide substrate and dissociation of the complex.
83-84
 In the case 
of telomerase and steroid hormones receptors, Hsp organizing protein (Hop), which contains 
tetretricopeptide repeats (TPRs) that are recognized by both Hsp70 and Hsp90,  binds the Hsp70-
protein complex and Hsp90, promoting transfer of the unfolded protein from Hsp70 to the Hsp90 
homodimer, resulting in dissociation of Hsp70, Hip and Hop.
32,34,64,85-87
 After which, 
immunophilins and co-chaperones bind Hsp90 to form a heteroprotein complex that binds ATP 
at the N-terminus, and wraps around the bound client protein substrate.
88
  N-terminal 
dimerization and conformational change occurs and p23 is recruited to the complex to stabilize 
the clamped, protein substrate-bound conformation, modulating ATP hydrolysis.
7
 Aha1 
(activator of Hsp90 ATPase homologue 1) then stimulates Hsp90’s inherent ATPase activity 
providing energy for conformational rearrangement of both Hsp90 and client protein.
13
  In an 
uncharacterized process, the client protein undergoes topological rearrangement to produce the 
bioactive conformation, which is subsequently released from the Hsp90 protein folding 
machinery.
63,89
 
 Structurally, Hsp90 must accommodate multiple conformations during the protein folding 
cycle, including protein loading, ATP binding and hydrolysis, co-chaperone binding, and client 
protein release (Figure 3).
22,90-93
 Hsp90 begins its conformational state in a CTD-dimerized, 
open state that is unable to bind ATP. In this conformation, Hsp90 reveals hydrophobic patches, 
ideal for client protein binding.
92
 Upon substrate binding, interactions between the NTD and MD 
are disrupted, opening the ATP binding cleft. Proximal to the ATP binding site exists a “lid” 
7 
region, and once ATP binds, the lid closes (Figure 3A/3C).
94
 Hydrophobic residues on the lid 
are exposed and primed to promote N-terminal dimerization. This reorganization from NTD 
open to NTD dimerized conformations is proposed to assist client protein restructuring. Once the 
NTD dimerizes, the Hsp90 homodimer achieves a fully closed, clamped conformation wherein 
multiple hydrophobic and hydrogen bonding interactions are observed between the two 
monomers.
22
 Together, the NTD and MD promote the hydrolysis of ATP. Upon hydrolysis, the 
 
Figure 3. Hsp90 Conformations. A.) Schematic of different Hsp90 conformations sampled during 
protein folding, adapted from Ref. 90; B.) Crystal structures of Hsp90 in open, twisted V, and closed 
conformations; C.) Crystal structure of Hsp90 ND highlighting lid region when ATP (blue) or ADP 
(green) is bound; NTD, N-terminal domain; MD, middle domain; CTD, C-terminal domain.  
8 
homodimer further compacts causing expulsion of the client protein, as all hydrophobic 
interactions are maintained between the two monomers, and not the substrate. Once the client 
protein is released, Hsp90 relaxes into its semi open state and the lid opens to release ADP and 
returns Hsp90 to its open conformation for subsequent processing. In addition to the important 
role ATP/ADP and the Hsp90 co-chaperones play throughout the conformational cycle, post-
translational modifications also impact Hsp90 conformation and function.
95-96
 
 Hsp90’s activity is in part regulated by post-translational modifications, including 
phosphorylation, acetylation, S-nitrosylation, oxidation, and ubiquitination (Figure 4). Hsp90 
contains multiple phosphorylation sites and phosphorylation appears to be a central mechanism 
used to control the activity of the chaperone machine.
95,97
 It has been shown that phosphorylation 
effects Hsp90s conformation,
93
 residence within the cell,
98-99
 interactions with client proteins,
100-
101
 inhibitor sensitivity,
102
 ATPase activity,
93
 and even Hsp90 degradation.
98
 In general, 
phosphorylation of Hsp90 results in a reduced chaperone activity and association with client 
proteins, while a fully dephosphorylated Hsp90 exhibits maximal activity. Hsp90 acetylation 
also results in destabilization of the Hsp90-client protein complex and subsequent degradation of 
client proteins. The clients ErbB2, v-Src, mutant p53, androgen receptor, Raf-1, and HIF1α as 
well as the co-chaperones CHIP, Hsp70 and p23 display weaker affinity for acetylated 
Hsp90.
95,103-104
 Cysteine oxidation of Hsp90 represents a response to oxidative stress and causes 
the proteasome-mediated degradation of several known Hsp90 client proteins, including Cdk4, 
cyclin D1, Raf-1, Akt and mutant p53.
95,105
  Cysteines located in the Hsp90 CTD also undergo S-
nitrosylation. Nitric oxide synthase (eNOS) depends upon Hsp90 for maturation and is 
responsible for the production of nitric oxide (NO). Cysteine nitrosylation results from this NO 
9 
production, and ultimately serves as a negative feedback mechanism, as S-nitrosylation results in 
an inhibitory effect on Hsp90. This inhibitory action has been attributed to a conformational shift 
as well as a decrease in Hsp90 ATPase activity.
106-108
 Lastly, Hsp90 lysines can be 
ubiquitinylated to signal Hsp90 degradation by the proteasome.
95,98,109-110
 These post-
translational modifications provide another essential layer to control Hsp90 activity. 
III. Heat Shock Protein 90 Inhibitors 
 
Figure 4. Hsp90α/β residues involved in post-translational modifications. Acetylated lysines shown 
in blue, S-nitrosylated cysteines shown in green, oxidized cysteines shown in brown, and 
phosphorylated residues shown in black (the responsible kinase is shown in red, if known); From 
from Ref. 95. 
10 
A. Therapeutic Opportunities 
Hsp90 is responsible for the conformational maturation of many nascent polypeptides. In 
addition, the Hsp90 protein folding machinery assists in the solubilization and refolding of 
aggregated and denatured proteins. As a result, small molecule modulators of Hsp90 can exert 
differing activities. Inhibition of Hsp90 by cytotoxic agents results in the degradation of Hsp90-
client proteins by preventing formation of the productive, closed clamped conformation between 
Hsp90 and substrate, thereby targeting the complex for ubiquitinylation and proteasomal 
degradation.
58,111-112
 Compounds that manifest such activities possess excellent therapeutic 
potential for the treatment of cancer, as multiple signaling cascades can be simultaneously 
disrupted via Hsp90 inhibition (Figure 5A).
113
  In contrast, induction of Hsp90 expression by 
non-toxic molecules can lead to increased chaperone levels that minimize the accumulation of 
aggregated proteins.
114-115
 Small molecules that induce Hsp expression represent novel 
approaches for the treatment of neurodegenerative diseases such as Alzheimer’s and Parkinson’s 
disease, as well as Multiple Sclerosis (Figure 5B). 
A.1. Cancer 
 
Figure 5. Modulation of Hsp90 via small molecules. Proposed mechanisms of Hsp90 modulation for 
the treatment of A.) cancer and B.) neurodegenerative diseases. 
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 Traditionally, therapeutic strategies for the treatment of cancer have focused on 
disruption of individual oncogenic enzymes and/or receptors. Newer paradigms for cancer 
chemotherapy have evolved to use combination therapies comprised of multiple drugs, each of 
which targets an individual protein. An alternative approach has been made available through 
Hsp90 inhibition, which allows for the simultaneous disruption of multiple signaling pathways, 
thus exerting a combinatorial attack on transformed cell machinery. Consequently, Hsp90 
inhibition represents a new and powerful therapeutic approach towards the treatment of 
cancer.
13,116
 In 2000, Hanahan and Weinberg described the six hallmarks of cancer manifested by 
alteration of key regulatory proteins, enzymes and receptors that become hijacked by malignant 
cells.
117-118
 These hallmarks include 1) self-sufficiency in growth signals, 2) insensitivity to 
antigrowth signals, 3) evasion of apoptosis, 4) limitless replicative potential, 5) sustained 
angiogenesis, and 6) tissue invasion/metastasis. As shown in Table 2,
55
 disruption of the Hsp90 
protein folding machinery directly affects all six hallmarks of cancer by preventing maturation of 
proteins associated directly with each hallmark.
14,112,119
 No other cellular target has been ascribed 
to effect all hallmarks of cancer, beyond Hsp90, making it one of the most sought after cancer 
targets at this time.
120
  
Table 2. Hsp90-dependent proteins associated with the six hallmarks of cancer; From Ref. 55. 
Hallmark Client Protein(s) 
1. Self-sufficiency in growth signals Raf-1, AKT, Her2, MEK, Bcr-Abl 
2. Insensitivity to anti-growth signals Plk, Wee1, Myt1, CDK4, CDK6,  
3. Evasion of apoptosis RIP, AKT, mutant p53, c-MET, Apaf-1, Survivin 
4. Limitless replicative potential Telomerase (h-Tert) 
5. Sustained angiogenesis FAK, AKT, Hif-1α, VEGFR, Flt-3 
6. Tissue invasion/metastasis c-MET 
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Due to the overwhelming need to fold overexpressed and mutated proteins, it is not 
surprising that Hsp90 and associated chaperones are elevated in human cancers.
121-122
 In 
addition, high Hsp90 expression in cancer has been correlated with decreased survival.
123
 More 
interesting, it has been demonstrated that Hsp90 in cancer cells exhibits a higher affinity for 
inhibitors than Hsp90 from normal cells, providing an opportunity to develop drugs that manifest 
high differential selectivity.
14,124-125
 In tumor cells, Hsp90 resides in a heteroprotein complex 
bound to both client proteins and co-chaperones, whereas Hsp90 in non-transformed cells resides 
in the homodimeric state.
124-125
 This heteroprotein complex exhibits a higher affinity for ATP. 
Consequently, small molecules that bind competitively versus ATP, bind and inhibit the client 
protein maturation process with higher selectively for the Hsp90 machinery present in malignant 
cells over normal cells. Inhibition of Hsp90 is an exciting therapeutic target for the treatment of 
cancer, and results from current clinical trials will significantly impact future cancer treatment 
strategies. 
A.2. Neurodegenerative Diseases 
 Neurodegenerative diseases are diseases that arise from cell death that occurs in the 
central nervous system, including neurons associated with movement, sensory, memory and 
decision making.
126
 Neuronal cell death in these diseases has a variety of origins, but one 
important commonality is the accumulation of misfolded proteins that result in cytotoxicity. 
Because molecular chaperones prevent protein aggregation, refold denatured proteins, and 
solubilize protein aggregates, it has been proposed that the heat shock proteins may be viable 
therapeutic targets for treatment of numerous neurodegenerative diseases, examples of which are 
provided in Table 3.
55,127
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Table 3. Example neurodegenerative diseases and pathogenic proteins associated with aggregation; From 
Ref. 55. 
Disease Protein 
Alzheimer's Disease Amyloid β 
 
Tau 
Parkinson's Disease α-Synuclein 
Huntington's Disease Mutant Huntingtin 
Spinal and Bulbar Muscular Atrophy Mutant Androgen Receptor 
Amyotrophic Lateral Dismutase Mutant Superoxide-Dismutase-1 
An example of this utility of a small molecule Hsp90 modulator is with Alzheimer’s 
disease (AD). Alzheimer’s disease is the most common neurodegenerative disorder, affecting 
more than 10% of the population 65 and older and nearly 30 million people worldwide.
128-129
 
Pathologically, AD is caused by formation of β-amyloid (Aβ) plaques and neurofibrillary tangles 
(NFT’s) in the extra (tau aggregates) and intracellular (Aβ aggregates) space of neurons and 
synapses. There are several hypotheses to describe how these aggregates cause disease. One 
scenario is that these oligomers are toxic to neuronal cells. However, it has also been postulated 
that Aβ plaques can initiate immune response by the recruitment of microglia and subsequent 
astrocytosis.
129-132
 Recently, Hsp90 emerged as a novel target for the treatment of AD. The 
rationale behind such an approach is based on the premise that small molecule inhibitors of 
Hsp90 induce expression of the heat shock proteins, which ultimately leads to solubilization of 
protein aggregates, refolding of misfolded proteins, and directing misfolded proteins and protein 
aggregates to the ubiquitin-proteasome pathway for degradation. Alternative hypothesis suggest 
that Hsp90 can prevent fibril formation by binding and stabilizing the susceptible 
polypeptides.
133
 
In 2003, Dou and coworkers demonstrated that upregulation of the heat shock response 
that occurs upon administration of the N-terminal Hsp90 inhibitor, geldanamycin (GDA), 
resulted in decreased formation of NFT’s, decreased levels of aggregated tau, and an increase in 
14 
soluble tau in both the hippocampus of transgenic mice containing mutant tau and in tissue 
samples from the brain of AD patients.
134
  Under non-pathogenic conditions, tau enhances 
microtubule stability.
135
 However, in AD the hyperphosphorylation of tau is observed and causes 
dissociation of microtubules, allowing incorporation into NFT’s.
115,134
  These researchers 
demonstrated that the level of microtubule associated tau increased after treatment with GDA. A 
reduction in microtubule associated tau was observed alongside a concomitant increase in 
cytosolic aggregated tau in cells treated with Hsp90- and Hsp70-targetied siRNA.
134
  
Human H4 neuroglioma cells were treated with synthetic Hsp90 inhibitors to investigate 
the effects of Hsp90 inhibition on both tau levels and heat shock response.
136
 It was observed 
that several inhibitors induced heat shock response, as evidenced by elevated levels of Hsp70, 
Hsp40 and Hsp27. Cells treated with these same compounds also exhibited decreased levels of 
tau, indicating a reciprocal relationship between tau and heat shock levels. No toxicity was 
observed in these studies, which has been one of the limiting factors in the development of 
Hsp90 inhibitors such as GDA,
137
 because GDA induces client protein degradation at the same 
concentration it induces heat shock response. Additionally, an Hsp90 inhibitor of the purine 
scaffold, EC102, caused reduction of aberrant tau in the brain of a mouse transgenic for 
tauopathy after i.p. injection. This result is promising as the inhibitor was capable of crossing the 
BBB and reduced tau levels without toxicity to the mice.
136
 
An alternative treatment for AD may involve regulation of Aβ formation and 
aggregation. During in vitro studies, it was observed that recombinant Hsp70/Hsp40 and Hsp90 
were able to suppress Aβ aggregate formation. Hsp90 and the Hsp70/Hsp40 complex inhibited 
Aβ formation and slowed the rate of aggregation in a chaperone concentration-dependent 
manner.
138
  Additionally, Hsp40/Hsp70 and Hsp90’s ATPase activity was necessary for 
15 
inhibition of protein aggregation, as experiments performed using ATPγS, an ATP analogue that 
is hydrolyzed at a much slower rate, inhibited the anti-aggregation properties of the chaperone 
machine, especially in the case of Hsp70/Hsp40, as Hsp90’s effect on aggregation was not 
significantly affected by ATPγS. Two mechanisms by which the heat shock proteins inhibit Aβ 
assembly have been proposed.  In one model, the chaperone binds misfolded amyloid in an ATP-
independent manner, preventing it from aggregation. This model is inconsistent with the 
observed dependency on Hsp90 ATPase activity. Alternately, the chaperone may bind Aβ in an 
ATP-dependent manner changing Aβ’s conformation to one that is less susceptible to 
aggregation.
138
 
Although geldanamycin is a potent inhibitor of Hsp90 and is a standard control used in 
Hsp90 inhibitory assays, its therapeutic window is very narrow as it manifests cytotoxicity. 
Therefore, efforts have been made to identify more suitable small-molecule inhibitors; 
specifically, those with the potential to cross the BBB, which is required for the treatment of 
neurological diseases.  In the Blagg Laboratory, a novobiocin analogue, A4 was developed that 
demonstrated exceptional promise as a neuroprotective agent with no signs of toxicity at 
100µM.
139
 In freshly prepared neuronal cells treated with Aβ alone, significant toxicity was 
observed, however, embryonic primary neurons treated with Aβ in the presence of A4 showed 
significantly decreased toxicity in a dose-dependent manner.  
Hsp90 has also been shown to play a role in other neurodegenerative diseases, such as 
Parkinson’s disease, amyotrophic lateral sclerosis, multiple sclerosis, and the polyglutamine 
(PolyQ) diseases spinal and bulbar muscular atrophy and Huntington’s disease.
55
 Hsp90 
modulators have been evaluated in cell culture and animal models of these diseases and have 
shown some promising activity. Subsequent identification of additional non-toxic Hsp90 
16 
 
Figure 6. Representative natural product 
Hsp90 N-terminal inhibitors.  
inhibitors that cause HSF-1 mediated induction of the heat shock response will be necessary for 
the development of this class of Hsp90 inhibitors. 
In summary, Hsp90 is a molecular chaperone responsible for the conformational 
maturation of nascent polypeptides and it may cooperate with Hsp70 to bring about the refolding 
of misfolded or denatured proteins. Inhibition of Hsp90 exhibits the potential to treat unrelated 
disease states ranging from cancer to neurodegeneration. Inhibition of Hsp90 by cytotoxic agents 
offers exciting promise for the treatment of cancer, which results in degradation of Hsp90-
dependent client proteins directly associated with all six hallmarks of cancer. As a therapeutic 
target, Hsp90 inhibitors possess the ability to simultaneously attack cancer through multiple 
signaling nodes simultaneously, resulting in a combinatorial attack that may be equivalent to the 
administration of multiple drugs. In contrast, modulation of Hsp90 by non-cytotoxic small 
molecules results in disassembly of the HSF-1/Hsp90 complex, and overexpression of the heat 
shock proteins. The resulting Hsps include Hsp90, Hsp70, Hsp40 and Hsp27, and together 
solubilize aggregated proteins that are often the causes or contributors to many 
neurodegenerative diseases. Consequently, Hsp90 represents a unique and exciting therapeutic 
target for the development of Hsp90 modulators that offer the potential to treat several disease 
states via a single protein target.
55
 
B. N-Terminal Inhibitors 
 Hsp90 contains several small molecule 
binding sites. The N-terminal ATP binding site 
has been the most widely studied while less is 
known about the binding site contained within 
the C-terminal and middle domains. The first 
17 
known inhibitors of Hsp90 bind competitively to the N-terminal nucleotide binding site (Figure 
6). In 1970, the benzoquinone-containing ansamycin, namely geldanamycin (GDA), was isolated 
from Streptomyces hygroscpicus and was later reported to manifest anti-tumor activity through 
Hsp90 inhibition.
140-141
 Radicicol (RDC), another natural product Hsp90 inhibitor, was also 
shown to manifest anti-tumor activity through competitive inhibition of the Hsp90 N-terminal 
ATP binding site.
142-143
 Unfortunately, neither GDA nor RDC are suitable for drug development. 
GDA administration manifests toxicity, likely due to the formation of superoxide radicals 
resulting from the redox-active nature of the quinone central to its core.
144-145
 RDC suffers from 
poor in vivo activity caused by the inherent reactivity of the α,β,γ,δ–unsaturated ketone and 
allylic epoxide which react with a variety of biological nucleophiles. These reaction products are 
unable to bind Hsp90 with significant affinity. However, both RDC and GDA have been co-
crystalized with Hsp90 and have been instrumental to the design of other classes of Hsp90 NTD 
inhibitors.  
Inhibitors of the NTD have been the subject of many clinical trials for the treatment of 
cancer, and currently, the geldanamycin derivative, 
17-allylamino-17-demethoxygeldanamycin (17-
AAG), is in Phase III clinical trials.
146-152
 Toxicity of 
the benzoquinone containing compound, 17-AAG, is 
of concern, however new formulations and structural 
analogues have improved tolerability.
153-154
 
Synthetic Hsp90 inhibitors have also been described 
that circumvent the toxic liabilities of 17-AAG 
(Figure 7).
150,152,155
 The first synthetic class of 
 
Figure 7. Representative synthetic Hsp90 
N-terminal inhibitors 
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Hsp90 inhibitors to be clinically evaluated was the purine-scaffold inhibitors, such as CNF2024, 
based on the natural ligand, ATP. SNX-5422 is a benzamide-containing inhibitor that manifested 
improved preliminary biological properties, but appears to produce cardiotoxicity.
150
 Another 
synthetic class of Hsp90 N-terminal inhibitors contain a resorcinol moiety, such as the Novartis 
compound, NVP-AUY922, which is currently in Phase I/II clinical trials.
152
 In addition to the 
binding site contained within the N-terminus, Hsp90 contains a putative nucleotide binding site 
at the C-terminus for small molecule inhibitors. 
C. C-Terminal Inhibitors 
 The natural product antibiotic, Novobiocin (NB), was identified as a putative Hsp90 
inhibitor (Figure 8). First discovered as a DNA gyrase inhibitor, it was originally thought that 
NB targeted the Hsp90 N-terminus due to its unique bent conformation observed when bound to 
DNA gyrase. Immobilized NB was able to pull down Hsp90 constructs containing N- but not C-
terminal truncations, with the binding site being localized to C-terminal fragments containing 
amino acids 538-728.
156-157
 Additionally, NB was shown to induce the degradation of Hsp90 
client proteins in a breast cancer cell line (SKBr-3).
156-157
 Mechanistically, the binding of NB to 
Hsp90 induces a 
conformation that is distinct 
from geladanamycin- or 
molybdate-bound Hsp90.
35-
36,158-159
 For example, in the 
presence of NB, two major 
sites hypersensitive to 
proteolysis by trypsin (R400 
 
Figure 8. C-terminal Hsp90 inhibitors.  
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and K615/R620 of human Hsp90α) and a minor site in Hsp90’s charged linker region become 
resistant to cleavage.
159-160
 In addition, NB binding protects recombinant Hsp90 C-terminal 
domain constructs from trypsin-mediated proteolysis and disrupts binding of TPR-containing co-
chaperones to the C-terminal MEEVD motif.
159,161
 Analogues of NB have been synthesized to 
overcome the low biological activity manifested by NB.
162-173
  
Other inhibitors of the Hsp90 C-terminal domain include (Figure 8): Epigallocatechin 
gallate (EGCG), a polyphenol found in green tea extracts;
174
 cisplatin, the platinum-containing 
chemotherapeutic agent;
175-176
 and ITZ-1, which was identified in 2010 as a C-terminal inhibitor 
by Kimura and co-workers.
177
 These inhibitors of the C-terminus, along with NB, provide a 
mechanistic advantage over N-terminal inhibitors and therefore may be more suitable for drug 
development, as discussed below and in Chapter 2. 
D. Other Inhibitors 
 A third class of 
Hsp90 inhibitors exist 
that bind Hsp90 and 
disrupt the protein-
protein interactions 
between Hsp90 and 
either the co-chaperone Cdc37 or Hop.
155
 Cdc37 assists Hsp90 in the maturation of protein 
kinase client proteins. Cdc37 prevents Hsp90 conformational rearrangement after ATP binding, 
facilitating the interaction between Hsp90 and its kinase client.
178-179
 Furthermore, genetic 
knockdown of Cdc37 results in the destabilization and subsequent degradation of Hsp90 kinase 
client proteins, Her2 (ErbB2), Raf-1 (cRAF), CDK4, CDK6, and Akt.
180
 Three natural products, 
 
Figure 9. Natural product inhibitors of Hsp90 that disrupt the Hsp90-
Cdc37 interaction. 
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celastrol,
181-183
 gedunin,
155
 and gambogic acid,
184
 prevent the association of Cdc37 with Hsp90 
and cause a dose-dependent degradation of Hsp90 kinase client proteins (Figure 9).
155
 Inhibitors 
of this class provide a mechanism to limit off-target effects, as they disrupt only one subset of 
Hsp90 client proteins.  
 In 2008, Yi and coworkers performed a high–throughput screen to identify molecules 
capable of disrupting interactions between Hsp90 and the co-chaperone, Hop.
185-186
 Hop, the Hsp 
organizing protein, mediates the interaction between Hsp70, Hsp90 and their shared client 
proteins and facilitates the delivery of the immature protein from Hsp70 to Hsp90.
64-65
 Molecules 
that disrupt the Hsp90–Hop interaction provide an alternative route to destabilize and degrade 
Hsp90 client proteins. These molecules may prove useful in combination therapy with 
conventional Hsp90 inhibitors as two subsequent steps in the Hsp90 protein folding pathway can 
be blocked.  
IV. Clinical Detriments and Liabilities of Hsp90 Inhibition  
Although there has been great interest and effort towards the development of Hsp90 
inhibitors for the treatment of cancer and other diseases, significant clinical challenges have 
emerged during clinical evaluation. Cardio-, hepato- and ocular toxicities, as well as significant 
dosing and scheduling issues, have been observed throughout phase I and II clinical trials. 
A. Heat Shock Induction 
 One important consideration in the pursuit of clinically relevant Hsp90 inhibitors is the 
fact that Hsp90 N-terminal inhibitors induce the pro-survival, heat shock response (Figure 
10).
187-188
 The heat shock response results in an increased expression of the heat shock proteins, 
mediated by the transcription factor heat shock factor 1 (HSF1). In unstressed cells, HSF1 is 
found in an inactive, Hsp90-bound state.
49,53
 Upon heat shock, or administration of an N-terminal 
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Hsp90 inhibitor, HSF1 is released from the heteroprotein complex.
189
 As a monomer, it lacks 
DNA binding capabilities, but once dissociated from Hsp90, HSF1 trimerizes, is 
hyperphosphorylated and translocates from the cytoplasm to the nucleus.
190
 As an activated 
trimer, HSF1 is able to bind the heat shock element sequence and initiates transcription, inducing 
the expression of Hsp90 and other heat shock proteins.
191
 N-terminal Hsp90 inhibitors also cause 
the dissociation of HSF1 from Hsp90 and initiate the heat shock response. Induction of this pro-
survival response upon N-terminal inhibition is concerning because it results in increased 
expression of Hsp90, Hsp70 and the other heat shock proteins that protect the cell and potentially 
negate the cytotoxic effects caused by Hsp90 inhibition. In addition, Hsp90 levels are 
significantly increased upon treatment with an inhibitor causes dosing and scheduling 
issues.
150,192
 Fortunately, C-terminal cytotoxic Hsp90 inhibitors manifest an opposing effect on 
the heat shock response. C-terminal inhibitors appear to lock HSF1 into an Hsp90-bound state 
and promote its ubiquitinylation and degradation via the proteasome.
187
 This facet of C-terminal 
Figure 10. HSF1 mediated induction of the heat shock response (HSR). 
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inhibition has garnered interest, as inhibitors of this class may overcome the liabilities associated 
with N-terminal inhibition.  
B. Toxicities 
 In addition to induction of the heat shock response, other problems have arisen during the 
clinical evaluation of Hsp90 inhibitors. Several toxicities have been observed, including cardio-, 
hepato-, and ocular toxicity. It is not completely clear if these toxicities are mechanism-based or 
are the consequence of specific chemical scaffolds. Throughout the clinical evaluation of 17-
AAG, hepatotoxicity was observed and was dose-limiting.
150,192
 This toxicity is likely scaffold-
dependent due to the quinone ring.
193-194
 Quinones are subject to oxidation by cytochromes P450 
producing intermediates capable of oxidative damage, such as DNA lesions.
195
 In addition, 
quinones are capable of reacting with a variety of biological molecules, specifically those that 
contain a thiol to produce toxic byproducts.
196
 Combined with only modest efficacy, the 
enthusiasm for 17-AAG as a monotherapy has been dampened. In addition, this quinone-
mediated hepatotoxicity highlights the potential difficulties inherent to the design of Hsp90 
inhibitors based on the geldanamycin scaffold.  
Cardiotoxicity represents a second toxicity observed throughout the clinical evaluation of 
structurally distinct Hsp90 inhibitors.
150
 Cardiotoxicity often results from disruption of the 
potassium rectifier channel expressed in heart tissue. The α-subunit of the voltage gated 
potassium channel, the human ether-a-gogo-related gene product, hERG, constitutes a major 
component of the ion channel responsible for repolarization of cardiac action potential.
197-198
 
Off-target pharmacological inhibition of the hERG channel results in elongation of the QT 
interval, torsades de pointes, and even sudden cardiac death.
198-199
 Compounds can bind directly 
to and inhibit the hERG channel, prevent the functional trafficking of hERG to the cell 
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membrane, or can both bind hERG and prevent trafficking.
200-201
 Of specific consideration for 
Hsp90 inhibitors, hERG has previously been identified as an Hsp90-dependent client protein and 
depends upon Hsp90 for its functional trafficking.
202-203
 In the presence of Hsp90 inhibitors, such 
as GDA, hERG is retained in the ER as its immature, core-glycosylated form, resulting in 
decreased hERG-associated current amplitudes.
202
 Clinically, it is not clear whether the hERG-
related therapeutic liability is severe enough to preclude further clinical evaluation. 
Another major toxicity observed in the clinical evaluation of several different Hsp90 
inhibitors is ocular toxicity.
204-206
 Cytostaticity and cytotoxicity in cultured human retinal 
pigment epithelial cells, critical components involved in photoreception, were observed upon 
exposure to 17-AAG. One hypothesis to explain this observation is the decrease in Akt and 
Erk1/2 signaling as these two kinases are required for both the survival and proliferation of 
retinal pigment epithelial cells.
206
 Drug tissue distribution and scheduling regimen greatly affect 
this toxicity and provide potential strategies to mitigate this detriment. 
C. Other Considerations  
 In addition to target-related toxicities, several other factors must be considered in the 
pursuit of a clinically relevant Hsp90 inhibitor. One important consideration is the development 
of both intrinsic and acquired resistance. Potential mechanisms of resistance include: altered 
drug metabolism, changes in drug influx/efflux, and mutation of the target itself. Target mutation 
was not originally a concern for Hsp90 inhibitors as it was believed that any mutation that causes 
a decreased affinity for an inhibitor would also cause decreased affinity for the natural ligand, 
ATP,
207
 which would ultimately reduce chaperone activity and compromise normal processes. 
Recently, studies performed in Humicola fuscoatra showed that a single point mutation in Hsp90 
could reduce its affinity for RDC but not ATP or GDA, challenging this hypothesis.
208-209
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Another mechanism of resistance includes altered cellular efflux/influx. 17-AAG has been 
shown to be substrate for the P-glycoprotein (PGP) efflux pump, causing a decrease in efficacy 
in PGP-expressing cells. In addition to target mutation and drug efflux, metabolism can greatly 
affect biological activity. One illustrative example is the bio-reduction of 17-AAG and other 
quinone-containing ansamycins. It has been established that the reduced, hydroquinone-
containing ansamycin analogues manifest higher affinities for Hsp90 as compared to their 
oxidized, quinone-containing counterparts.
210
 DT-diaphorase (DTD), the enzyme encoded by the 
NQO1 gene, is an NAD(P)H-dependent reductase and is responsible for reduction of the 17-
AAG quinone.
211-212
 A small percentage of the population (5-20%) has a mutation in the NQO1 
gene, a mutation resulting in expression of DTD with reduced activity.
213
 In addition, NQO1 
expression is variable across tumor types.
214-216
 This example highlights the necessity to 
understand the metabolic liability of each Hsp90 inhibitor and demonstrates that the metabolic 
fate may result in a variable clinical response based on the genetic makeup of the patients.  
 It will be essential to the Hsp90 community to delineate and elucidate the mechanisms of 
toxicity, resistance, metabolism and other downstream biological effects. The results from these 
studies will aid in the design of clinical trials and the determination of certain tumor types and 
patient populations that will benefit from Hsp90 inhibition without significant toxicities. 
V. Conclusions and Future Directions of Hsp90 Inhibition 
 Interest in Hsp90 inhibitors for the treatment of cancer and neurodegerenative diseases 
has grown exponentially since identification of geldanamycin as the first Hsp90 inhibitor in 
1994.
141
 Over the last 25 years, several classes of Hsp90 inhibitors have been identified, each 
with unique mechanisms of inhibition and each displaying somewhat differing biological effects. 
Several of these inhibitors have been clinically evaluated for a variety of different cancers, 
25 
unfortunately, the results of these trials has somewhat been disappointing. The results from these 
trials emphasize the need to thoroughly understand the biology of the target, to better understand 
how different classes of inhibitors affect the molecular chaperone, and to determine how cellular 
environments affect drug efficacy. 
  Several strategies exist that may help circumvent the known pitfalls resulting from 
Hsp90 inhibition. First, inhibitors of the C-terminal domain do not cause induction of the heat 
shock response, but maintain anti-proliferative activity. Compounds in this class should not 
suffer from dosing and scheduling issues observed with N-terminal inhibitors. Second, the 
development of isoform-selective inhibitors may result in fewer negative effects upon Hsp90 
inhibition. All known Hsp90 inhibitors exhibit pan-inhibition, i.e. they target all four human 
isoforms simultaneously. An isoform-selective inhibitor will not only help delineate the roll of 
each isoform, but may prove to be clinically more viable. Lastly, inhibitors that work by alternate 
mechanisms, such as co-chaperone disruptors, provide a mechanism to disrupt only a subset of 
Hsp90 client proteins, and may also result in less undesired effects. In summary, Hsp90 is still an 
attractive therapeutic target, but new strategies for inhibition are necessary to overcome the 
clinical liabilities observed for prototypical N-terminal inhibitors.  
VI. References 
1. Ellis, R. J.; Minton, A. P. Protein aggregation in crowded environments. Biol. Chem. 2006, 387, 
485-497. 
2. Hartl, F. U. Molecular chaperones in cellular protein folding. Nature 1996, 381, 571-580. 
3. Hartl, F. U.; Bracher, A.; Hayer-Hartl, M. Molecular chaperones in protein folding and 
proteostasis. Nature 2011, 475, 324-332. 
4. Walter, S.; Buchner, J. Molecular chaperones-cellular machines for protein folding. Angew. 
Chem. Int. Ed. 2002, 41, 1098-1113. 
5. Saibil, H. R. Chaperone machines in action. Curr. Opin. Struc. Biol. 2008, 18, 35-42. 
6. Meyer, P.; Prodromou, C.; Hu, B.; Vaughan, C.; Roe, S. M.; Panaretou, B.; Piper, P. W.; Pearl, L. 
H. Structural and functional analysis of the middle segment of Hsp90: implications for ATP 
hydrolysis and client protein and cochaperone interactions. Mol. Cell 2003, 11, 647-658. 
7. Pratt, W. B.; Toft, D. O. Regulation of Signaling Protein Function and Trafficking by the 
Hsp90/Hsp70-based Chaperone Machinery. Exp. Biol. Med. 2003, 228, 111-133. 
26 
8. Soti, C.; Nagy, E.; Giricz, Z.; Vigh, L.; Csermely, P.; Ferdinandy, P. Heat shock proteins as 
emerging therapeutic targets. Brit. J. Pharmacol. 2005, 146, 769-780. 
9. Sreedhar, A. S.; Csermely, P. Novel roles of Hsp90 inhibitors and Hsp90 in: redox regulation and 
cytoarchitecture. Rec. Res. Devel. Life Sci. 2003, 1, 153-171. 
10. Chiosis, G.; Vilenchik, M.; Kim, J.; Solit, D. Hsp90: the vulnerable chaperone. Drug Discov. 
Today 2004, 9, 881-888. 
11. Picard, D. http://www.picard.ch/downloads/Hsp90interactors.pdf. 
12. Picard, D. http://www.picard.ch/downloads/Hsp90facts.pdf. 
13. Whitesell, L.; Lindquist, S. L. Hsp90 and the chaperoning of cancer. Nat. Rev. Cancer 2005, 5, 
761-772. 
14. Zhang, H.; Burrows, F. Targeting multiple signal transduction pathways through inhibition of 
Hsp90. J. Mol. Med. 2004, 82, 488-499. 
15. Chen, B.; Piel, W. H.; Gui, L.; Bruford, E.; Monteiro, A. The HSP90 family of genes in the 
human genome: Insights into their divergence and evolution. Genomics 2005, 86, 627-637. 
16. Csermely, P.; Schnaider, T.; Soti, C.; Prohaszka, Z.; Nardai, G. The 90-kDa molecular chaperone 
family structure, function, and clinical applications. a comprehensive review. Pharmacol. Ther. 
1998, 79, 129-168. 
17. Sreedhar, A. S.; Kalmar, E.; Csermely, P. Hsp90 isoforms: functions, expression and clinical 
importance. FEBS Lett. 2004, 562, 11-15. 
18. Johnson, J. L. Evolution and function of diverse Hsp90 homologs and cochaperone proteins. BBA 
- Mol. Cell Res. 2012, 1823, 607-613. 
19. Altieri, D. C.; Stein, G. S.; Lian, J. B.; Languino, L. R. TRAP-1, the mitochondrial Hsp90. BBA - 
Mol. Cell Res. 2012, 1823, 767-773. 
20. Marzec, M.; Eletto, D.; Argon, Y. GRP94: An HSP90-like protein specialized for protein folding 
and quality control in the endoplasmic reticulum. BBA - Mol. Cell Res. 2012, 1823, 774-787. 
21. McLaughlin, M.; Vandenbroeck, K. The endoplasmic reticulum protein folding factory and its 
chaperones: new targets for drug discovery? Brit. J. Pharmacol. 2011, 162, 328-345. 
22. Ali, M. M.; Roe, S. M.; Vaughan, C. K.; Meyer, P.; Panaretou, B.; Piper, P. W.; Prodromou, C.; 
Pearl, L. H. Crystal structure of an Hsp90-nucleotide-p23/Sba1 closed chaperone complex. 
Nature 2006, 440, 1013-1017. 
23. Krishna, P.; Gloor, G. The Hsp90 family of proteins in Arabidopsis thaliana. Cell Stress 
Chaperon. 2001, 6, 238-246. 
24. Nemoto, T.; Sato, N.; Iwanari, H.; Yamashita, H.; Takegi, T. Domain structures and 
immunogenic regions of the 90-kDa heat-shock protein (Hsp90). J. Biol. Chem. 1997, 272, 
26179-26187. 
25. Prodromou, C.; Pearl, L. H. Structure and functional relationships of Hsp90. Curr. Cancer Drug 
Tar. 2003, 3, 301-323. 
26. Young, J. C.; Schneider, C.; Hartl, F. U. In vitro evidence that Hsp90 contains two independent 
chaperone sites. FEBS Lett. 1997, 418, 139-143. 
27. Dutta, R.; Inouye, M. GHKL, An emergent ATPase/kinase superfamily. Trends Biochem. Sci. 
2000, 25, 24-28. 
28. Bergerat, A.; Massy, B. d.; Gadelle, D.; Varoutas, P.-C.; Nicolas, A.; Forterre, P. An atypical 
topoisomerase II from archaea with implications for meiotic recombination. Nature 1997, 386, 
414-417. 
29. Nemoto, T.; Ohara-Nemoto, Y.; Ota, M.; Takagi, T.; Yokoyama, K. Mechanism of dimer 
formation of the 90-kDa heat-shock protein. Eur. J. Biochem. 1995, 233, 1-8. 
30. Wayne, N.; Bolon, D. B. Dimerization of Hsp90 is required for in vivo function: Design and 
analysis of monomers and dimers. J. Biol. Chem. 2007, 282, 35386-35395. 
31. Blatch, G. L.; Lässle, M. The tetratricopeptide repeat: a structural motif mediating protein-protein 
interactions. BioEssays 1999, 21, 932-939. 
27 
32. Carrello, A.; Ingley, E.; Minchin, R. F.; Tsai, A.; Ratajczak, T. The Common Tetratricopeptide 
Repeat Acceptor Site for Steroid Receptor-associated Immunophilins and HOP Is Located in the 
Dimerization Domain of Hsp90. J. Biol. Chem. 1999, 274, 2682-2689. 
33. D'Andrea, L. D.; Regan, L. TPR proteins: the versatile helix. Trends Biochem. Sci. 2003, 28, 655-
662. 
34. Das, A. K.; Cohen, P. T. W.; Barford, D. The structure of the tetratricopeptide repeats of protein 
phosphatase 5: implications for TRP-mediated protein-protein interactions. EMBO J. 1998, 17, 
1192-1199. 
35. Soti, C.; Racz, A.; Csermely, P. A nucleotide-dependent molecular switch controls ATP binding 
at the C-terminal domain of Hsp90. J. Biol. Chem. 2002, 277, 7066-7075. 
36. Soti, C.; Vermes, A.; Haystead, T. A. J.; Csermely, P. Comparative analysis of the ATP-binding 
sites of Hsp90 by nucleotide affinity cleavage: a distinct nucleotide specificity of the C-terminal 
ATP-binding site. Eur. J. Biochem. 2003, 270, 2421-2428. 
37. Huai, Q.; Wang, H.; Liu, Y.; Kim, H.-Y.; Toft, D.; Ke, H. Structures of the N-terminal and 
middle domains of E. coli Hsp90 and conformational changes upon ADP binding. Structure 2005, 
13, 579-590. 
38. Ferrarini, M.; Heltai, S.; Zocchi, M. R.; Rugarli, C. Unusual expression and localization of heat-
shock proteins in human tumor cells. Int. J. Cancer 1992, 51, 613-619. 
39. Nathan, D. F.; Vos, M. H.; Lindquist, S. In vivo functions of the Saccharomyces Cerevisiae 
Hsp90 chaperone. P. Natl. Acad. Sci. 1997, 94, 12949-12956. 
40. Schneider, C.; Sepp-Lorenzino, L.; Nimmesgern, E.; Ouerfelli, O.; Danishefsky, S.; Rosen, N.; 
Hartl, F. U. Pharmacologic shifting of a balance between protein refolding and degredation 
mediated by Hsp90. P. Natl. Acad. Sci. 1996, 93, 14536-14541. 
41. Ali, A.; Bharadwaj, S.; O'Carrol, R.; Ovsenek, N. Hsp90 interacts with and regulates the activity 
of heat shock factor 1 in Xenopus oocytes. Mol. Cell Biol. 1998, 18, 4949-4960. 
42. Bharadwaj, S.; Ali, A.; Ovsenek, N. Multiple components of the Hsp90 chaperone complex 
function in regulation of heat shock factor 1 in vivo. Mol. Cell Biol. 1999, 19, 8033-8041. 
43. Guo, Y.; Guettouche, T.; Fenna, M.; Boellmann, F.; Pratt, W. B.; Toft, D. O.; Smith, D. F.; 
Voellmy, R. Evidence for a mechanism of repression of heat shock factor 1 transcriptional 
activity by a multichaperone complex. J. Biol. Chem. 2001, 276, 45791-45799. 
44. Kim, H. R.; Kang, H. S.; Kim, H. D. Geldanamycin induces heat shock protein expression 
through activation of HSF1 in K562 erythroleukemic cells. IUBMB Life 1999, 48, 429-433. 
45. Marchler, G.; Wu, C. Modulation of Drosophila heat shock transcription factor activity by the 
molecular chaperone DroJ1. EMBO J. 2001, 20, 499-509. 
46. Morimoto, R. I. Cells in Stress: Transcriptional Activation of Heat Shock Genes. Science 1993, 
259, 1409-1410. 
47. Rabindran, S. K.; Wisniewski, J.; Li, L.; Li, G. C.; Wu, C. Interaction between heat shock factor 
and Hsp70 is insufficient to suppress induction of DNA-binding activity in vivo. Mol. Cell Biol. 
1994, 14, 6552-6560. 
48. Shamovsky, I.; Ivannikov, M.; Kandel, E. S.; Gershon, D.; Nudler, E. RNA-mediated response to 
heat shock in mammalian cells. Nature 2006, 440, 556-560. 
49. Shi, Y.; Mosser, D. D.; Morimoto, R. I. Molecular chaperones as HSF1-specific transcriptional 
repressors. Genes Dev. 1998, 12, 654-666. 
50. Trinklein, N. D.; Murray, J. I.; Hartman, S. J.; Botstein, D.; Myers, R. M. The role of heat shock 
transcription factor 1 in the genome-wide regulation of the mammalian heat shock response. Mol. 
Biol. Cell 2004, 15, 1254-1261. 
51. Whitesell, L.; Bagatell, R.; Falsey, R. The stress response: implications for the clinical 
development of Hsp90 inhibitors. Curr. Cancer Drug Tar. 2003, 3, 349-358. 
52. Zhao, C.; Hashiguchi, K.; Kondoh, W.; Du, W.; Hata, J.; Yamada, T. Exogenous expression of 
heat shock protein 90 kDa retards the cell cycle and impairs the heat shock response. Exp. Cell 
Res. 2002, 275, 200-214. 
28 
53. Zou, J.; Guo, Y.; Guettouche, T.; Smith, D. F.; Voellmy, R. Repression of heat shock 
transcription factor HSF1 activation by Hsp90 (Hsp90 complex) that forms a stress-sensitive 
complex with HSF1. Cell 1998, 94, 471-480. 
54. Zou, J.; Rungger, D.; Voellmy, R. Multiple layers of regulation of human heat shock transcription 
factor 1. Mol. Cell Biol. 1995, 15, 4319-4330. 
55. Peterson, L. B.; Blagg, B. S. J. To fold or not to fold: modulation and consequences of Hsp90 
inhibition. Future Med. Chem. 2009, 1. 
56. Lotz, G. P.; Lin, H.; Harst, A.; Obermann, W. M. Aha1 binds to the middle domain of Hsp90, 
contributes to client protein activation, and stimulates the ATPase activity of the molecular 
chaperone. J. Biol. Chem. 2003, 278, 17228-17235. 
57. Vaughan, C. K.; Mollapour, M.; Smith, J. R.; Truman, A.; Hu, B.; Good, V. M.; Panaretou, B.; 
Neckers, L.; Clarke, P. A.; Workman, P.; Piper, P. W.; Prodromou, C.; Pearl, L. H. Hsp90-
dependent activation of protein kinases is regulated by chaperone-targeted dephosphorylation of 
Cdc37. Mol. Cell 2008, 31, 886-895. 
58. Connell, P.; Ballinger, C. A.; Jiang, J., Wu, Y.; Thompson, L. J.; Hohfeld, J.; Patterson, C. The 
co-chaperone CHIP regulates protein triage decisions mediated by heat-shock proteins. Nat. Cell 
Biol. 2001, 3, 93-96. 
59. Murata, S.; Minami, Y.; Minami, M.; Chiba, T.; Tanaka, K. CHIP is a chaperone-dependent E3 
ligase that ubiquitylates unfolded protein. EMBO Rep. 2001, 2, 1133-1138. 
60. Hatakeyama, S.; Matsumoto, M.; Yada, M.; Nakayama, K. I. Interaction of U-box-type ubiquitin-
protein ligases (E3s) with molecular chaperones. Genes Cells 2004, 9, 533-548. 
61. Hoffmann, K.; Handschumacher, R. E. Cyclophilin-40: evidence for a dimeric complex with 
hsp90. Biochem. J. 1995, 307, 5-8. 
62. Pirkl, F.; Buchner, J. Functional analysis of the Hsp90-associated human peptidyl prolyl cis/trans 
isomerases FKBP51, FKBP52 and Cyp40. J. Mol. Biol. 2001, 308, 795-806. 
63. Chen, S.; Sullivan, W. P.; Toft, D. O.; Smith, D. F. Differential interactions of p23 and the TRP-
containing proteins Hop, Cyp40, FKBP52 and FKBP51 with Hsp90 mutants. Cell Stress 
Chaperon. 1998, 3, 118-129. 
64. Chen, S.; Smith, D. F. Hop as an adaptor in the heat shock protein 70 (Hsp70) and hsp90 
chaperone machinery. J. Biol. Chem. 1998, 273, 35194-35200. 
65. Johnson, B. D.; Schumacher, R. J.; Ross, E. D.; Toft, D. O. Hop modulates hsp70/hsp90 
interactions in protein folding. J. Biol. Chem. 1998, 273, 3679-3686. 
66. Hernández, M. P.; Chadli, A.; Toft, D. O. Hsp40 binding is the first step in the Hsp90 
chaperoning pathway for the progesterone receptor. J. Biol. Chem. 2002, 277, 11873-11881. 
67. Minami, Y.; Minami, M. Hsc70/Hsp40 chaperone system mediates the Hsp90-dependent 
refolding of firefly luciferase. Genes Cells 1999, 4, 721-729. 
68. Freeman, B. C.; Morimoto, R. I. The human cytosolic molecular chaperones hsp90, hsp70 
(hsc70) and hdj-1 have distinct roles in recognition of a non-native protein and protein refolding. 
EMBO J. 1996, 15, 2969-2979. 
69. Frydman, J. Folding of newly translated proteins in vivo: the role of molecular chaperones. Ann. 
Rev. Biochem. 2001, 70, 603-647. 
70. Hutchison, K. A.; Dittmar, K. D.; Czar, M. J.; Pratt, W. B. Proof that hsp70 is required for 
assembly of the glucocorticoid receptor into a heterocomplex with hsp90. J. Biol. Chem. 1994, 
269, 5043-5049. 
71. Alekseev, O. M.; Widgren, E. E.; Richardson, R. T.; O'Rand, M. G. Association of NASP with 
HSP90 in mouse spermatogenic cells: stimulation of ATPase activity and transport of linker 
histones into nuclei. J. Biol. Chem. 2005, 280, 2904-2911. 
72. Chen, M.-S.; Silverstein, A. M.; Pratt, W. B.; Chinkers, M. The tetratricopeptide repeat domain of 
protein phosphatase 5 mediates binding to glucocorticoid receptor heterocomplexes and acts as a 
dominant negative mutant. J. Biol. Chem. 1996, 271, 32315-32320. 
29 
73. Conde, R.; Xavier, J.; McLoughlin, C.; Chinkers, M.; Ovsenek, N. Protein phosphatase 5 is a 
negative modulator of heat shock factor 1. J. Biol. Chem. 2005, 280, 28989-28996. 
74. Silverstein, A. M.; Galigniana, M. D.; Chen, M. S.; Owens Grillo, J. K.; Chinkers, M.; Pratt, W. 
B. Protein phosphatase 5 is a major component of glucocorticoid receptor.hsp90 complexes with 
properties of an FK506-binding immunophilin. J. Biol. Chem. 1997, 272, 16224-16230. 
75. Catlett, M. G.; Kaplan, K. B. Sgt1p is a unique co-chaperone that acts as a client adaptor to link 
Hsp90 to Skp1p. J. Biol. Chem. 2006, 281, 33739-33748. 
76. Millson, S. H.; Vaughan, C. K.; Zhai, C.; Ali, M. M. U.; Panaretou, B.; Piper, P. W.; Pearl, L. H.; 
Prodromou, C. Chaperone ligand-discrimination by the TPR-domain protein Tah1. Biochem. J. 
2008, 413, 261-268. 
77. Fan, A. C.; Bhangoo, M. K.; Young, J. C. Hsp90 functions in the targeting and outer membrane 
translocation steps of Tom70-mediated mitochondrial import. J. Biol. Chem. 2006, 281, 33313-
33324. 
78. Young, J. C.; Hoogenraad, N. J.; Hartl, F. U. Molecular chaperones Hsp90 and Hsp70 deliver 
preproteins to the mitochondrial import receptor Tom70. Cell 2003, 112, 41-50. 
79. Brychzy, A.; Rein, T.; Winklhofer, K. F.; Hartl, F. U.; Young, J. C.; Obermann, W. M. Cofactor 
Tpr2 combines two TPR domains and a J domain to regulate the Hsp70/Hsp90 chaperone system. 
EMBO J. 2003, 22, 3613-3623. 
80. Jascur, T.; Brickner, H.; Salles-Passador, I.; Barbier, V.; El Khissiin, A.; Smith, B.; Fotedar, R.; 
Fotedar, A. Regulation of p21(WAF1/CIP1) stability by WISp39, a Hsp90 binding TPR protein. 
Mol. Cell 2005, 17, 237-249. 
81. Moffatt, N. S.; Bruinsma, E.; Uhl, C.; Obermann, W. M.; Toft, D. O. Role of the cochaperone 
Tpr2 in Hsp90 chaperoning. Biochemistry 2008, 47, 8203-8213. 
82. Caplan, A. J. What is a co-chaperone? Cell Stress Chaperon. 2003, 8, 105-107. 
83. Hohfeld, J.; Jentsch, S. GrpE-like regulation of the Hsc70 chaperone by the anti-apoptotic protein 
BAG-1. EMBO J. 1997, 16, 6209-6216. 
84. Sondermann, H.; Scheufler, C.; Schneider, C.; Hohfeld, J.; Hartl, F. U.; Moarefi, I. Structure of a 
Bag/Hsc70 complex: convergent functional evolution of Hsp70 nucleotide exchange factors. 
Science 2001, 291, 1553-1557. 
85. Forsythe, H. L.; Jarvis, J. L.; Turner, J. W.; Elmore, L. W.; Holt, S. E. Stable association of 
Hsp90 and p23, but not Hsp70, with active human telomerase. J. Biol. Chem. 2001, 19, 15571-
15574. 
86. Kosano, H.; Stensgard, B.; Charlesworth, M. C.; McMahon, N.; Toft, D. The assembly of 
progesterone receptor-hsp90 complexes using purified proteins. J. Biol. Chem. 1998, 273, 32973-
32979. 
87. Murphy, P. J. M.; Kanelakis, K. C.; Galigniana, M. D.; Morishima, Y.; Pratt, W. B. 
Stoichiometry, abundance, and functional significance of the Hsp90/Hsp70-based multiprotein 
chaperone machinery in reticulocyte lysate. J. Biol. Chem. 2001, 276, 30092-30098. 
88. Prodromou, C.; Panaretou, B.; Chohan, S.; Siligardi, G.; O'Brien, R.; Ladbury, J. E.; Roe, S. M.; 
Piper, P. W.; Pearl, L. H. The ATPase cycle of Hsp90 drives a molecular 'clamp' via transient 
dimerization of the N-terminal domains. EMBO J. 2000, 19, 4383-4392. 
89. Ratajczak, T.; Carrello, A. Cyclophilin 40 (CyP-40), mapping of its Hsp90 binding domain and 
evidence that FKBP52 competes with CyP-40 for Hsp90 binding. J. Biol. Chem. 1996, 271, 
2961-2965. 
90. Hessling, M.; Richter, K.; Buchner, J. Dissection of the ATP-induced conformational cycle of the 
molecular chaperone Hsp90. Nat. Struct. Mol. Biol. 2009, 16, 287-293. 
91. Krukenberg, K. A.; Forster, F.; Rice, L. M.; Sali, A.; Agard, D. A. Multiple conformations of E. 
coli Hsp90 in solution: insights into the conformational dynamics of Hsp90. Structure 2008, 16, 
755-765. 
92. Shiau, A. K.; Harris, S. F.; Southworth, D. R.; Agard, D. A. Structural Analysis of E. coli hsp90 
reveals dramatic nucleotide-dependent conformational rearrangements. Cell 2006, 127, 329-340. 
30 
93. Soroka, J.; Wandinger, Sebastian K.; Mäusbacher, N.; Schreiber, T.; Richter, K.; Daub, H.; 
Buchner, J. Conformational switching of the molecular chaperone Hsp90 via regulated 
phosphorylation. Mol. Cell 2012, 45, 517-528. 
94. Colombo, G.; Morra, G.; Meli, M.; Verkhivker, G. Understanding ligand-based modulation of the 
Hsp90 molecular chaperone dynamics at atomic resolution. P. Natl. Acad. Sci. 2008, 105, 7976-
7981. 
95. Mollapour, M.; Neckers, L. Post-translational modifications of Hsp90 and their contributions to 
chaperone regulation. BBA - Mol. Cell Res. 2012, 1823, 648-655. 
96. Scroggins, B. T.; Neckers, L. Post-translational modification of heat-shock protein 90: impact on 
chaperone function. Expert. Opin. Drug Discov. 2007, 2, 1403-1414. 
97. Zhao, Y.-G.; Gilmore, R.; Leone, G.; Coffey, M. C.; Weber, B.; Lee, P. W. K. Hsp90 
Phosphorylation Is Linked to Its Chaperoning Function. J. Biol. Chem. 2001, 276, 32822-32827. 
98. Mollapour, M.; Tsutsumi, S.; Donnelly, A. C.; Beebe, K.; Tokita, M. J.; Lee, M.-J.; Lee, S.; 
Morra, G.; Bourboulia, D.; Scroggins, B. T.; Colombo, G.; Blagg, B. S.; Panaretou, B.; Stetler-
Stevenson, W. G.; Trepel, J. B.; Piper, P. W.; Prodromou, C.; Pearl, L. H.; Neckers, L. Swe1
Wee1
-
dependent tyrosine phosphorylation of Hsp90 regulates distinct facets of chaperone function. 
Mol. Cell 2010, 37, 333-343. 
99. Lei, H.; Venkatakrishnan, A.; Yu, S.; Kazlauskas, A. Protein Kinase A-dependent Translocation 
of Hsp90α Impairs Endothelial Nitric-oxide Synthase Activity in High Glucose and Diabetes. J. 
Biol. Chem. 2007, 282, 9364-9371. 
100. Duval, M.; Le Bœuf, F.; Huot, J.; Gratton, J.-P. Src-mediated phosphorylation of Hsp90 in 
response to vascular endothelial growth factor (VEGF) is required for VEGF receptor-2 signaling 
to endothelial NO synthase. Mol. Biol. Cell 2007, 18, 4659-4668. 
101. Ogiso, H.; Kagi, N.; Matsumoto, E.; Nishimoto, M.; Arai, R.; Shirouzu, M.; Mimura, J.; Fujii-
Kuriyama, Y.; Yokoyama, S. Phosphorylation Analysis of 90 kDa Heat Shock Protein within the 
Cytosolic Arylhydrocarbon Receptor Complex†. Biochemistry 2004, 43, 15510-15519. 
102. Mollapour, M.; S. Tsutsumi; Kim, Y. S.; Trepel, J.; Neckers, L. Casein kinase 2 phosphorylation 
of Hsp90 threonine 22 modulates chaperone function and drug sensitivity. Oncotarget 2011, 2, 
407-417. 
103. Scroggins, B. T.; Robzyk, K.; Wang, D.; Marcu, M. G.; Tsutsumi, S.; Beebe, K.; Cotter, R. J.; 
Felts, S.; Toft, D.; Karnitz, L.; Rosen, N.; Neckers, L. An Acetylation Site in the Middle Domain 
of Hsp90 Regulates Chaperone Function. Mol. Cell 2007, 25, 151-159. 
104. Yang, Y.; Rao, R.; Shen, J.; Tang, Y.; Fiskus, W.; Nechtman, J.; Atadja, P.; Bhalla, K. Role of 
Acetylation and Extracellular Location of Heat Shock Protein 90α in Tumor Cell Invasion. 
Cancer Res. 2008, 68, 4833-4842. 
105. Chen, W.-Y.; Chang, F.-R.; Huang, Z.-Y.; Chen, J.-H.; Wu, Y.-C.; Wu, C.-C. Tubocapsenolide 
A, a Novel Withanolide, Inhibits Proliferation and Induces Apoptosis in MDA-MB-231 Cells by 
Thiol Oxidation of Heat Shock Proteins. J. Biol. Chem. 2008, 283, 17184-17193. 
106. Martínez-Ruiz, A.; Villanueva, L.; de Orduña, C. G.; López-Ferrer, D.; Higueras, M. Á.; Tarín, 
C.; Rodríguez-Crespo, I.; Vázquez, J.; Lamas, S. S-nitrosylation of Hsp90 promotes the inhibition 
of its ATPase and endothelial nitric oxide synthase regulatory activities. P. Natl. Acad. Sci. 2005, 
102, 8525-8530. 
107. Morra, G.; Verkhivker, G.; Colombo, G. Modeling Signal Propagation Mechanisms and Ligand-
Based Conformational Dynamics of the Hsp90 Molecular Chaperone Full-Length Dimer. PLoS 
Comput. Biol. 2009, 5, e1000323. 
108. Retzlaff, M.; Stahl, M.; Eberl, H. C.; Lagleder, S.; Beck, J.; Kessler, H.; Buchner, J. Hsp90 is 
regulated by a switch point in the C-terminal domain. EMBO Rep. 2009, 10, 1147-1153. 
109. Blank, M.; Mandel, M.; Keisari, Y.; Meruelo, D.; Lavie, G. Enhanced ubiquitinylation of heat 
shock protein 90 as a potential mechanism for mitotic cell death in cancer cells induced with 
hypericin. Cancer Res. 2003, 63, 8241-8247. 
31 
110. Kundrat, L.; Regan, L. Identification of residues on Hsp70 and Hsp90 ubiquitinated by the 
cochaperone CHIP. J. Mol. Biol. 2010, 395, 587-594. 
111. Ballinger, C. A.; Connell, P.; Y., W.; Hu, Z.; Thompson, L. J.; Yin, L. Y.; Patterson, C. 
Identification of CHIP, a novel tetratricopeptide repeat-containing protein that interacts with heat 
shock proteins and negatively regulates chaperone functions. mol. Cell Biol. 1999, 19, 4535–
4545. 
112. Workman, P. Combinatorial attack on multistep oncogenesis by inhibiting the Hsp90 molecular 
chaperone. Cancer Lett. 2004, 206, 149-157. 
113. Taldone, T.; Gozman, A.; Maharaj, R.; Chiosis, G. Targeting Hsp90: small-molecule inhibitors 
and their clinical development. Curr. Opin. Pharmacol. 2008, 8, 370-374. 
114. Muchowski, P. J. Protein misfolding, amyloid formation, and neurodegeneration: a critical role 
for molecular chaperones? Neuron 2002, 35, 9-12. 
115. Muchowski, P. J.; Wacker, J. L. Modulation of neurodegeneration by molecular chaperones. Nat. 
Rev. Neurosci. 2005, 6, 11-22. 
116. Bishop, S. C.; Burlison, J. A.; Blagg, B. S. J. Hsp90: a novel target for the disruption of multiple 
signaling cascades. Curr. Cancer Drug Tar. 2007, 7, 369-388. 
117. Hanahan, D.; Weinberg, R. A. The hallmarks of cancer. Cell 2000, 100, 57-70. 
118. Hanahan, D.; Weinberg, Robert A. Hallmarks of cancer: The next generation. Cell 2011, 144, 
646-674. 
119. Workman, P.; Burrows, F.; Neckers, L.; Rosen, N. Drugging the cancer chaperone Hsp90: 
Combinatorial therapeutic exploitation of oncogene addiction and tumor stress. Ann. NY Acad. 
Sci. 2007, 1113, 202-216. 
120. Neckers, L. Chaperoning oncogenes: Hsp90 as a target of geldanamycin. Handb. Exp. 
Pharmacol. 2006, 172, 259-277. 
121. Jameel, A.; Skilton, R. A.; Campbell, T. A.; Chander, S. K.; Coombes, R. C.; Luqmani, Y. A. 
Clinical and biological significance of Hsp89α in human breast cancer. Int. J. Cancer 1992, 50, 
409-415. 
122. Yufu, Y.; Nishimura, J.; Nawata, H. High constitutive expression of heat shock protein 90α in 
human acute leukemia cells. Leuk. Res. 1992, 16, 597-605. 
123. Pick, E.; Kluger, Y.; Giltnane, J. M.; Moeder, C.; Camp, R. L.; Rimm, D. L.; Kluger, H. M. High 
HSP90 expression is associated with decreased survival in breast cancer. Cancer Res. 2007, 67, 
2932-2937. 
124. Chiosis, G.; Huezo, H.; Rosen, N.; Mimnaugh, E.; Whitesell, L.; Neckers, L. 17AAG: low target 
binding affinity and potent cell activity - finding an explanation. Mol. Cancer Ther. 2003, 2, 123-
129. 
125. Kamal, A.; Thao, L.; Sensintaffar, J.; Zhang, L.; Boehm, M. F.; Fritz, L. C.; Burrows, F. J. A 
high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 
2003, 425, 407-410. 
126. Ross, C. A.; Poirier, M. A. Protein aggregation and neurodegenerative disease. Nat. Med. 2004, 
S10-S17. 
127. Chaudhury, S.; Welch, T. R.; Blagg, B. S. J. Hsp90 as a target for drug development. 
ChemMedChem 2006, 1, 1331-1340. 
128. Mattson, M. P. Pathways towards and away from Alzheimer's disease. Nature 2004, 430, 631-
639. 
129. Selkoe, D. J. Alzheimer disease: mechanistic understanding predicts novel therapies. Ann. Intern. 
Med. 2004, 140, 627-638. 
130. Akiyama, H.; Barger, S.; Barnum, S.; Bradt, B.; Bauer, J.; al., G. M. C. e. Inflammation and 
Alzheimer's disease. Neurobiol. Aging 2000, 21, 383-421. 
131. Lambert, M. P.; Barlow, A. K.; Chromy, B. A.; Edwards, C.; Freed, R.; Liosatos, M.; Morgan, T. 
E.; Rozovsky, I.; Trommer, B.; Viola, K. L.; Wals, P.; Zhang, C.; Finch, C. E.; Krafft, G. A.; 
32 
Klein, W. L. Diffusible, nonfibriallar ligands derived from Aβ1-42 are potent central nervous 
system neurotoxins. P. Natl. Acad. Sci. 1998, 95, 6448-6453. 
132. Walsh, D. M.; Klyubin, I.; Fadeeva, J. V.; Cullen, W. K.; Anwyl, R.; Wolfe, M. S.; Rowan, M. J.; 
Selkoe, D. J. Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal 
long-term potentiation in vivo. Nature 2002, 416, 535-539. 
133. Yan, Y.; Wang, C. Protection mechanisms against Aβ42 aggregation Curr. Alzheimer Res. 2008, 
5, 548-554. 
134. Dou, F.; Netzer, W. J.; Tanemura, K.; Li, F.; Hartl, U.; Takashima, A.; Gouras, G. K.; Greengard, 
P.; Xu, H. Chaperones increase association of Tau protein with microtubules. P. Natl. Acad. Sci. 
2003, 100, 721-726. 
135. Richter-Landsberg, C. The cytoskeleton in oligodendrocytes: microtubule dynamics in health and 
disease. J. Mol. Neurosci. 2008, 35, 55-63. 
136. Dickey, C. A.; Kamal, A.; Lundgren, K.; Klosak, N.; Bailey, R. M.; Dunmore, J.; Ash, P.; 
Shoraka, S.; Zlatkovic, J.; Eckman, C. B.; Patterson, C.; Dennis, W. D.; Nahman Jr, N. S.; 
Hutton, M.; Burrows, F.; Petrucelli, L. The high-affinity Hsp90-CHIP complex recognizes and 
selectively degrades phosphorylated tau client proteins. J. Clin. Invest. 2007, 117, 648-658. 
137. Dickey, C. A.; Eriksen, J.; Kamal, A.; Burrows, F.; Kasibhatla, S.; Eckman, C. B.; Hutton, M.; 
Petrucelli, L. Development of a high thoughput drug screening assay for the detection of changes 
in tau levels - proof of concept with Hsp90 inhibitors. Curr. Alzheimer Res. 2005, 2, 231-238. 
138. Evans, C. G.; Wisen, S.; Gestwicki, J. E. Heat shock proteins 70 and 90 inhibit early stages of 
amyloid -(1-42) aggregation in vitro. J. Biol. Chem. 2006, 281, 33182-33191. 
139. Ansar, S.; Burlison, J. A.; Hadden, M. K.; Yu, X. M.; Desino, K. E.; Bean, J.; Neckers, L.; 
Audus, K. L.; Michaelis, M. L.; Blagg, B. S. J. A non-toxic Hsp90 inhibitor protects neurons 
from A-induced toxicity Bioorg. Med. Chem. Lett. 2007, 17, 1984-1990. 
140. DeBoer, C.; Meulman, R. J.; Wnuk, R. J.; Peterson, D. H. Geldanamycin, a new antibiotic. J. 
Antibiotics 1970, 23, 442-447. 
141. Whitesell, L.; Mimnaugh, E. G.; De Costa, B.; Myers, C. E.; Neckers, L. M. Inhibition of heat 
shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: 
essential role for stress proteins in oncogenic transformation. P. Natl. Acad. Sci. 1994, 91, 8324-
8328. 
142. Schulte, T. W.; Akinaga, S.; Soga, S.; Sullivan, W.; Stensgard, B.; Toft, D.; Neckers, L. M. 
Antibiotic Radicicol Binds to the N-Terminal Domain of Hsp90 and Shares Important Biological 
Activities with Geldanamycin. Cell Stress Chaperones. Cell Stress Chaperon. 1998, 3, 100-108. 
143. Sharma, S. V.; Agatsuma, T.; Nakano, H. Targeting of the protein chaperone, HSP90, by the 
transformation suppressing agent, radicicol. Oncogene 1998, 16, 2639-2645. 
144. Benchekroun, N. M.; Myers, C. E.; Sinha, B. K. Free radical formation by ansamycin 
benzoquinone in human breast tumor cells: implications for cytotoxicity and resistance. Free 
Radic. Biol. Med. 1994, 17, 191-200. 
145. Samuni, Y.; Ishii, H.; Hyodo, F.; Samuni, U.; Krishna, M. C.; Goldstein, S.; Mitchell, J. B. 
Reactive oxygen species mediate hepatotoxicity induced by the Hsp90 inhibitor geldanamycin 
and its analogues. Free Radic. Biol. Med. 2010, 48, 1559-1563. 
146. Banerji, U.; O'Donnell, A.; Scurr, M.; Pacey, S.; Stapleton, S.; Asad, Y.; Simmons, L.; Maloney, 
A.; Raynaud, F.; Campbell, M.; Walton, M.; Lakhani, S.; Kaye, S.; Workman, P.; Judson, I. 
Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-
demethoxygeldanamycin in patients with advanced malignancies. J. Clin. Oncol. 2005, 23, 4152-
4161. 
147. Modi, S.; Stopeck, A. T.; Gordon, M. S.; Mendelson, D.; Solit, D. B.; Bagatell, R.; Weining, M.; 
Wheler, J.; Rosen, N.; Norton, L.; Cropp, G. F.; Johnson, R. G.; Hannah, A. L.; Hudis, C. A. 
Combination of Trastuzumab and Tanespimycin (17-AAG, KOS-953) is safe and active in 
Trastuzumab-refractory Her2 overexpressing breast cancer: A Phase I dose-escalation study. J. 
Clin. Oncol. 2007, 25, 5410-5417. 
33 
148. Schnur, R. C.; Corman, M. L.; Gallaschun, R. J.; Cooper, B. A.; Dee, M. F.; Doty, J. L.; Muzzi, 
M. L.; DiOrio, C. I.; Barbacci, E. G.; Miller, P. E.; Pollack, V. A.; Savage, D. M.; Sloan, D. E.; 
Pustilnik, L. R.; Moyer, J. D.; Moyer, M. P. erB-2 Oncogene inhibition by geldanamycin 
derivatives: synthesis, mechanism of action, and structure-activity relationships. J. Med. Chem. 
1995, 38, 3813-3820. 
149. Schnur, R. C.; Corman, M. L.; Gallaschun, R. J.; Cooper, B. A.; Dee, M. F.; Doty, J. L.; Muzzi, 
M. L.; Moyer, J. D.; DiOrio, C. I.; Barbacci, E. G.; Miller, P. E.; O'Brien, A. T.; Foster, M. J.; 
Pollack, B. A.; Savage, D. M.; Sloan, D. E.; Pustilnik, L. R.; Moyer, M. P. Inhibition of the 
oncogene product p185erbB-2 in vitro and in vivo by geldanamycin and dihydrogeldanamycin 
derivatives. J. Med. Chem. 1995, 1995, 3806-3812. 
150. Biamonte, M. A.; Van de Water, R.; Arndt, J. W.; Scannevin, R. H.; Perret, D.; Lee, W. Heat 
shock protein 90: inhibitors in clinical trials. J. Med. Chem. 2010, 53, 3-17. 
151. Gao, Z.; Garcia-Echeverria, C.; Jensen, M. R. Hsp90 inhibitors: Clinical development and future 
opportunities in oncology therapy. Curr. Opin. Drug Discov. Devel. 2010, 13, 193-202. 
152. Kim, Y. S.; Alarcon, S. V.; Lee, S.; Lee, M. J.; Giaccone, G.; Neckers, L.; Trepel, J. B. Update on 
Hsp90 inhibitors in clinical trial. Curr. Top. Med. Chem. 2009, 9, 1479-1492. 
153. Banerji, U. Preclinical and Clinical Activity of the Molecular Chaperone Inhibitor 17-Allylamino, 
17-Demethoxygeldanamycin in Malignant Melanoma. Proc. Am. Assoc. Cancer Res. 2003, 44, 
677. 
154. Sausville, E. A. Clinical Development of 17-Allylamino, 17-demethoxygeldanamycin. Curr. 
Cancer Drug Tar. 2003, 3, 377-383. 
155. Brandt, G. E.; Blagg, B. S. J. Alternate strategies of Hsp90 modulation for the treatment of cancer 
and other diseases. Curr. Top. Med. Chem. 2009, 9, 1447-1461. 
156. Marcu, M. G.; Chadli, A.; Bouhouche, I.; Catelli, M. G.; Neckers, L. The heat shock protein 90 
antagonist novobiocin interacts with a previously unrecognized ATP-binding domain in the 
carboxyl terminus of the chaperone. J. Biol. Chem. 2000, 2000, 37181-37186. 
157. Marcu, M. G.; Schulte, T. W.; Neckers, L. Novobiocin and related coumarins and depletion of 
heat shock protein 90-dependent signalling proteins. J. Natl. Cancer Inst. 2000, 92, 242-248. 
158. Garnier, C.; Lafitte, D.; Tsvetkov, P. O.; Barbier, P.; Leclerc-Devin, J.; Millot, J. M.; Briand, C.; 
Makarov, A. A.; Catelli, M. G.; Peyrot, V. Binding of ATP to heat shock protein 90: evidence for 
an ATP-binding site in the C-terminal domain. J. Biol. Chem. 2002, 277, 12208-12214. 
159. Yun, B.-G.; Huang, W.; Leach, N.; Hartson, S. D.; Matts, R. L. Novobiocin induces a distinct 
conformation of Hsp90 and alters Hsp90-cochaperone-client interactions. Biochemistry 2004, 43, 
8217-8229. 
160. Matts, R. L.; Manjarrez, J. R. Assays for identification of Hsp90 inhibitors and biochemical 
methods for discriminating their mechanism of action. Curr. Top. Med. Chem. 2009, 9, 1462-
1478. 
161. Allan, R. K.; Mok, D.; Ward, B. K.; Ratajczak, T. Modulation of chaperone function and 
cochaperone interaction by novobiocin in the C-terminal domain of Hsp90: evidence that 
coumarin antibiotics disrupt Hsp90 dimerization. J. Biol. Chem. 2006, 281, 7161-7171. 
162. Burlison, J. A.; Avila, C.; Vielhauer, G.; Lubbers, D. J.; Holzbeierlein, J.; Blagg, B. S. J. 
Development of novobiocin analogues that manifest anti-proliferative activity against several 
cancer cell lines. J. Org. Chem. 2008, 73, 2130-2137. 
163. Burlison, J. A.; Blagg, B. S. J. Synthesis and Evaluation of Coumermycin A1 Analogues that 
Inhibit the Hsp90 Protein Folding Machinery. Org. Lett. 2006, 8, 4855-4858. 
164. Burlison, J. A.; Neckers, L.; Smith, A. B.; Maxwell, A.; Blagg, B. S. J. Novobiocin:  Redesigning 
a DNA Gyrase Inhibitor for Selective Inhibition of Hsp90. J. Am. Chem. Soc. 2006, 128, 15529-
15536. 
165. Donnelly, A.; Blagg, B. S. J. Novobiocin and additional inhibitors of the Hsp90 C-terminal 
nucleotide binding pocket. Curr. Med. Chem. 2008, 15, 2702-2717. 
34 
166. Donnelly, A.; Mays, J. R.; Burlison, J. A.; Nelson, J. T.; Vielhauer, G.; Holzbeierlein, J.; Blagg, 
B. S. J. The design, synthesis, and evaluation of coumarin ring derivatives of the novobiocin 
scaffold that exhibit antiproliferative activity. J. Org. Chem. 2008, 73, 8901-8920. 
167. Donnelly, A. C.; Zhao, H.; Reddy, K. B.; Blagg, B. S. J. Cytotoxic sugar analogues of an 
optimized novobiocin scaffold. Med. Chem. Comm. 2010, 1, 165-170. 
168. Shelton, S. N.; Shawgo, M. E.; Matthews, S. B.; Lu, Y.; Donnelly, A. C.; Szabla, K.; Tanol, M.; 
Vielhauer, G. A.; Rajewski, R. A.; Matts, R. L.; Blagg, B. S.; Robertson, J. D. KU135, a novel 
novobiocin-derived C-terminal inhibitor of the 90-kDa heat shock protein, exerts potent 
antiproliferative effects in human leukemic cells. Mol. Pharmacol. 2009, 76, 1314-1322. 
169. Zhao, H.; B., R. K.; Blagg, B. S. J. Synthesis and Evaluation of Noviose Replacements on 
Novobiocin That Manifest Antiproliferative Activity. ACS Med. Chem. Lett 2010, 1, 311-315. 
170. Yu, X. M.; Shen, G.; Neckers, L.; Blake, H.; Holzbeierlein, J.; Cronk, B.; Blagg, B. S. Hsp90 
inhibitors identified from a library of novobiocin analogues. J. Am. Chem. Soc. 2005, 127, 12778-
12779. 
171. Kusuma, B. R.; Peterson, L. B.; Zhao, H.; Vielhauer, G.; Holzbeierlein, J.; Blagg, B. S. J. 
Targeting the heat shock protein 90 dimer with dimeric inhibitors. J. Med. Chem. 2011, 54, 6234-
6253. 
172. Zhao, H.; Donnelly, A. C.; Kusuma, B. R.; Brandt, G. E. L.; Brown, D.; Rajewski, R. A.; 
Vielhauer, G.; Holzbeierlein, J.; Cohen, M. S.; Blagg, B. S. J. Engineering an Antibiotic to Fight 
Cancer: Optimization of the Novobiocin Scaffold to Produce Anti-proliferative Agents. J. Med. 
Chem. 2011, 54, 3839-3853. 
173. Peterson, L. B.; Blagg, B. S. J. Click chemistry to probe Hsp90: Synthesis and evaluation of a 
series of triazole-containing novobiocin analogues. Bioorg. Med. Chem. Lett. 2010, 20, 3957-
3960. 
174. Palermo, C. M.; Westlake, C. A.; Gasiewicz, T. A. Epigallocatechin gallate inhibits aryl 
hydrocarbon receptor gene transcription through an indirect mechanism involving binding to a 90 
kDa heat shock protein. Biochemistry 2005, 44, 5041-5052. 
175. Sreedhar, A. S.; Soti, C.; Csermely, P. Inhibition of Hsp90: a new strategy for inhibiting protein 
kinases. Biochim. Biophys. Acta. 2004, 1697, 233-242. 
176. Itoh, H.; Ogura, M.; Komatsuda, A.; Wakui, H.; Miura, A. B.; Tashima, Y. A novel chaperone-
activity-reducing mechanism of the 90-kDa molecular chaperone Hsp90. Biochem. J. 1999, 343, 
697-703. 
177. Kimura, H.; Yukitake, H.; Tajima, Y.; Suzuki, H.; Chikatsu, T.; Morimoto, S.; Funabashi, Y.; 
Omae, H.; Ito, T.; Yoneda, Y.; Takizawa, M. ITZ-1, a Client-selective Hsp90 inhibitor, 
efficiently induces heat shock factor 1 activation. Chem. Biol. 2010, 17, 18-27. 
178. Roe, S. M.; Ali, M. M.; Meyer, P.; Vaughan, C. K.; Panaretou, B.; Piper, P. W.; Prodromou, C.; 
Pearl, L. H. The Mechanism of Hsp90 regulation by the protein kinase-specific cochaperone 
p50(cdc37). Cell 2004, 116, 87-98. 
179. Siligardi, G.; Panaretou, B.; Meyer, P.; Singh, S.; Woolfson, D. N.; Piper, P. W.; Pearl, L. H.; 
Prodromou, C. Regulation of Hsp90 ATPase activity by the co-chaperone Cdc37p/p50
cdc37
. J. 
Biol. Chem. 2002, 277, 20151-20159. 
180. Smith, J. R.; Clarke, P. A.; de Billy, E.; Workman, P. Silencing the cochaperone CDC37 
destabilizes kinase clients and sensitizes cancer cells to HSP90 inhibitors. Oncogene 2008, 28, 
157-169. 
181. Sreeramulu, S.; Gande, S. L.; Göbel, M.; Schwalbe, H. Molecular mechanism of inhibition of the 
human protein complex Hsp90–Cdc37, a kinome chaperone–cochaperone, by triterpene Celastrol. 
Angew. Chem. Int. Ed. 2009, 48, 5853-5855. 
182. Trott, A.; West, J. D.; Klaić, L.; Westerheide, S. D.; Silverman, R. B.; Morimoto, R. I.; Morano, 
K. A. Activation of heat shock and antioxidant responses by the natural product Celastrol: 
Transcriptional signatures of a thiol-targeted molecule. Mol. Biol. Cell 2008, 19, 1104-1112. 
35 
183. Westerheide, S. D.; Bosman, J. D.; Mbadugha, B. N. A.; Kawahara, T. L. A.; Matsumoto, G.; 
Kim, S.; Gu, W.; Devlin, J. P.; Silverman, R. B.; Morimoto, R. I. Celastrols as inducers of the 
heat shock response and cytoprotection. J. Biol. Chem. 2004, 279, 56053-56060. 
184. Davenport, J.; Manjarrez, J. R.; Peterson, L.; Krumm, B.; Blagg, B. S. J.; Matts, R. L. Gambogic 
Acid, a natural product inhibitor of Hsp90. J. Nat. Prod. 2011, 74, 1085-1092. 
185. Yi, F.; Regan, L. A Novel class of small molecule inhibitors of Hsp90. ACS Chem. Biol. 2008, 3, 
645-654. 
186. Yi, F.; Zhu, P.; Southall, N.; Inglese, J.; Austin, C. P.; Zheng, W.; Regan, L. An AlphaScreen
TM
-
based high-throughput screen to identify inhibitors of Hsp90-cochaperone interaction. J. Biomol. 
Screen. 2009, 14, 273-281. 
187. Conde, R.; Belak, Z. R.; Nair, M.; O'Carroll, R. F.; Ovsenek, N. Modulation of Hsf1 activity by 
novobiocin and geldanamycin. Biochem. Cell Biol. 2009, 87, 845-851. 
188. McCollum, A. K.; TenEyck, C. J.; Stensgard, B.; Morlan, B. W.; Ballman, K. V.; Jenkins, R. B.; 
Toft, D. O.; Erlichman, C. P-Glycoprotein–mediated resistance to Hsp90-directed therapy is 
eclipsed by the heat shock response. Cancer Res. 2008, 68, 7419-7427. 
189. Bagatell, R.; Paine-Murrieta, G. D.; Taylor, C. W.; Pulcini, E. J.; Akinaga, S.; Benjamin, I. J.; 
Whitesell, L. Induction of a heat shock factor 1-dependent stress response alters the cytotoxic 
activity of Hsp90-binding agents. Clin. Cancer Res. 2000, 6, 3312-3318. 
190. Zuo, J.; Rungger, D.; Voellmy, R. Multiple layers of regulation of human heat shock transcription 
factor 1. Mol. Cell Biol. 1995, 15, 4319-4330. 
191. Xia, W.; Voellmy, R. Hyperphosphorylation of heat shock transcription factor 1 is correlated with 
transcriptional competence and slow dissociation of active factor trimers. J. Biol. Chem. 1997, 
272, 4094-4102. 
192. Holzbeierlein, J.; Windsperger, A.; Vielhauer, G. Hsp90: A Drug Target? Curr. Oncol. Rep. 
2010, 12, 95-101. 
193. Ishihara, Y.; Ishii, S.; Sakai, Y.; Yamamura, N.; Onishi, Y.; Shimamoto, N. Crucial role of 
cytochrome P450 in hepatotoxicity induced by 2,3-dimethoxy-1,4-naphthoquinone in rats. J. App. 
Tox. 2011, 31, 173-178. 
194. Ishihara, Y.; Shimamoto, N. A Role of Cytochrome P450 in Quinone-Induced Hepatotoxicity. 
Hepatotoxicity; John Wiley & Sons, Ltd, 2008, 287-297. 
195. Berlin, V.; Haseltine, W. A. Reduction of adriamycin to a semiquinone-free radical by NADPH 
cytochrome P-450 reductase produces DNA cleavage in a reaction mediated by molecular 
oxygen. J. Biol. Chem. 1981, 256, 4747-4756. 
196. Brunmark, A.; Cadenas, E. Redox and addition chemistry of quinoid compounds and its 
biological implications. Free Radic. Biol. Med. 1989, 7, 435-437. 
197. Perrin, M. J.; Subbiah, R. N.; Vandenberg, J. I.; Hill, A. P. Human ether-a-go-go related gene 
(hERG) K+ channels: Function and dysfunction. Prog. Biophys. Mol. Bio. 2008, 98, 137-148. 
198. Vandenberg, J. I.; Walker, B. D.; Campbell, T. J. HERG K+ channels: friend and foe. Trends 
Pharmacol. Sci. 2001, 22, 240-246. 
199. Fermini, B.; Fossa, A. A. The impact of drug-induced QT interval prolongation on drug discovery 
and development. Nat. Rev. Drug Discov. 2003, 2, 439-447. 
200. Brown, A. M. hERG Assay, QT Liability, and Sudden Cardiac Death. Cardiac Safety of 
Noncardiac Drugs; Humana Press, 2005, 67-81. 
201. Wible, B. A.; Hawryluk, P.; Ficker, E.; Kuryshev, Y. A.; Kirsch, G.; Brown, A. M. HERG-Lite: 
A novel comprehensive high-throughput screen for drug-induced hERG risk. J. Pharmacol. 
Toxicol. 2005, 52, 136-145. 
202. Ficker, E.; Dennis, A. T.; Wang, L.; Brown, A. M. Role of the cytosolic chaperones Hsp70 and 
Hsp90 in maturation of the cardiac potassium channel hERG. Circ. Res. 2003, 92, e87-e100. 
203. Nanduri, J.; Bergson, P.; Wang, N.; Ficker, E.; Prabhakar, N. R. Hypoxia inhibits maturation and 
trafficking of hERG K+ channel protein: Role of Hsp90 and ROS. Biochem. Biophys. Res. 
Commun. 2009, 388, 212-216. 
36 
204. Elfiky, A.; Saif, M. W.; Beeram, M.; Brien, S. O.; Lammanna, N.; Castro, J. E.; Woodworth, J.; 
Perea, R.; Storgard, C.; Hoff, D. D. V. J. Clin. Oncol. 26: 2008 (May 20 suppl; abstr 2503). 
205. Rajan, A.; Kelly, R. J.; Trepel, J. B.; Kim, Y. S.; Alarcon, S. V.; Kummar, S.; Gutierrez, M.; 
Crandon, S.; Zein, W. M.; Jain, L.; Mannargudi, B.; Figg, W. D.; Houk, B. E.; Shnaidman, M.; 
Brega, N.; Giaccone, G. A Phase I Study of PF-04929113 (SNX-5422), an Orally Bioavailable 
Heat Shock Protein 90 Inhibitor, in Patients with Refractory Solid Tumor Malignancies and 
Lymphomas. Clin. Cancer Res. 2011, 17, 6831-6839. 
206. Wu, W.-C.; Wu, M.-H.; Chang, Y.-C.; Hsieh, M.-C.; Wu, H.-J.; Cheng, K.-C.; Lai, Y.-H.; Kao, 
Y.-H. Geldanamycin and its analog induce cytotoxicity in cultured human retinal pigment 
epithelial cells. Exp. Eye Res. 2010, 91, 211-219. 
207. Solit, D. B.; Chiosis, G. Development and application of Hsp90 inhibitors. Drug Discov. Today 
2008, 13, 38-43. 
208. Duerfeldt, A. S.; Blagg, B. S. J. Hydrating for Resistance to Radicicol. ACS Chem. Biol. 2009, 4, 
245-247. 
209. Prodromou, C.; Nuttall, J. M.; Millson, S. H.; Roe, S. M.; Sim, T.-S.; Tan, D.; Workman, P.; 
Pearl, L. H.; Piper, P. W. Structural basis of the radicicol resistance displayed by a fungal Hsp90. 
ACS Chem. Biol. 2009, 4, 289-297. 
210. Kelland, L. R.; Sharp, S. Y.; Rogers, P. M.; Myers, T. G.; Workman, P. DT-Diaphorase 
expression and tumor cell sensitivity to 17-allylamino,17-demethoxygeldanamycin, an inhibitor 
of heat shock protein 90. J. Natl. Cancer Inst. 1999, 91, 1940-1949. 
211. Guo, W.; Reigan, P.; Siegel, D.; Zirrolli, J.; Gustafson, D.; Ross, D. Formation of 17-Allylamino-
demethoxygeldanamycin (17-AAG) hydroquinone by NAD(P)H:Quinone Oxidoreductase 1: 
Role of 17-AAG hydroquinone in heat shock protein 90 inhibition. Cancer Res. 2005, 65, 10006-
10015. 
212. Guo, W.; Reigan, P.; Siegel, D.; Zirrolli, J.; Gustafson, D.; Ross, D. The bioreduction of a series 
of benzoquinone ansamycins by NAD(P)H:Quinone oxidoreductase 1 to more potent heat shock 
protein 90 inhibitors, the hydroquinone ansamycins. Mol. Pharmacol. 2006, 70, 1194-1203. 
213. Kelsey, K. T.; Ross, D.; Traver, R. D.; Christiani, D. C.; Zuo, Z. F.; Spitz, M. R.; Wang, M.; Xu, 
X.; Lee, B. K.; Schwartz, B. S.; Wiencke, J. K. Ethnic variation in the prevalence of a common 
NAD(P)H quinone oxidoreductase polymorphism and its implications for anti-cancer 
chemotherapy. Brit. J. Cancer 1997, 76, 852-854. 
214. Belinsky, M.; Jaiswal, A. K. NAD(P)H:quinone oxidoreductase1 (DT-diaphorase) expression in 
normal and tumor tissues. Cancer Metastasis Rev. 1993, 12, 103-117. 
215. Fitzsimmons, S. A.; Workman, P.; Grever, M.; Paull, K.; Camalier, R.; Lewis, A. D. Reductase 
enzyme expression across the national cancer institute tumor cell line panel: correlation with 
sensitivity to Mitomycin C and EO9. J. Natl. Cancer Inst. 1996, 88, 259-269. 
216. Robertson, N.; Stratford, I. J.; Houlbrook, S.; Carmichael, J.; Adams, G. E. The sensitivity of 
human tumour cells to quinone bioreductive drugs: What role for DT-diaphorase? Biochem. 
Pharmacol. 1992, 44, 409-412. 
 
 
37 
Chapter II 
Exploration of the Hsp90 C-terminal Binding Site 
I. Introduction 
Hsp90 is the core component of a chaperone machine that modulates the folding, 
activation, and stability of more than 200 substrates. Hsp90 functions by undergoing a series of 
conformational changes that are driven by the binding and hydrolysis of ATP, which are 
modulated through Hsp90’s interactions with a variety of co-chaperones and partner proteins.
1-2
  
Because Hsp90-dependent clients are directly associated with all six hallmarks of cancer,
3-4
 
Hsp90 is under intense investigation as a pharmacological target for the treatment of cancer.
5-6
 
Hsp90 contains druggable sites at both its N- and C-terminal domains. High affinity 
Hsp90 inhibitors that bind the Hsp90 N-terminal nucleotide binding site are well characterized, 
as they have been co-crystallized with this domain (i.e., geldanamycin and radicicol).
7-8
 In fact, 
several N-terminal inhibitors are currently in clinical trials for the treatment of cancer.
9-10
 In 
Figure 11. C-terminal Hsp90 inhibitors. 
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2000, Neckers and co-workers identified the first C-terminal inhibitor of Hsp90 by 
demonstrating the ability of the Hsp90 C-terminus to bind novobiocin (NB) and proposed this 
domain to represent a nucleotide–binding site that allosterically regulates nucleotide binding at 
the N-terminus.
11-12
 
Not only does NB inhibit Hsp90 function by binding to the C-terminus of Hsp90, but 
related family members chlorobiocin (CB) and coumermycin A1 also display Hsp90 inhibitory 
profiles that are different from those manifested by N-terminal inhibitors (Figure 11). In 
addition, C-terminal inhibitors exhibit unique effects on Hsp90’s conformation, activity, and 
interactions with co-chaperones and clients,
11-14
 highlighting this site as a potential target for 
Hsp90 modulation. Unfortunately, the mechanism of action for Hsp90 “C-terminal inhibitors” 
has not been adequately pursued in large part due to their poor pharmacological potency (100-
700 µM) and the lack of concrete structural data regarding the C-terminal binding site.
11-12,14-15
 
A. C-terminal Domain Structure 
The C-terminal domain (CTD) of Hsp90 mediates dimerization of the chaperone. Prior to 
crystal structure determination, several groups used Native polyacrylamide gel electrophoresis 
(PAGE), sedimentation, circular dichroism, and other spectroscopic techniques to determine the 
oligomeric state and overall topology of Hsp90. It was evident from these studies that Hsp90 was 
predominantly homodimeric in nature. In 1995, Nemoto and co-workers used mutational 
analysis to determine the domain of Hsp90 that was responsible for dimerization. They found 
that residues 533-732 (hHsp90α) in the CTD were sufficient to form dimers, and furthermore 
postulated that duplicate interactions existed between the two monomers, i.e. the same residues 
on each monomer were responsible for dimerization and that the dimerization domain was 
symmetrical.
16
 The first crystal structure of the Hsp90 CTD was solved in 2004 and confirmed 
39 
Figure 12. Structure of HtpG C-Terminal Domain. A.) Overall structure of the CTD and B.) 4-Helix 
bundle dimerization domain. One monomer represented in blue, the other in red. Helices labeled H1-
H5, subscript denotes different monomers; strands of β-sheet labeled a-c. 
prior work by Nemoto et al. Harris and co-workers solved the structure of high temperature 
protein-G (HtpG), the bacterial homologue of Hsp90 to 2.6 Å (Figure 12A).
17
 This crystal 
structure provided insights into how this domain modulates the function of Hsp90. The Hsp90 
CTD is comprised of 5 α-helices (H1 – H5) and a 3-stranded anti-parallel β-sheet. Helix 1 (H1) 
connects the middle domain (MD) to the β-sheet. H1 leads directly to strands a and b, while H2 
is located in the loop between strands b and c. Strand c is followed by the three helices H3, H4, 
and H5, while the CTD terminates at the MEEVD sequence recognized by tetratricopeptide 
repeat containing proteins. HtpG and other prokaryotic Hsp90s do not contain the MEEVD motif 
40 
so this moiety was not observed in the HtpG crystal structure.   
A four-helix bundle was evident as the major contributor to CTD dimerization. Helix 4 
and Helix 5 from each monomer are arranged with C2 symmetry and maintain hydrophobic 
interactions with each other (Figure 12B). In addition, the dissociation constant, KD, for 
dimerization of this domain was determined to be 24 nM, which correlates well with the yeast 
Hsp90 CTD dimerization KD of 60 nM.
17-18
 Another important feature displayed in the CTD 
structure is the largely amphiphathic helix (H2) that projects towards the N-terminus in a region 
that is solvent exposed. This helix is believed to play a role in the binding of client proteins and 
mediating protein-protein interactions. Since 2004, subsequent structures of the CTD have been 
solved including the full length yeast Hsp90 (hsp82) and the full length human ER isoform 
(Grp94).
19-21
 Overlays of these structures highlight conservation of the 4-helix bundle, while 
slight reorientation of the other helices and the beta sheet is observed amongst the different 
structures (Figure 13).  
Figure 13. Overlay of Hsp90 CTD from various species, A.) Overlay of yeast Hsp82 CTD (red) and 
bacterial HtpG CTD (blue); B.) Overlay of canis lupus Grp94 (dog, green) CTD and bacterial HtpG 
CTD (blue).  
41 
SAXS and cryo-electron microscopy studies have clearly demonstrated the Hsp90 C-
terminus adopts distinct conformations.
22-24
 In addition, as first suggested by Agard and co-
workers, Hugel et al. have recently confirmed that the Hsp90 C-terminus undergoes significant 
conformational changes including opening of the dimerization domain. This equilibrium shifts 
from 43% CTD open (no nucleotide) to either 58% or 77% CTD open when ATP or ADP is 
bound, respectively.
25
  Opening of the CTD can be inhibited by the Hsp90 co-chaperone Hop 
(yeast = Sti1). The opening of the CTD provides a potential mechanism for client protein release, 
much like the mechanism of the related GHKL family member, DNA gyrase, which passes 
double stranded DNA through the protein. In addition, Retzlaff et al. identified a conserved 
cysteine residue in the Hsp90 CTD that upon nitrosylation effects Hsp90 conformation, ATPase 
activity, and chaperone function.
26
 This cysteine residue has been named the “switch point,” 
highlighting its importance in regulating chaperone activity. The structural information that has 
been collected over the last 15 years has been essential in understanding and interpreting the 
function of Hsp90, specifically the function of its CTD. 
B. C-terminal Domain Function and Modulation 
 The Hsp90 CTD plays several integral roles in maintaining chaperone function. The CTD 
mediates dimerization, contains a binding site for co-chaperones that influence the ATPase 
activity, contains a substrate binding site, and potentially houses a second nucleotide binding 
site. In fact, yeast engineered to express a CTD-deficient Hsp90 (yHsp82) resulted in an 
organism with compromised viability.
27
 The first role elucidated for the Hsp90 CTD was its 
ability and necessity to mediate dimerization. Nemoto et al. identified the last 200 residues in the 
CTD to be necessary for dimerization while deletion of the N-terminal domain (NTD) had no 
effect on dimerization.
16
 They also noted that the last 129 residues are not sufficient to form 
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dimers, which indicates that the 4-helix bundle is not sufficient for dimerization, as it resides 
within the last 100 residues. Moreover, deletion of residues 665-681 (hHsp90α) resulted in 
Hsp90 monomers that were unable to hydrolyze ATP.
28-29
 Residues 665-681 are contained 
within the 4-helix bundle (residues hHsp90α 661-696). Using the yeast homologue of Hsp90, 
Hsp82, which contains no cysteine residues, Wegele and co-workers engineered several Hsp82 
mutants that express C-terminal cysteines that could be chemically ligated to form disulphide-
containing dimers.
30
 These mutants actually manifested similar ATPase activities as the wild 
type protein, suggesting that dimerization is the main function of the CTD. Mutants lacking both 
the CTD and MD manifested significantly diminished ATPase activity (2% of wt) indicating that 
the MD and CTD must also be present to provide additional interactions with the NTD to 
promote ATP hydrolysis.
30
  
 The role of the CTD in chaperoning client proteins was first realized in 1997 when Yang 
and co-workers identified two separate regions of Hsp90 that were capable of preventing the 
aggregation of denatured polypeptides.
31
  These sites were identified in both the NTD and CTD, 
indicating that both Hsp90 termini play a role in stabilizing and chaperoning client proteins. It 
was later realized that the CTD chaperone site binds partially folded proteins independent of 
ATP binding but dependent upon the binding of partner proteins and co-chaperones.
32
 Many 
Hsp90 co-chaperones and partner proteins contain tetratricopeptide repeat (TPR) domains. This 
motif recognizes the MVEED sequence contained within the last five residues of the cytosolic 
Hsp90s (hHsp90α/β). Mutation of the Hsp90 MVEED domain to MAAVD prevented the 
interaction of Hsp90 with the co-chaperones Hop, Cyp40, FKBP51, and FKBP52.
29
 Surprisingly, 
in the same study by Chen et al., deletion of residues 665-681 (hHsp90α) also resulted in 
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diminished interactions with the above co-chaperones and p23, indicating that dimerization may 
also be critical for co-chaperone recognition and binding.
29
  
 In addition to mediating dimerization, facilitating co-chaperone binding, and housing 
client protein binding sites, the Hsp90 CTD also contains a putative nucleotide binding site. First 
described in 2000, Marcu and co-workers demonstrated that truncated proteins that contain only 
the Hsp90 CTD were able to bind immobilized ATP-sepharose.
11
 It was later demonstrated that 
this nucleotide binding site becomes accessible only upon occupation of the N-terminal ATP 
binding site.
33-34
 Using sequence alignment and topology prediction tools, this nucleotide binding 
site was proposed to represent a Rossman fold.
34
 However, this was later contested as the CTD 
nucleotide binding site did not bind nicotinamide adenine dinucleotide (NAD
+
), which is the 
nucleotide of choice for Rossman folds.
35
 The CTD binds both pyrimidine and purine-containing 
nucleotides when the NTD binding site is occupied. Both GTP and UTP are able to bind the 
CTD, unlike the NTD nucleotide binding site, which is specific for adenine-containing 
nucleotides.
35
 The CTD does not display ATPase activity, but instead has been hypothesized to 
regulate the various Hsp90 conformations.  
 Simultaneous with discovery of the CTD nucleotide binding site, the natural product 
Novobiocin (NB) was shown to bind within the CTD. NB is a natural product antibiotic 
previously known to bind DNA gyrase and originally was hypothesized to bind Hsp90’s NTD 
due to similarities in the ATP conformation when bound to both proteins.
36
 Hsp90 was shown to 
bind immobilized NB-sepharose, and was only competitively removed by the addition of other 
soluble coumarins or ATP, but not with N-terminal inhibitors, GDA or RDC.
12
 Subsequent 
studies with NB showed that NB prevented nucleotide binding to both the NTD and CTD 
nucleotide binding sites.
33
 The NB binding site was localized to residues 384-732 (hHsp90α) 
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through truncation studies. Surprisingly, NB competed for Hsp90 binding to immobilized GDA 
or RDC. In addition, NB was able to cause the proteasome-mediated degradation of ErbB2, v-
src, and Raf-1, three Hsp90-dependent client proteins. In subsequent studies by the same group, 
the NB binding site was further localized to residues 542-732 (hHsp90α), while the peptide 
corresponding to residues 666-680 (hHsp90α) was able to block NB binding.
11
 In addition, the 
deletion mutant, ∆661-681, failed to bind immobilized NB, which indicated the NB binding site 
and the CTD dimerization domain were overlapping. In the same study, NB was found to 
prevent interactions between Hsp90 and both Hsc70 and p23.
11
 Hsc70 is known to bind near the 
C-terminus, while p23 binds to the NTD, demonstrating cross-talk between the N- and C- 
termini, as NB causes structural reorganization in the NTD that prevents p23 binding. Prior to 
these studies, Hartson and co-workers demonstrated that molybdate prevents GDA from binding, 
inhibited firefly luciferase refolding while protected the CTD from proteolysis, and enhanced 
interactions with p23.
37
 At the time of this study, the CTD binding site had not been discovered, 
but in hindsight it can be rationalized that molybdate binds to the CTD to affect chaperone 
function and conformation. 
 Yun and co-workers determined the effect of NB on Hsp90 in rabbit reticulolysate.
14
 NB 
was able to inhibit the maturation of heme-regulated eIF2α kinase (HRI) and cause 
disassociation of Hsp70, p23, and FKBP52 from the chaperone complex, but did not cause 
disruption of the Hsp90-Hop or Hsp90-Cdc37 interactions. In the same study, NB and other C-
terminal inhibitors were shown to protect the Hsp90 CTD from proteolysis, presumably by 
altering its conformation and shielding specific residues from the protease. A related dimeric 
coumarin-containing antibiotic, coumermycin A1, prevented dimerization of the Hsp90 CTD.
13
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 C-terminal inhibitors exhibit unique effects on Hsp90’s conformation, activity, and 
interactions with co-chaperones and clients, highlighting this site as a target for Hsp90 
modulation. One of the most unique and important features of C-terminal inhibition is lack of 
induction of the heat shock response. The heat shock response represents one of the biggest 
detriments associated with N-terminal inhibition. Therefore, C-terminal inhibitors have garnered 
significant attention. Unfortunately, the mechanism of Hsp90 “C-terminal inhibitors” has not 
been adequately pursued in large part due to the poor pharmacological potency of first generation 
analogues (100-700 µM). Subsequent analogues of NB have been explored that manifest 
improved Hsp90-inhibitory and anti-cancer activity, however the inability to obtain co-crystal 
structures with these molecules bound to the chaperone has hampered further development. This 
chapter describes the pursuit of uncovering the Hsp90 C-terminal inhibitor binding site through 
molecular modeling, inhibitor design, and biochemical techniques. 
II. Development of a CoMFA for Hsp90 C-Terminal Inhibitors 
Although, initial development of C-terminal Hsp90 inhibitors based on the novobiocin 
scaffold has generated interesting lead compounds, further drug design has been hindered by the 
lack of concrete structural and biochemical data regarding the exact location of the binding 
pocket.
38-50
 At first, analogue design had been carried out without information regarding the 
nature of the binding pocket as no binding models existed for the C-terminal binding site. 
Consequently, we sought to develop a 3-dimensional quantitative structure-activity relationship 
(3D QSAR) model to describe the C-terminal binding site. A comparative molecular field 
analysis (CoMFA) was performed to correlate structural features with biological activity in a 
quantitative manner. Novobiocin analogues previously synthesized in the Blagg laboratory were 
used to generate the CoMFA (IC50 anti-proliferation = 500 nM to >100 M; See Materials and 
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Methods).
40,42
 The compounds were first aligned using the coumarin ring as the core moiety after 
energy minimization and partial charge assignment (Figure 14). A CoMFA was then generated 
in SYBYL v8.0, using partial least squares regression analysis, which correlates the biological 
activity (IC50 values experimentally determined) with the CoMFA parameters of sterics and 
electronics. The overall value of the CoMFA was analyzed using a 3-D cross-validated 
correlation score (Q
2
) using the leave-one-out technique. Compounds that caused the Q
2
 value to 
fall below 0.5 were considered outliers and eliminated from the data set, while a CoMFA with a 
cross-validated correlation score above 0.6 exhibits predictive value. Several iterations of 
compound removal were necessary, resulting in a final CoMFA model that utilized 72 
compounds and generated a Q
2
 value of 0.617. The statistical parameters of the CoMFA 
generated are shown in Table 4.  
Figure 14. Alignment of select Novobiocin analogues used in CoMFA generation. 
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Table 4. Statistical parameters for final CoMFA model. 
Statistical Parameter Value 
Q
2
 0.617 
Number of Components 6 
R
2
 0.919 
Predictive R
2
 0.880 
Standard Error of Prediction 0.184 
Fratio 90.4 
Field Contributions 
 
Steric 0.413 
Electrostatic 0.587 
 
The CoMFA parameters demonstrate the utility and reliability of this model, while the predicted 
IC50 values generated using the CoMFA model compare well with the actual IC50 values (Figure 
15, R
2
 = 0.88). The CoMFA model can by graphically displayed in contour maps that provide 
insights into the structural (both steric and electrostatic) properties that influence biological 
 
Figure 15. Plot of predicted LogIC50 versus experimentally derived LogIC50 values. 
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activity. 
The contour maps generated from this CoMFA using KU174 (IC50 10 M) and KU122 
(IC50 570 nM) as reference molecules are shown in Figure 16. Regions that tolerate steric bulk 
(green) are evident in Figure 16. Specifically the areas surrounding both the noviose sugar and 
the amide side chain (biaryl or indole) seem to accommodate steric bulk. In addition the 
coumarin 8-methyl seems to project towards a pocket that allows somewhat bulky substituents. 
Figure 16. Contour maps generated from CoMFA analysis. All fields shown for A.) KU174 and B.) 
KU122; C.) electrostatic fields for KU174; D.) steric fields for KU122; E.) chemical structures of the 
two novobiocin analogues KU174 and KU122; and F.) legend for CoMFA contour colors. 
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The 4-substituent of the biaryl ring does not seem to allow steric bulk, indicated by the yellow 
area.  
Red and blue contours describe the electrostatic contributions generated in the CoMFA.  
The indole contained within KU122 appears to provide an important hydrogen bond via its N–H 
bond (Figure 16B). Several other areas surrounding the amide side chain play an important 
electrostatic role in binding.  
This CoMFA provided insight into the nature of the C-terminal Hsp90 binding site and 
correlated well with observed structure-activity relationships (SAR) delineated through small 
molecule design and synthesis (Figure 17). Another group from Lanzhou University in China 
has also reported the development of a CoMFA and CoMSIA (comparative molecular similarity 
indices analysis) using 53 compounds synthesized in the Blagg laboratory.
51
 Their CoMFA 
analysis provided similar features to the one described above, but also suggested that an H-bond 
acceptor near the amide bond would increase activity. Although the CoMFA helped describe the 
 
Figure 17. Common structure activity relationships established through CoMFA and inhibitor design 
and synthesis; Adapted from Ref. 41. 
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nature of the Hsp90 C-terminal binding site, this method was plagued by several disadvantages. 
First, the CoMFA model only has predictive value for novel compounds within the IC50 range of 
the compounds that were used to design the CoMFA, 500 nM to >100 M. Second, the 
alignment strategy assumes one moiety of the input molecules is rigid and only binds in one 
orientation, in this case, the coumarin core. More realistically, the coumarin may bind in a 
manner that can accommodate other functionalities present in the molecule. For these reasons, 
we sought to pursue a more biochemical approach to interrogate the C-terminal binding site.  
III. Development of a C-terminal Binding Site Model  
To circumvent limitations imposed upon the rational development of NB analogues 
through a structure–based approach, the NB binding site located in the Hsp90 C-terminus was 
sought after via photolabile NB derivatives, which upon covalent attachment to Hsp90 could aid 
in elucidation of the Hsp90 C-terminal binding site. As revealed by co-crystal structures of NB 
bound to closely related enzymes (e.g., DNA gyrase/topoisomerase
52-53
), the active conformation 
of NB could then be docked, and subjected to a ligand-supported refinement followed by a 
systematic molecular dynamics (MD) based methodology to identify the binding site for NB and 
its analogues. 
A. Identification of the Novobiocin Binding Site in Hsp90’s C-terminal Domain  
In collaboration with the Matts Laboratory at 
Oklahoma State University, residues in the Hsp90 
CTD, proximal to the inhibitor binding site, were 
identified using a NB-based photoaffinity label.
54
 
Photolabile derivatives of NB were previously 
synthesized for the purpose of identifying the Hsp90 C-
Figure 18. Novobiocin derivatives 
used in photoaffinity labeling studies; 
From Ref. 54. 
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terminal binding site (Figure 18).
55
  As noted earlier, the Hsp90 C-terminus is resistant to 
proteolysis by trypsin in the presence of chlorobiocin. Similarly, compound 1a also protected the 
Hsp90 C-terminus from tryptic digest indicating that the photoaffinity probe bound Hsp90 in a 
manner similar to novobiocin and chlorobiocin.
14
 
Novobiocin analogues containing a photo-reactive azide moiety placed in the para- 
(1a/1b) or meta-position (2) were used in lieu of the phenol and prenyl side chain present in NB, 
respectively. A recombinant His-tagged Hsp90 C-terminal construct was incubated in the 
presence or absence of 1a followed by UV-irradiation. No change in the m/z of Hsp90CT was 
detected upon MALDI-TOF analysis of the Hsp90 C-terminus upon UV-irradiation in the 
absence of 1a (Figure 19A), however, in the presence of 1a a new polypeptide peak (m/z= 
25,125) with a mass approximately 545 Da greater than the parental peak (m/z= 24,580) was 
detected (Figure 19B). This mass corresponds to the molecular weight of compound 1a minus 
one molecule of N2.  To confirm 
that both the azide–containing 
molecule and the non-labeled 
novobiocin bind to the same 
location,  crosslinking studies were 
carried out in the presence of an 
equimolar concentration of NB 
and 1a, resulting in a >80% 
decrease in the intensity of the 
25,125 peak (Figure 19C), 
indicating the inhibitors bind 
 
Figure 19. Crosslinking of 1a to Hsp90CT is specific.  
Hsp90CT (A-C) or apomyoglobin (D) were UV irradiated in 
the presence of A.) DMSO; B/D.) 5 mM 1a; C.) 5 mM 1a 
plus 5 mM NB and analyzed by MALDI-TOF mass 
spectrometry; From Ref. 54. 
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competitively.  A small portion of the Hsp90CT was found to be modified by two molecules of 
1a, therefore an experiment was performed with 10-fold lower concentrations of the photolabile 
inhibitor. A significant reduction in the amount of doubly modified Hsp90CT was observed, 
indicating that the first binding event is most specific. To demonstrate crosslinking specificity, 
apomyoglobin was irradiated in the presence of 1a, and no crosslinking was observed, 
confirming selectivity of these compounds for Hsp90 (Figure 19D). Identical crosslinking peaks 
were detected when 2 was irradiated in the presence of Hsp90, confirming that azide placement 
on the benzamide side chain did not affect the reaction.  
To determine the peptide sequence to which the photoactivatable derivative was 
crosslinked, control and 1b-crosslinked and 2-crosslinked Hsp90 were digested with trypsin, and 
the masses of the tryptic peptides were analyzed by ultra-high mass accuracy Fourier transform 
ion cyclotron resonance (FTICR) mass spectroscopy (mass accuracy of 10 ppm). Crosslinking of 
2 is calculated to increase the theoretical mass of a crosslinked peptide by 527.1613 Da.  
Analysis of the data identified a peptide corresponding to a mass of ~527 amu greater than that 
predicted for an unlabeled peptide sequence, namely: 559-KKQEEK-564 or 560-KQEEKK-565 
(1316.6093/~MH1+ 789.4465+527.1540). Through analysis of the fragmentation pattern and the 
MS2 and MS3 spectra, the photolabile novobiocin derivatives were determined to bind alongside 
the peptide 559-KKQEEK-564, and attach directly to K560.  This segment is located in the 
Hsp90 C-terminus, within the region of the C-terminal fragment that is protected from 
proteolysis upon binding to chlorobiocin and novobiocin. 
B. Modeling of Novobiocin’s Conformation 
53 
To further refine the 
NB binding site in Hsp90, 
conformations of NB co-
crystallized with DNA 
gyrase/topoisomerase (PDB 
IDs: 1S14, 1AJ6, 1KIJ) were 
analyzed. NB was found to 
adopt a partially folded 
conformation in each of 
these structures (Figure 20). This conformation of NB was extracted and used to dock into the 
site of Hsp90 identified via photoaffinity labeling. 
 C. Modeling of the Hsp90 Novobiocin Binding Site 
The data generated from the photoaffinity labeling studies with NB provides information 
regarding the putative binding site of NB. After careful analysis of the homologous peptide in the 
full length, closed crystal structure of yeast Hsp90 (538-AEREKE-543), it was not clear whether 
a pocket large enough to accommodate NB was present in the regions flanking this peptide 
(Figure 21). Initial attempts to dock novobiocin into this crystal structure were unsuccessful. 
However in 2008, the solution structure of the bacterial Hsp90 homologue, HtpG, was 
determined by Agard and co-workers.
23
 As the full length yeast crystal structure depicts Hsp90 
in its closed, clamped conformation, it was postulated that the extended form, as found in 
solution, would unveil the C-terminal binding site. Generation of this open model allowed for 
identification of the C-terminal inhibitor binding site using the information garnered from the 
photoaffinity and proteolytic studies.  
Figure 20. Conformation of NB as bound to DNA gyrase used in 
molecular modeling studies with Hsp90 CTD. 
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 In an effort to correlate the binding site identified by photoaffinity studies with the open 
structure of Hsp90α, a homology model of hHsp90α was generated using the SAXS structure of 
HtpG as the template in collaboration with the Gennady Verkhivker Laboratory at the University 
of Kansas. The homology model of hHsp90α was constructed using software “Modeller”.
56
 The 
solution structure of HtpG (dimer) was used as a template for building of the model. The 
modeled structure was subsequently subjected to a molecular dynamics protocol for further 
refinement.  
Docking of NB into the hHsp90α homology model was guided by the following 
constraints: 1) Binding of NB to the C-terminal domain protects residues in the N-terminal 
region of the construct from proteolysis; 2) proteolytic fingerprinting identified the peptide 
KKQEEK in human Hsp90α as the site of crosslinking for a photo-reactive NB derivative; and 3) 
the bioactive conformation of NB as shown in Figure 20. NB was docked rigidly in the hHsp90α 
C-terminus by maintaining a distance constraint of 3.5Å between the hydroxyl of the noviose 
Figure 21. Hsp90 closed clamped crystal structure. A.) Full length yeast structure, yellow represents 
photoaffinity labeled peptide; B.) Close-up on Hsp90 CTD; PDB 2CG9. 
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 Figure 22. Modeled structure of the Novobiocin binding site in hHsp90α. A.) The Hsp90α homology 
model homodimer and the C-terminal binding site with NB (spheres) docked at the interface of two 
monomers (blue and yellow) B.) close-up of NB (grey sticks) docked in Hsp90α homology model, 
the crosslinked fragment (lines) and predicted hydrogen bonds (dashes) are depicted in magenta and 
C.) close-up of NB noviose (grey sticks) docked in Hsp90α homology model, predicted hydrogen 
bonds (dashes) are represented in magenta, D.) surface representation of Hsp90α homology model CT 
binding site with NB (grey sticks) docked. Only one molecule of NB is shown to be bound to Hsp90 
homodimer, an equivalent binding site contained on the other monomer has not been shown for 
clarity; From Ref. 54. 
56 
and the amide nitrogen of Asn686. A multiple sequence alignment of related proteins from 
different organisms indicated three conserved residues adjacent to the photoaffinity–labeled 
peptide fragment, Lys538, Lys558 and Glu562 in hHsp90α. Minimization of protein side chains 
with a distance constraint of 3.5 Å between NB and residues Asn686, Lys538, and Glu562 was 
carried out while keeping NB and the protein backbone rigid to allow relaxation of the side 
chains and minimization of negative interactions. The binding site was subsequently defined as 
residues that reside within 8Å of NB and were subjected to minimization while keeping the rest 
of the protein and NB fixed to remove unfavorable steric and hydrophobic contacts and to allow 
side chains to relax and to facilitate NB alignment in the cavity. The resulting complex was 
further refined by a short MD simulation (100ps). This Hsp90α-NB complex was found to be 
stable after simulation (RMSD<2Å). The interactions manifested between NB and Hsp90α are 
depicted in Figure 22. 
The NB binding site is located proximal to the 4-helix bundle, the CTD beta sheet and 
Helix 1 (Figure 22). It is evident from Figure 22B/C that NB maintains several interactions with 
multiples residues present in the binding site. These interactions can be summarized as follows: 
1) A hydrogen bond (HB) interaction between the noviose sugar hydroxyl of novobiocin and 
Asn686 (H5) and Thr540 of hHsp90α; 2) HB interactions between the oxygen of the prenylated 
hydroxylphenyl ring of novobiocin and both Asn590 and  Lys560 (H1) of hHsp90α, a residue 
identified via photoaffinity labeling studies; 3) the CO and -NH of the noviose carbamate of 
novobiocin maintain HB interactions with Glu537 and Gln682 (H5);  4) Thr594 provides HB 
interactions with the oxygen of the glycosidic bond linking the noviose and coumarin ring; and 
5) a HB interaction between the noviose methoxy group and Arg591. 
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Biochemically–guided modeling based on the open structure from bacterial Hsp90, HtpG, 
produced a human Hsp90 model that upon further refinement, unveiled the binding mode for 
Hsp90 C-terminal inhibitors. This mode of binding explains many of the previously observed 
biological and biochemical consequences that result upon Hsp90 C-terminal inhibition. 
D. Correlation to Observed Effects Resulting from C-Terminal Inhibition 
Although there have been previous attempts to model the NB binding site, the results 
were not consistent with available biochemical data. Prior models developed for the Hsp90 C-
terminal inhibitor binding site were generated using homology modeling, MD simulations, and 
pocket-finder algorithms.
57-58
 However, using biochemical analyses, affinity labeling, and 
homology modeling, we have identified a binding site for C-terminal Hsp90 inhibitors that 
supports prior biochemical studies. 
For example, Neckers and co-workers originally proposed the existence of a binding site 
in the Hsp90 C-terminus and determined that NB binding was localized to residues 542-732 
(hHsp90α).
11-12
 Additionally, it was demonstrated that addition of the C-terminal peptide 667-
680 (hHsp90α) reduced Hsp90’s ability to bind immobilized NB, and Hsp90 binding to 
immobilized NB could be competed with this peptide.
11
 In the model proposed, this peptide 
sequence is located in the α-helix proximal to the sugar binding pocket of NB, and is important 
for interactions with the noviose moiety on NB. Consistent with this pocket being adjacent to the 
NB binding site, Hartson and coworkers have shown that NB blocks the AC88 antibody (a 
monoclonal antibody that recognizes an epitope within the amino acids 668-684 in hHsp90α) 
from binding Hsp90, thus providing two key pieces of previously reported biochemical data that 
supports the location of this binding site.
14,37
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Furthermore, ATP binding plays an important role in the conformational reorganization 
of Hsp90, in a manner complementary to the dimerization of two Hsp90 monomers at the C-
terminus, which is essential for Hsp90 activity. Once dimerization occurs at the C-terminus, 
Hsp90 undergoes a complex conformational cycle that facilitates reorganization and folding of 
client proteins.
19,59
 The C-terminal inhibitor, Coumermycin A1, was shown to disrupt C-terminal 
dimerization, and halt the conformational cycle.
13
 In addition, the protein folding process 
involves a multitude of co-chaperones and partner proteins. Novobiocin and related antibiotics 
have been shown to disrupt interactions with partner proteins that bind Hsp90 to both the C- and 
N-terminus, i.e. Cdc37, p23, Hsc70, FKBP52 and PP5.
11,13-14
 Additionally, prior proteolysis 
experiments with NB and related family members demonstrate that C-terminal occupation 
protects Hsp90 from proteolysis by altering its conformational state. Specifically, NB shields 
Lys615 and Arg620 from cleavage. This result can be explained by the examination of Hsp90 in 
its various conformational states. Lys615 and Arg620 are solvent exposed on the surface of an 
alpha helix in the semi-closed and closed states. However, in the extended form, Lys615 and 
Arg620 are shielded by surrounding residues, and hence, are not accessible to proteases. 
Interestingly, the pivot point of Hsp90’s movement between the middle and C-terminal domains 
of Hsp90 (hHsp90α residue 550) is located within close proximity to this binding site.
21,23-24
 
Taken together, these data indicate that conformational changes within the C-terminus occur 
upon inhibitor binding and cause global conformational changes within the entire homodimer. 
Additionally, Retzlaff and co-workers have demonstrated through mutational analyses 
that Hsp90 is regulated by a switch point in its C-terminal domain.
26
 Mutation of the residue 
equivalent to Cys598 in hHsp90α (Ile538 in HtpG) altered Hsp90’s ATPase and chaperone 
activity, modified N-terminal and C-terminal domain associations, and shifted the 
59 
conformational equilibrium of Hsp90 within its ATPase cycle.
26
  In our model, Cys598 forms 
part of the NB binding pocket (Figure 22 B/C). Thus, the model suggests that C-terminal 
inhibitors have the ability to interact with and stabilize the region around this pivot point, and 
potentially lock the Hsp90 homodimer in a single conformation. Consequently, upon C-terminal 
occupation, the Hsp90 machinery is stalled in the open conformation, which results in protection 
of Lys615 and Arg620 from proteolysis, hinders N-terminal ATP hydrolysis, and prevents the 
binding of N-terminal inhibitors. Once again, occupation of this putative binding pocket in the 
Hsp90 C-terminus can finally explain previously observed biochemical observations. 
In addition, Hugel and coworkers recently determined the dynamics and kinetics of C-
terminal dimerization, whereby the C-terminus is capable of opening in the presence of N-
terminal ligands (i.e. ATP and ATP analogues). It was observed that N- and C-terminal 
dimerization is intimately related, and that C-terminal dimerization is not required for N-terminal 
dimerization. These findings suggest that the C-terminus is in constant flux, whereby a multitude 
of conformations exist.
25
 In the model presented herein, novobiocin predominantly interacts with 
one monomer of the Hsp90 homodimer. Together with the data presented by Hugel, it can be 
reasoned that small molecule binding of the Hsp90 C-terminus may occur while this domain is 
open, preventing dimerization and continuation through the catalytic cycle. Alternatively, C-
terminal inhibitors may bind after dimerization, preventing occupation of the N-terminal binding 
pocket by ATP, which is supported by prior studies by Marcu et al. whom demonstrated that 
novobiocin binding to the C-terminus prevented N-terminal occupation.
12
 
Hsp90 C-terminal inhibitors have garnered significant attention during the past decade, 
specifically due to problems associated with N-terminal inhibition as observed in the clinic.
60
 
Structural information regarding the C-terminus, especially the NB binding site, has been scarce, 
60 
and attempts at co-crystallization have been unsuccessful. Accordingly, effective analogue 
design and data analysis have been hindered. Therefore, we have utilized photoaffinity labeling 
and proteolytic studies to identify residues that form the NB binding site. Through elucidation of 
the cross-linked peptide and molecular modeling alongside the reported solution structure of 
Hsp90, potential binding sites were carefully evaluated. As a result of these studies and those 
before us, we are finally able to provide a binding site for NB and other C-terminal inhibitors 
that accounts for the biological activities manifested by NB. This model provides a new standard 
for the development of future Hsp90 inhibitors that target the C-terminal binding pocket. In 
addition to the biochemical approach used to elucidate the Hsp90 C-terminal binding site, 
interest in C-terminal inhibitor design and synthesis has been a central focus in the Blagg 
Laboratory to establish structure–activity relationships for this class of inhibitors.  
IV. Synthesis and Evaluation of a Series of Triazole Containing Novobiocin Analogues 
A series of triazole-containing novobiocin analogues has been designed, synthesized and 
their inhibitory activity determined.
61
 These compounds contain a triazole ring in lieu of the 
amide moiety present in the natural product. The anti-proliferative effects of these compounds 
were evaluated against two breast cancer cell lines (SKBr-3 and MCF-7) and manifested 
activities similar to their amide-containing counterparts. In addition, Hsp90-dependent client 
protein degradation was observed via western blot analyses, further supporting a common mode 
of Hsp90 inhibition for both structural classes. 
A. Rationale for the Development of Triazole Containing Novobiocin Analogues 
Since the discovery of the Hsp90 C-terminal binding site, analogues of novobiocin have 
been synthesized and evaluated, with many of the compounds manifesting micromolar anti-
proliferative activities.
38-44,48-50
 Modifications to both the coumarin core and benzamide side 
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chain have been pursued, resulting in the production of preliminary structure–activity 
relationships (Figure 16). The hydrogen bonding capabilities and the geometry of the amide 
bond appear to be important for novobiocin binding, however modifications to this moiety have 
not been evaluated for SAR. It was proposed that inclusion of 1,2,3-triazoles as a bioisosteric 
replacement for the amide 
moiety could facilitate SAR 
analysis for the aryl side chain 
by utilizing “click” chemistry 
while simultaneously 
examining the necessity of the amide. The triazole serves as an amide bond replacement due to 
similarities in spatial characteristics. In addition, it is metabolically stable to hydrolysis and 
easily incorporated into small molecules.
62-63
 Although similar, triazoles do exhibit different 
hydrogen bonding capabilities and an altered geometry as compared to their amide counterparts, 
which aids in further elucidation of SAR (Figure 23). For these reasons, a series of 1,2,3-triazole 
containing novobiocin analogues was prepared.  
B. Synthesis of Triazole Containing Novobiocin Analogues 
Synthesis of the 8-methyl coumarin core, as found in novobiocin, commenced with 
commercially available 2-methyl resorcinol, 3 (Scheme 1). Compound 3 was formylated under 
Vilsmeier-Haack conditions enlisting POCl3 and DMF, followed by hydrolysis to afford formyl-
resorcinol 4. Similar to the procedure of Sivakumar and co-workers, condensation of 4 with N-
acetyl glycine in the presence of acetic anhydride, produced the bis-acylated coumarin, 5.
64
 
Deacetylation of both the phenol and amine was accomplished upon heating with HCl and EtOH 
to afford 3-amino-7-hydroxy-8-methyl-coumarin, 6. Conversion of amino-coumarin 6 to the 
Figure 23. Amide- and Triazole-containing Novobiocin 
analogues. 
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azide, which was required for the 
copper-catalyzed Huisgen 1,3-
dipolar cycloaddition, was 
accomplished by in-situ generation 
of the 3-diazonium salt upon 
treatment with sodium nitrite in 
aqueous acid, followed by the 
addition of sodium azide to afford 3-
azido-coumarin, 7a.
64
 Acetylation of coumarin 7a was accomplished with acetic anhydride in 
pyridine to afford 7b. 
 Upon the generation of compounds 7a and 7b, the copper-catalyzed Huisgen 1,3-dipolar 
cycloaddition with the corresponding alkynes was set to generate compounds 8–16a and 8–16b 
(Scheme 2). Standard conditions were used to effect this transformation, and a combination of 
DMSO and H2O were found most suitable for optimal product formation and isolation. Alkynes 
8–12 were chosen to 
investigate the electronic 
nature of the aryl side 
chain, including neutral 
(Me), electron withdrawing 
(F) and electron donating 
(OMe, NMe2) properties as 
originally identified during 
classical novobiocin SAR 
Scheme 2. "Click" procedure with various alkynes used. 
a
The TMS 
protected alkynes were used in these reaction with the addition of 1 
eq. TBAF; From Ref. 61. 
Scheme 1. Reagents:(a) (i) POCl3, DMF, MeCN; (ii) H2O 
(55%); (b) N-acetyl glycine, NaOAc, Ac2O; (c) HCl, EtOH 
(d) NaNO2, HCl, EtOH, H2O, then NaN3 (52% 3 steps); (e) 
Ac2O, pyridine, CH2Cl2 (> 95%); From Ref. 61. 
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studies.
38
 Alkynes 13–16 were chosen based on prior observations that the analogous amide 
derivatives manifested good anti-proliferative activities against multiple cell lines, and thus 
provide direct comparison between amide and triazole analogues.
38
  
Completion of the triazole-containing novobiocin analogues was achieved by 
incorporation of the noviose sugar into 8–16a (Scheme 3). The phenols of compounds 8–16a 
were noviosylated with the trichloroacetimidate of noviose carbonate (15) in the presence of 
boron trifluoride etherate.
55
 The activated noviose, 17, is synthesized from L-arabinose in 11 
steps (9% yield overall, See Materials and Methods). Solvolysis of the cyclic carbonate with 
methanolic triethylamine afforded novobiocin analogues 8–16c.  
 
C. Biological Evaluation of Triazole Containing Novobiocin Analogues 
Upon preparation of compounds 8–16 a, b and c, their growth inhibitory activities against 
MCF-7(ER+) and SKBr-3(ER-, Her2 over-expressing) breast cancer cell lines were determined 
(Table 5). These results provide evidence that compounds 16a, 16b, 16c, and 13c are the most 
potent analogues prepared in this series. The structure–activity relationships suggest that 
analogues bearing sterically demanding side chains exhibit greater potency, as compounds with 
biaryl, indole, or homologated aryl groups (13–16) were more efficacious than substituted aryl 
compounds (8–12). In addition, comparison of compounds 8–12 suggests that para-substitution 
of the aryl ring with Me, OMe, NMe2 or F is not well tolerated, as these compounds displayed 
 
Scheme 3. Noviosylation of triazole appended coumarins; From Ref. 61. 
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minimal anti-proliferative activity. These results suggest that the C-terminal binding pocket has a 
large hydrophobic pocket that can easily accommodate substituents as in compounds 13–16. 
Table 5. Anti-proliferative activities of triazole containing novobiocin analogues
a
; From Ref. 61.
 
 
MCF-7 SKBr-3 
Compound 
(IC50, µM)
b
 (IC50, µM)
b
 
a b c a b c 
NB 481.3 ± 1.5 474.7 ± 13.9 
8 25.2 ± 4.5 40.8 ± 8.4 64.4 ± 5.8 39.0 ± 3.1 76.34 ± 2.3 >100 
9 23.2 ± 0.8 >100 >100 >100 90.8 ± 9.2 >100 
10 33.5 ± 1.6 >100 >100 34.2 ± 4.1 >100 >100 
11 >100 >100 >100 >100 >100 >100 
12 >100 >100 >100 >100 >100 >100 
13 28.0 ± 0.6 42.4 ± 4.9 13.2 ± 3.9 44.9 ± 3.4 50.8 ± 0.7 21.2 ± 6.0 
14 33.7 ± 3.2 28.5 ± 2.2 14.6 ± 0.4 33.9 ± 6.7 65.1 ± 12.7 51.9 ± 3.0 
15 38.3 ± 6.0 76.1 ± 8.4 NT 42.5 ± 0.9 50.4 ± 1.8 NT 
16 8.2 ± 0.02 7.5 ± 0.7 18.3 ± 4.7 13.3 ± 2.9 6.5 ± 0.8 8.2 ± 0.1 
a
Values represent mean ± standard error for at least two separate experiments performed in triplicate 
b
IC50 is defined as the concentration of compound necessary to inhibit cellular growth by 50% 
NT = Not Tested 
 
Additionally, comparison between the amide containing analogues and triazole 
containing analogues provides further SAR (Table 6). As evident from the data presented in 
Table 6, the triazole moiety has little effect on anti-proliferative activity. Comparing the triazole 
and amide analogues containing the biaryl and 3-indole side chains indicate the activities for 
both sets of compounds are comparable against the two cell lines tested. One discrepancy 
observed between the amide and triazole analogues is that in which simple aryl side chains (8-
12) manifest IC50 values in the 10-20 µM range for the amide–containing molecules while the 
triazole compounds 8 and 11 display IC50 values above 50 µM.
38
 These results suggest that the 
triazole moiety affects biological activity in two ways: the availability of a hydrogen bond donor 
in the amide linkage and the steric bulk of the side chain. This hydrogen bond donor is lost upon 
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introduction of the triazole moiety, but interactions can be increased by the introduction of steric 
bulk in the side chain. This phenomenon correlates well with the CoMFA model described 
above, as a large area of steric bulk was a predictor for increased activity. In addition, the 
CoMFA model prepared by Huang and co-workers incorporated the triazole containing 
analogues.
51
 Their CoMFA predicts that the amide bond hydrogen-bond donor is necessary for 
biological activity.  A preference for steric bulk has been observed in several series of 
novobiocin analogues, and appears to be a contributing factor to biological activity. 
Table 6. Comparison of anti-proliferative activities: amide-containing versus triazole-containing 
novobiocin analogues; From Ref. 61. 
 
After analysis of the triazole containing analogues anti-proliferative activity, Western 
blot analysis was preformed for 
the most active compound, 16b, 
to confirm that anti-proliferative 
activity results from Hsp90 
inhibition (Figure 24). Western 
blot analysis of MCF-7 cells 
treated with increasing 
concentrations of 16b, show the compound to induce Hsp90-dependent client protein 
R=Biaryl R=Biaryl (13c)
IC50 (MCF-7) 18.7 1.8
a
13.2  3.9
IC50 (SKBr-3) 7.5  1.0
a
21.2  6.0
R=3-Indole R=3-Indole (16c)
IC50 (MCF-7) 5.3  0.3
a
18.3  4.7
IC50 (SKBr-3) 12.2  1.5
a
8.2  0.1
a
Biological data taken from Ref. 16
Figure 24. Western blot analysis for compound 16b from 
MCF-7 cell lysates; From Ref. 61. 
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degradation in a dose-dependent manner, with an apparent IC50 value that correlates directly to 
the anti-proliferative IC50 value. Her2 and c-Raf are client proteins of Hsp90, and 
pharmacological inhibition of Hsp90 leads to their degradation via ubiquitinylation and 
proteome-mediated hydrolysis. Additionally, compound 16b appears to have little effect on the 
heat shock response, as unaltered levels of Hsp90 were observed, consistent with inhibition of 
the Hsp90 C-terminus. Western blot analysis indicates that these compounds are interfering with 
the Hsp90-mediated protein folding process, and that the anti-proliferative activities for these 
compounds are directly related to Hsp90 inhibition. 
 A series of triazole containing novobiocin analogues was prepared and evaluated against 
two breast cancer cell lines. Western blot analysis affirmed Hsp90 inhibition by this class of 
compounds. The compounds described herein exhibit comparable activities to the corresponding 
amide-containing analogues. These results indicate that the amide moiety can be replaced by the 
triazole functionality, however, in some cases the loss of the hydrogen bond donor appears 
detrimental, but can be overcome by the inclusion of steric bulk in the triazole substituent. 
V. Conclusions and Future Work  
 Throughout the work described above, we have been able to define the binding pocket for 
C-terminal Hsp90 inhibitors for the first time. The CoMFA model provided valuable insights 
into the nature of the binding pocket and correlated well with observed SAR trends derived from 
prior studies. Subsequent biochemical elucidation of the C-terminal binding site using a NB-
based photoaffinity label coupled with mass spectrometry was accomplished.
54
 This model 
provides a means to design novel compounds in aims to generate a rational approach towards 
Hsp90 inhibitor development. Lastly, using a bioisosteric replacement method, we investigated 
the role of the amide bond contained within Novobiocin. Triazole-containing novobiocin 
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analogues were synthesized and evaluated, and demonstrated that the amide bond is not critical 
to biological activity, as amide-containing and triazole-containing analogues manifested similar 
activities.
61
 This work has lead to an extensive structure-based design approach to Hsp90 C-
terminal inhibitors; in addition, the pursuit of an Hsp90C-terminal inhibitor crystal structure is 
underway.  
A. Structure Based Drug Design of Novel C-terminal Inhibitors 
 Using the model of the C-terminal binding site, the Blagg laboratory has been able to 
pursue novel NB analogues using a structure-based approach (Figure 25). As evidenced from the 
C-terminal model, there were several regions on the NB scaffold that could be modified to 
produce more additional interactions with the binding site. Several polar residues exist proximal 
to the lactone moiety and synthesis of coumarin-scaffold mimics will aid in the evaluation of 
these interactions. Second, there appears to be a large hydrophobic space adjacent to the amide 
bond. Using Diels–Alder chemistry, compounds can be synthesized that have cyclohexyl-derived 
moieties capable of occupying this region. In addition, a deep pocket resides near the sugar 
Figure 25. Structure-based drug design effort using the Hsp90 C-terminal binding site model. 
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binding region. Various mimics of the sugar moiety may fit in this pocket and provide additional 
interactions. Several colleagues in the Blagg Laboratory have utilized this model to design these 
and other C-terminal inhibitory compounds and to help explain previously observed SAR trends. 
B. Progress towards a C-terminal Inhibitor Co-Crystal Structure 
 Although the C-terminal binding site model derived from photoaffinity studies has been 
very useful, we and others are still interested in the attainment of a C-terminal inhibitor bound 
co-crystal structure. During a research rotation in the Laurence Pearl – Chrisostomos Prodromou 
laboratory at the Institute of Cancer Research (now at The University of Sussex), I was involved 
in this effort. Previous attempts to obtain a co-crystal structure utilized yeast CTD constructs. 
These protein constructs were able to from crystals but produced very poor diffraction data. We 
sought to utilize the human proteins, Hsp90α and Hsp90β, of varying lengths to optimize the 
Figure 26. hHsp90α constructs prepared in efforts to obtain an Hsp90 C-terminal inhibitor co-crystal 
structure. 
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crystals for diffraction. A depiction of the varying constructs, ten total for each isoform (five 
terminate at residue 689, five terminate at residue 732 (C-terminal end)), are shown in Figure 
26. The rationale behind these different constructs was that we aimed to simultaneous improve 
crystallization and stability properties while maintaining the CTD binding site. Constructs that 
were too short would not contain the inhibitor binding site, while the longer constructs may 
suffer from crystallization and diffraction issues as observed with the yeast constructs. In pursuit 
of this co-crystal structure, cloning of the hHsp90α and hHsp90β DNA was performed. The 
clones were ligated into the pET vector suitable for protein expression. Plasmids were 
transformed into a suitable competent e. coli and colonies were selected based on ampicilin 
resistance. Colonies were grown in liquid media followed by plasmid DNA isolation, 
purification, and sequencing. Following correct sequencing, protein expression and purification 
was carried out and preliminary crystallography screens were performed in a 96-well format. 
Upon the completion of my research rotation, Chrisostomos Prodromou continued this work by 
preparing the remaining constructs and expressing/purifying the proteins. Further crystallography 
screens were performed, producing several crystals capable of diffraction. To date, the resolution 
of these structures has not been adequate, and further refinement of the crystallization set up is 
underway.  
VI. Materials and Methods 
A. Development of a CoMFA for Hsp90 C-Terminal Inhibitors 
Data Set. The structures of all compounds used to generate the CoMFA model, their anti-
proliferative IC50 values (MCF-7), and  pIC50 (LogIC50) values are shown in Table 7. 
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Table 7. Novobiocin analogues used in the development of a C-terminal inhibitor CoMFA model. 
 
 
Compound R
1
R
2
R
3
IC50 (M, MCF-7) pIC50
DNBA1 OH OH Me >100 2.00
DNBA2 OC(O)NH2 OH Me >100 2.00
DNBA3 H H Me >100 2.00
DNBA4 OH OH Biaryl 7.7 0.89
DNBA5 OC(O)NH2 OH Biaryl 1.7 0.23
DNBA6 H H Biaryl 1.7 0.23
Compound R
1
R
2
R
3
IC50 (M, MCF-7) pIC50
DNBA7 OH OH Me >100 2.00
DNBA8 OC(O)NH2 OH Me >100 2.00
DNBA9 H H Me 32.6 1.51
JAB-CIDA -- -- -- >100 2.00
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Compound R IC50 (M, MCF-7) pIC50
KU36 H 21.0 1.32
KU91 2-OMe 5.3 0.72
KU92 3-OMe 5.6 0.75
KU93 4-OMe 10.3 1.01
KU94 2-Ph 19.0 1.28
KU95 3-Ph 18.0 1.26
KU96 4-Ph 8.1 0.91
KU97 2-NO2 28.7 1.46
KU98 3-NO2 >100 2.00
KU99 4-NO2 >100 2.00
KU100 2-NH2 17.2 1.24
KU101 3-NH2 30.1 1.48
KU102 4-NH2 14.0 1.15
KU105 3-I, 4-OMe 6.3 0.80
KU106 3-Ph, 4-OMe 19.5 1.29
Compound R IC50 (M, MCF-7) pIC50
KU107 2-Me 18.9 1.28
KU108 3-Me 20.4 1.31
KU109 4-Me 16.7 1.22
KU110 2-OMe 15.6 1.19
KU111 3-OMe 18.7 1.27
KU112 4-OMe 37.9 1.58
KU113 2-OH 1.5 0.18
KU114 3-OH 5.3 0.72
KU115 4-OH 2.3 0.36
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Compound R IC50 (M, MCF-7) pIC50
KU103 16.4 1.21
KU104 6.9 0.84
KU118 >100 2.00
KU119 2-Pyridyl 20.3 1.31
KU120 3-Pyridyl 47.8 1.68
KU121 4-Pyridyl >100 2.00
KU122 2-Indole 0.57 -0.24
KU123 3-Indole 5.3 0.72
KU124 4 0.60
KU126 >100 2.00
KU130 1.7 0.23
KU136 >100 2.00
KU137 28.6 1.46
KU138 96.3 1.98
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Compound R IC50 (M, MCF-7) pIC50
KU111OAc Me 1.4 0.15
KU131 Et 2.9 0.46
KU132 Cyclohexyl 4.2 0.62
KU133 Cyclopropyl 3.4 0.53
KU134 2-OMe-phenyl >100 2.00
KU139 n-Pentyl 2.9 0.46
KU140 Phenyl 29.5 1.47
KU141 4-Et-phenyl >100 2.00
KU142 2-Napthyl 77.5 1.89
Compound R
1
R
2
R
3
R
4
IC50 (M, MCF-7) pIC50
KU144 Me OMe H Biaryl >100 2.00
KU146 Et H H Biaryl 14.4 1.16
KU147 Et H H 2-Indole 4.3 0.63
KU149 Me OPr H Biaryl >100 2.00
KU150 Me OPr H 2-Indole 2.1 0.32
KU153 CH2Ph H H Biaryl >100 2.00
KU154 CH2Ph H H 2-Indole 38.0 1.58
KU157 Me H OMe Biaryl 82.8 1.92
KU158 Me H OMe 2-Indole 9.0 0.95
KU161 Me O
i
Pr H Biaryl 66.9 1.83
KU162 Me O
i
Pr H 2-Indole 20.7 1.32
KU165 Ph H H Biaryl >100 2.00
KU166 Ph H H 2-Indole 38.8 1.59
KU169 Me OMe H 2-Indole 24.4 1.39
KU174 OMe H H Biaryl 9.0 0.95
KU175 OMe H H 2-Indole 9.7 0.99
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Molecular Database Alignment. All molecular structures in the data set were built in Sybyl 
v8.0 and were minimized in the Tripos force field utilizing a distance dependent dielectric 
function, leaving all other parameters set to default. Gasteiger-Marsili partial charges were then 
calculated and assigned for each molecule. All compounds in the molecular database were then 
aligned using the coumarin ring as the core structure. The aligned database was then subjected to 
CoMFA analysis. 
CoMFA. Steric energy (Lennard-Jones potential) and electrostatic (Coulomb potential) energy 
were measured for each molecule using a probe atom (sp3-hybridized carbon; +1 charge; 1.52Å 
van der Waals radius) in Sybyl using default settings with the Tripos force field. A partial least-
squares (PLS) analysis was then performed. LogIC50 (pIC50; MCF-7 anti-proliferation) values 
were used as the dependent variable while the calculated steric and electrostatic CoMFA 
parameters served as the independent variable. The generated models were evaluated using the 
leave-one-out cross-validation strategy (q
2
). The optimum number of components (ONC) was the 
Compound IC50 (M, MCF-7) pIC50
KU117 6.0 0.78
KU125 >100 2.00
KU129 36.4 1.56
KU135 1.5 0.18
KU148 14.9 1.17
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value that gave the highest q
2
 value (6). The ONC was then used in the generation of the final, 
non-cross validated PLS regression model which can be used to predict the activities of 
compounds not in the data set. For evaluation purposes, this model was used to predict the 
activities of the compounds in the training set (R
2
 = 0.88).  
B. Identification of the NB binding site in Hsp90’s C-terminal Domain 
Photoaffinity Labeling and Mass Spectrometry. Recombinant His-tagged Hsp90CT (amino 
acids 531-732 human Hsp90α) was exposed to four flashes of 184 µJ of UV radiation in the 
presence of 0.5 mM of either 1, 2 or DMSO (vehicle control), followed by digestion of the 
samples with trypsin. The tryptic peptides were subjected to capillary LC-MS/MS experiments 
using tandem LTQ-FT Mass Spectrometer (ThermoFinnigan) under conditions described 
previously,
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 followed by data analysis. 
Docking of NB into HtpG Structure. Docking of NB into the open Hsp90 structure (HtpG 
solution structure) was performed in Sybyl v8.0 using Surflex-Dock docking software. The 
peptide identified in photoaffinity labeling studies (HtpG 500-SEKEAE-505) was used as a 
guide to build the binding site (protomol). The top 10 binding modes were analyzed and 
subjected to a molecular dynamics protocol. The binding model giving the best binding score 
after the MD protocol was used in generation of the binding model and homology model of 
hHsp90α. 
Hsp90α Homology Model. The sequence of hHsp90α was used to search similar sequences 
using NCBI blast.
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 A multiple sequence alignment was performed using ClustalW with default 
parameters to align these sequences and to identify structurally conserved regions and important 
residues, specifically between hHsp90α and HtpG.
67
 Homology modeling was performed with 
the program Modeller using the structure of HtpG as template.
56
 The sequence alignment was 
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done as discussed previously and ten models were built followed by refinement using molecular 
dynamics as implied in Modeller (refine_fast). The model corresponding to the lowest value of 
the probability density function (pdf) and fewest restraints violations out of the generated models 
was used for further analysis. The minimization of the side chains was performed using Sybyl 
molecular modeling software.
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 Initially, the protein was held fixed except for the binding site 
residues (residues falling within 8Å of novobiocin molecule). Thereafter, all side chains and the 
binding site were kept free and minimization was done.  All the minimization was done until the 
RMS gradient of 0.05 Kcal/MolÅ was obtained using AMBER9 force field. 
C. Synthesis and Evaluation of a Series of Triazole Containing Novobiocin Analogues 
Experimental Procedures: 
 
2,4-dihydroxy-3-methylbenzaldehyde (4). 2-Methyl-resorcinol (10.00 g, 80.58 mmol) in 
anhydrous CH3CN (100 mL) was cooled to 0 °C, then N,N-dimethylformamide (7.45 mL, 96.22 
mmol) and freshly distilled phosphorus oxychloride (8.98 mL, 96.34 mmol) were added in 
sequence, and the resulting solution was warmed to rt over 18 h. The white precipitate was 
collected by filtration, resuspended in H2O (100 mL), and heated to reflux for 1 h. The 
suspension was cooled to 0 °C and the precipitate was collected by filtration to give 4 as a 
colorless solid (6.67 g, 54%): 
1
H NMR (CDCl3, 500 MHz) δ 11.68 (s, 1H), 9.69 (s, 1H), 7.29 (d, 
J = 8.5 Hz, 1H), 6.48 (d, J = 8.5 Hz, 1H), 2.14 (s, 3H); 
13
C NMR (CDCl3, 125 MHz) δ 194.9, 
162.4, 161.5, 133.2, 115.2, 111.3, 108.2, 7.3; IR (film) νmax 3281, 1618, 1595, 1493, 1439, 1379, 
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1304, 1250, 1217, 1095, 793, 710 cm
-1
; HRMS (ESI
+
) m/z: [M + H]
+
 calcd for C8H8O3, 
153.0552; found, 153.0559. 
 
3-azido-7-hydroxy-8-methyl-2H-chromen-2-one (7a). Aldehyde 4 (3.50 g, 23.0 mmol), N-
acetylglycine (2.69 g, 23 mmol) and sodium acetate (5.66 g, 69 mmol) in acetic anhydride (100 
mL) was stirred at reflux for 4 h.
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 Cooling to rt then to 0°C provided a yellow precipitate which 
was filtered and rinsed with DI H2O (5). Without purification, 5 was dissolved in concentrated 
HCl and EtOH (2:1, 30 mL) and refluxed for 1 hour. Water (40 mL) was added and the solution 
cooled to 0°C. NaNO2 (3.178 g, 46 mmol) was added and stirred for 15 minutes. NaN3 (4.50 g, 
69 mmol) was then added in portions at 0°C and stirred for 1 h. at 0°C before filtering the 
resulting brown solid. The solid was then washed with cold water affording a brown solid (2.5 g, 
52%): 
1
H NMR (500 MHz, DMSO) δ 10.49 (s, 1H), 7.60 (d, J = 1.6, 1H), 7.36 (d, J = 8.5, 1H), 
6.91 (d, J = 8.5, 1H), 2.20 (s, 3H); 
13
C NMR (126 MHz, DMSO) δ 158.1, 157.4, 150.8, 128.2, 
125.8, 120.6, 112.6, 111.3, 110.6, 7.9; IR (film) νmax 3402 (br), 2922, 2359, 2341, 2212, 2113, 
1734, 1686, 1601, 1578, 1340, 1288, 1261, 1232, 1150, 1072, 980, 912 cm
-1
. 
 
3-azido-8-methyl-2-oxo-2H-chromen-7-yl acetate (7b). To compound 7a (500 mg, 2.30 mmol) 
in anhydrous CH2Cl2 (35 mL), acetic anhydride (325 µL, 3.45 mmol) then pyridine (100 µL, 
1.20 mmol) were added and stirred for 16 h. at rt. The reaction was diluted with EtOAc, washed 
with water (100 mL), brine, and dried (Na2SO4). The solvent was removed in vacuuo affording a 
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yellow solid that was used without further purification (860 mg, 98%): 
1
H NMR (500 MHz, 
DMSO) δ 7.68 (s, 1H), 7.54 (d, J = 8.4, 1H), 7.15 (d, J = 8.5, 1H), 2.35 (s, 3H), 2.17 (s, 3H); 
13
C 
NMR (126 MHz, DMSO) δ 168.8, 156.8, 150.1, 149.7, 126.5, 125.5, 124.8, 119.3, 118.0, 117.0, 
20.5, 8.7; IR (film) νmax 2934, 2359, 2343, 2137, 1753, 1722, 1624, 1605; 1447, 1431, 1371, 
1339, 1223, 1144, 1090, 1018, 912 cm
-1
.   
General Procedure A: Cu-Mediated Triazole Formation 
 
7-hydroxy-8-methyl-3-(4-phenyl-1H-1,2,3-triazol-1-yl)-2H-chromen-2-one (8a). Using a 
procedure similar to Sivakumar et al.
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, azide 7a (203.3 mg, 0.93 mmol) was dissolved in 1:1 
H2O:DMSO (10 mL). Phenylacetylene (101 µL, 0.93 mmol), CuSO4 (7.5% in DI H2O, 310 µL, 
0.09 mmol), and NaAsc (1 M in H2O, 180 µL, 0.18 mmol) were added in that order and stirred 
for 16 h. at rt in the dark. H2O was then added to, and the resulting precipitate was filtered and 
rinsed with H2O. The triazole product was then purified by flash column chromatography. (SiO2, 
1:2 EtOAc:Hexanes) to afford 8a as a yellow amorphous solid (128.4 mg, 43%): 
1
H NMR (500 
MHz, Acetone) δ 8.93 (s, 1H), 8.58 (s, 1H), 8.05 – 7.97 (m, 2H), 7.66 (d, J = 8.5 Hz, 1H), 7.49 
(t, J = 7.7 Hz, 2H), 7.38 (t, J = 7.4 Hz, 1H), 7.06 (d, J = 8.5 Hz, 1H), 2.34 (s, 3H); 
13
C NMR (126 
MHz, DMSO) δ 160.4, 156.5, 152.7, 146.4, 137.2, 130.1, 129.0(2C), 128.2, 127.8, 125.4(2C), 
122.1, 118.8, 113.2, 110.9, 110.3, 7.9; IR (film) νmax 3416 (br), 2955, 2922, 2852, 1745, 1730, 
1697, 1643, 1609, 1587, 1454, 1265, 1244, 1213, 1177, 1092, 1078 cm
-1
; HRMS (ES
+
) m/z: [M 
+ H] calcd for C18H14N3O3 320.1035; found 320.1022. 
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8-methyl-2-oxo-3-(4-phenyl-1H-1,2,3-triazol-1-yl)-2H-chromen-7-yl acetate (8b). Compound 
8b was prepared following General Procedure A with azide 7b (15 mg, 0.06 mmol) and 
phenylacetylene (6.5 µL, 0.06mmol) and was purified by column chromatography (SiO2, 1:1 
EtOAc:Hexanes) to afford a yellow amorphous solid (16.3 mg, 78%): 
1
H NMR (400 MHz, 
DMSO) δ 9.08 (s, 1H), 8.80 (s, 1H), 7.99 (d, J = 7.1, 2H), 7.86 (d, J = 8.5, 1H), 7.49-7.53 (m, 
2H), 7.40 (t, J = 7.25, 1H), 7.30 (d, J = 8.4, 1H), 2.40 (s, 3H), 2.26 (s, 3H); 
13
C NMR (126 MHz, 
Acetone) δ 168.9, 156.2, 153.3, 152.4, 151.4, 147.8, 134.5, 131.2, 129.5, 128.9, 127.7, 126.8, 
126.2, 126.0, 121.7, 120.4, 120.0, 116.8, 20.2, 8.7; IR (film) νmax 3063, 2955, 2926, 2127, 1763, 
1726, 1607, 1447, 1418, 1369, 1236, 1196, 1165, 1134, 1084, 1013, 924, 903 cm
-1
; HRMS (ES
+
) 
m/z: [M + H] calcd for C20H16N3O4  362.1141; found 362.1133. 
General Procedure B: Noviosylation and Carbonate Hydrolysis 
 
7-((2S,3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-dimethyltetrahydro-2H-pyran-2-yloxy)-8-
methyl-3-(4-phenyl-1H-1,2,3-triazol-1-yl)-2H-chromen-2-one (8c). Boron trifluoride etherate 
(65 μL, 0.53 mmol) was added to compound 8a (85 mg, 0.27 mmol) and (3aR,4S,7R,7aR)-7-
methoxy-6,6-dimethyl-2-oxo-tetrahydro-3aH-[1.3]dioxolo[4,5-c]pyran-4-yl 2,2,2-
trichloroacetimidate (17) (0.532 mmol) in anhydrous CH2Cl2 (3 mL).
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 After stirring at rt for 18 
h, triethylamine (100 μL, 0.72 mmol) was added and the solvent was concentrated. The residue 
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was partially purified via column chromatography (SiO2, 3:1:1 Hexanes:CH2Cl2:EtOAc) and the 
coupled carbonate was used without further purification. 
The isolated carbonate was dissolved in MeOH (40 mL), CH2Cl2 (2 mL), and 
triethylamine (4 mL) and stirred for 18 h at rt. The solvent was concentrated and the residue 
purified via column chromatography (SiO2, 24:1 CH2Cl2:MeOH) to afford a white amorphous 
solid (44 mg, 34% over two steps): 1H NMR (400 MHz, DMSO) δ 9.03 (s, 1H), 8.70 (s, 1H), 
7.97 (d, J = 8.0, 2H), 7.79 (d, J = 8.7, 1H), 7.50 (m, 2H), 7.39 (t, J = 7.3, 1H), 7.27 (d, J = 8.8, 
1H), 5.60 (s, 1H), 5.37 (d, J = 4.6, 1H), 5.06 (d, J = 6.1, 1H), 4.03 (dd, J = 12.1, 6.1 1H), 3.93 (s, 
1H), 3.50 (s, 3H), 3.29 (d, J = 9.2, 1H), 2.26 (s, 3H), 1.26 (s, 3H), 1.02 (s, 3H); 13C NMR (126 
MHz, DMSO) δ 158.1, 156.1, 151.7, 146.5, 136.5, 130.0, 129.0, 128.2 (2C), 127.9, 125.4 (2C), 
122.1, 120.2, 113.0, 112.0, 111.1, 98.3, 83.2, 77.9, 70.7, 67.5, 61.1, 28.5, 22.8, 8.2; IR (film) νmax 
3496 (br), 1742, 1720, 1609, 1504, 1472, 1302, 1286, 1246, 1219, 1182, 1126, 1086, 1043, 1014, 
984, 945 cm
-1
; HRMS (ES+) m/z: [M + H] calcd for C26H28N3O7  494.1927; found 494.1907. 
 
7-hydroxy-8-methyl-3-(4-p-tolyl-1H-1,2,3-triazol-1-yl)-2H-chromen-2-one (9a). Compound 
9a was prepared following General Procedure A with azide 7a (150 mg, 0.69 mmol) and 1-
ethynyl-4-methylbenzene (92µL, 0.73 mmol) and was purified by column chromatography 
(SiO2, 3:1:1 Hexanes:EtOAc:CH2Cl2) to afford a yellow amorphous solid (98.9 mg, 42%): 
1
H 
NMR (500 MHz, DMSO) δ 10.86 (s, 2H), 8.94 (s, 2H), 8.63 (s, 1H), 7.84 (d, J = 8.1, 2H), 7.62 
(d, J = 8.5, 1H), 7.30 (d, J = 7.9, 2H), 6.98 (d, J = 8.5, 1H), 2.35 (s, 3H), 2.23 (s, 3H); 
13
C NMR 
(126 MHz, DMSO) 160.3, 156.4, 152.6, 146.4, 137.6, 137.1, 129.5(2C), 127.8, 127.2, 
125.3(2C), 121.7, 118.8, 113.1, 110.9, 110.3, 20.8, 7.9; IR (film) νmax 3339 (br), 3300, 1757, 
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1713, 1682, 1537, 1375, 1319, 1288, 1211, 1112, 1061, 1014, 962, 933, 914 cm
-1
; HRMS (ES
+
) 
m/z: [M + H] calcd for C19H16N3O3  334.1192; found 334.1175. 
 
8-methyl-2-oxo-3-(4-p-tolyl-1H-1,2,3-triazol-1-yl)-2H-chromen-7-yl acetate (9b). Compound 
9b was prepared following General Procedure A with azide 7b (150 mg, 0.58 mmol) and 1-
ethynyl-4-methylbenzene (88 µL, 0.69 mmol) and was purified by column chromatography 
(SiO2, 3:1:1 Hexanes:EtOAc:CH2Cl2) to afford a white amorphous solid (117 mg, 54%): 
1
H 
NMR (500 MHz, DMSO) δ 9.01 (s, 1H), 8.78 (s, 1H), 7.84-7.88 (m, 3H), 7.28-7.32 (m, 3H), 
2.39 (s, 3H), 2.36 (s, 3H), 2.25 (s, 3H); 
13
C NMR (126 MHz, DMSO) δ 168.7, 155.7, 152.1, 
151.5, 146.7, 137.8, 135.0, 129.7(2C), 127.4, 127.0, 125.5(2C), 122.4, 121.4, 119.8, 118.4, 
116.0, 20.8, 20.5, 8.8; IR (film) νmax 3175, 3069, 2916, 1767, 1724, 1628, 1605, 1497, 1450, 
1406, 1387, 1369, 1269, 1238, 1196, 1165, 1132, 1086, 1013, 926 cm
-1
; HRMS (ES
+
) m/z: [M + 
H] calcd for C21H18N3O4  376.1297; found 376.1281. 
 
7-((2S,3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-dimethyltetrahydro-2H-pyran-2-yloxy)-8-
methyl-3-(4-p-tolyl-1H-1,2,3-triazol-1-yl)-2H-chromen-2-one (9c). Compound 9c was 
prepared following General Procedure B with coumarin 9a (70 mg, 0.21 mmol) and was purified 
by column chromatography (SiO2, 99:1 to 32:1 CH2Cl2:MeOH) to afford an off-white 
amorphous solid (34.2 mg, 32% over two steps): 
1
H NMR (500 MHz, DMSO) δ 8.96 (s, 1H), 
8.68 (s, 1H), 7.85 (d, J = 8.1, 2H), 7.77 (d, J = 8.7, 1H), 7.30 (d, J = 7.9, 2H), 7.26 (d, J = 8.9, 
1H), 5.59 (d, J = 2.5, 1H), 5.37 (d, J = 4.7, 1H), 5.06 (d, J = 6.2, 1H), 4.02 (ddd, J = 3.3, 6.3, 9.4, 
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1H), 3.95 – 3.89 (m, 1H), 3.50 (s, 3H), 3.29 (d, J = 9.2, 1H), 2.35 (s, 3H), 2.25 (s, 3H), 1.26 (s, 
3H), 1.01 (s, 3H) 
13
C NMR (126 MHz, DMSO) δ 158.1, 156.2, 151.7, 146.5, 137.6, 136.3, 
129.5(2C), 127.9, 127.2, 125.3(2C), 121.6, 120.2, 113.0, 112.0, 111.2, 98.3, 83.2, 78.0, 70.7, 
67.5, 61.1, 28.5, 22.8, 20.8, 8.2; IR (film) νmax 3433 (br), 2386, 1724, 1715, 1607, 1165, 1128, 
1107, 1086, 1070, 1049, 987, 962, 926 cm
-1
; HRMS (ES
+
) m/z: [M + H] calcd for C27H30N3O7  
508.2084; found 508.2067. 
 
3-(4-(2,4-difluorophenyl)-1H-1,2,3-triazol-1-yl)-7-hydroxy-8-methyl-2H-chromen-2-one 
(10a). Compound 10a was prepared following General Procedure A with azide 7a (150mg, 0.69 
mmol) and 1-ethynyl-2,4-difluorobenzene (105 mg, 0.76 mmol) and was purified by column 
chromatography (SiO2, 2:1:1 Hexanes:EtOAc:CH2Cl2) to afford a yellow amorphous solid (50 
mg, 20%): 
1
H NMR (500 MHz, DMSO) δ 10.88 (s, 1H), 8.82 (d, J = 3.5, 1H), 8.65 (s, 1H), 8.22 
(td, J = 6.6, 8.7, 1H), 7.62 (d, J = 8.5, 1H), 7.47 (ddd, J = 2.6, 9.3, 11.5, 1H), 7.28 (ddd, J = 1.3, 
2.7, 8.3, 1H), 6.98 (d, J = 8.5, 1H), 2.22 (s, 3H); 
13
C NMR (126 MHz, DMSO) δ 161.0 (d, JCF = 
10.6), 160.5, 159.6 (d, JCF = 13.2), 157.6 (d, JCF = 12.8), 156.6, 152.7, 139.2 (d, JCF = 3.6), 
137.2, 128.7 (d, JCF = 4.8), 127.8, 124.2 (d, JCF = 11.7), 118.7, 114.6 (d, JCF = 4.1), 113.2, 112.6 
(d, JCF = 3.6), 110.6 (d, JCF = 83.2), 104.7 (t, JCF = 27.0), 7.9; IR (film) νmax 3421 (br), 2849, 
2772, 1732, 1715, 1626, 1593, 1560, 1493, 1441, 1321, 1267, 1090 cm
-1
; HRMS (ES
+
) m/z: [M 
+ H] calcd for C18H12F2N3O3  356.0847; found 356.0844. 
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3-(4-(2,4-difluorophenyl)-1H-1,2,3-triazol-1-yl)-8-methyl-2-oxo-2H-chromen-7-yl acetate 
(10b). Compound 10b was prepared following General Procedure A with azide 7b (150 mg, 0.58 
mmol) and 1-ethynyl-2,4-difluorobenzene (96 mg, 0.69 mmol) and was purified by column 
chromatography (SiO2, 3:1:1 Hexanes:EtOAc:CH2Cl2) to afford a white amorphous solid (62 
mg, 27%): 
1
H NMR (500 MHz, DMSO) δ 8.88 (d, J = 3.5, 1H), 8.81 (s, 1H), 8.24 (td, J = 6.6, 
8.7, 1H), 7.85 (d, J = 8.4, 1H), 7.49 (ddd, J = 2.6, 9.3, 11.5, 1H), 7.27-7.31 (m, 2H), 2.39 (s, 3H), 
2.25 (s, 3H); 
13
C NMR (126 MHz, DMSO) δ 168.7, 163.0 (d, JCF = 11.9), 161.0 (d, JCF = 12.0), 
155.8, 152.1, 151.5, 139.4 (d, JCF = 3.0), 135.5, 128.9 (d, JCF = 4.8), 128.8 (d, JCF = 4.4), 127.4, 
123.9 (d, JCF = 11.9), 122.3, 119.8, 118.5, 115.9, 112.5 (d, JCF = 20.8), 104.8 (t, JCF = 26.4), 20.2, 
9.1; IR (film) νmax 3061, 2932, 2513, 1761, 1728, 1609, 1562, 1493, 1460, 1412, 1373, 1271, 
1244, 1219, 1205, 1134, 1086, 1070, 1032, 926, 910 cm
-1
; HRMS (ES
+
) m/z: [M + H] calcd for 
C20H14F2N3O4  398.0952; found 398.0965. 
 
3-(4-(2,4-difluorophenyl)-1H-1,2,3-triazol-1-yl)-7-((2S,3R,4S,5R)-3,4-dihydroxy-5-methoxy-
6,6-dimethyltetrahydro-2H-pyran-2-yloxy)-8-methyl-2H-chromen-2-one (10c). Compound 
10c was prepared following General Procedure B with coumarin 10a and was purified by column 
chromatography (SiO2, 99:1 to 32:1 CH2Cl2:MeOH) to afford a white amorphous solid (35.1 mg, 
59% over two steps): 
1
H NMR (500 MHz, DMSO) δ 8.84 (d, J = 3.5, 1H), 8.71 (s, 1H), 8.23 (td, 
J = 6.6, 8.7, 1H), 7.78 (d, J = 8.7, 1H), 7.48 (ddd, J = 2.6, 9.3, 11.6, 1H), 7.28 (ddd, J = 2.8, 8.8, 
11.4, 1H), 7.27 (d, J = 8.6, 1H), 5.59 (d, J = 2.5, 1H), 5.37 (d, J = 4.7, 1H), 5.06 (d, J = 6.2, 1H), 
4.02 (ddd, J = 3.3, 6.2, 9.4, 1H), 3.94 – 3.90 (m, 1H), 3.50 (s, 3H), 3.29 (d, J = 9.2, 1H), 2.25 (s, 
3H), 1.26 (s, 3H), 1.01 (s, 3H); 
13
C NMR (126 MHz, DMSO) δ 161.0 (d, JCF = 16.7), 159.6 (d, 
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JCF = 12.8), 158.1, 157.5 (d, JCF = 16.8), 156.3, 154.4 (d, JCF = 29.6) 151.7, 139.2 (d, JCF = 2.3) 
136.5, 128.8, (d, JCF = 9.9) 128.0, 124.0 (d, JCF = 12.6), 120.2, 113.0, 112.5 (d, JCF = 22.3), 111.4 
(d, JCF = 93.5), 104.8 (t, JCF = 26.0), 98.3, 83.3, 77.9, 70.7, 67.4, 61.1, 28.5, 22.8, 8.1; IR (film) 
νmax 3389 (br), 1726, 1717, 1609, 1250, 1236, 1198, 1132, 1086, 1070, 997, 966, 947 cm
-1
; 
HRMS (ES
+
) m/z: [M + H] calcd for C26H26F2N3O7  530.1739; found 530.1727. 
 
7-hydroxy-3-(4-(4-methoxyphenyl)-1H-1,2,3-triazol-1-yl)-8-methyl-2H-chromen-2-one 
(11a). Compound 11a was prepared following General Procedure A with azide 7a (150 mg, 0.69 
mmol) and 1-ethynyl-4-methoxybenzene (94 µL, 0.72 mmol) and was purified by column 
chromatography (SiO2, 2:1:1 Hexanes:EtOAc:CH2Cl2) to afford a yellow amorphous solid (91.3 
mg, 38%): 
1
H NMR (500 MHz, d6-Acetone) δ 8.69 (s, 1H), 8.43 (s, 1H), 7.81 (d, J = 9.3, 2H), 
7.52 (d, J = 8.9, 1H), 6.93 (d, J = 9.1, 1H), 6.92 (d, J = 9.3, 2H), 3.73 (s, 1H), 2.20 (s, 3H); 
13
C 
NMR (126 MHz, d6-Acetone) δ 160.8, 160.8, 157.2, 153.9, 147.9, 136.4, 128.6, 127.8(2C), 
124.2, 121.1, 120.7, 115.1(2C), 114.0, 112.5, 112.0, 55.5, 8.1; IR (film) νmax 3433 (br), 2956, 
2920, 2849, 1726, 1713, 1606, 1591, 1556, 1502, 1454, 1418, 1385, 1308, 1261, 1175, 1128, 
1086, 1028, 959 cm
-1
; HRMS (ES
+
) m/z: [M + H] calcd for C19H16N3O4  350.1141; found 
350.1149. 
 
3-(4-(4-methoxyphenyl)-1H-1,2,3-triazol-1-yl)-8-methyl-2-oxo-2H-chromen-7-yl acetate 
(11b). Compound 11b was prepared following General Procedure A with azide 11b (150 mg, 
0.58 mmol) and 1-ethynyl-4-methoxybenzene (90 µL, 0.70 mmol) and was purified by column 
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chromatography (SiO2, 2:1:1 Hexanes:EtOAc:CH2Cl2) to afford a pale yellow amorphous solid 
(78.9 mg, 35%): 
1
H NMR (500 MHz, DMSO) δ 8.96 (s, 1H), 8.77 (s, 1H), 7.91 (d, J = 8.7, 2H), 
7.85 (d, J = 8.6, 1H), 7.28 (d, J = 8.5, 1H), 7.06 (d, J = 8.8, 2H), 3.81 (s, 3H), 2.39 (s, 3H), 2.25 
(s, 3H); 
13
C NMR (126 MHz, DMSO) δ 168.7, 159.3, 155.6, 152.1, 151.4, 146.6, 135.0, 135.0, 
127.3, 126.8(2C), 122.3, 121.1, 119.7, 118.3, 116.0, 114.4(2C), 55.1, 20.5, 8.7; IR (film) νmax 
3421, 3171, 3076, 2935, 1763, 1720, 1609, 1562, 1499, 1454, 1410, 1369, 1350, 1304, 1252, 
1205, 1163, 1132, 1084, 1020, 927 cm
-1
; HRMS (ES
+
) m/z: [M + H] calcd for C21H18N3O5  
392.1246; found 392.1232. 
 
7-((2S,3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-dimethyltetrahydro-2H-pyran-2-yloxy)-3-
(4-(4-methoxyphenyl)-1H-1,2,3-triazol-1-yl)-8-methyl-2H-chromen-2-one (11c). Compound 
11c was prepared following General Procedure B with coumarin 11a (70 mg, 0.20 mmol) and 
was purified by column chromatography (SiO2, 49:1 CH2Cl2:MeOH) to afford a white 
amorphous solid (35.5 mg, 34% over two steps): 
1
H NMR (500 MHz, DMSO) δ 8.91 (s, 1H), 
8.67 (s, 1H), 7.89 (d, J = 8.8, 2H), 7.77 (d, J = 8.7, 1H), 7.26 (d, J = 8.9, 1H), 7.05 (d, J = 8.9, 
2H), 5.59 (d, J = 2.5, 1H), 5.37 (d, J = 4.7, 1H), 5.06 (d, J = 6.2, 1H), 4.02 (ddd, J = 3.3, 6.3, 9.4, 
1H), 3.94 – 3.90 (m, 1H), 3.81 (s, 3H), 3.50 (s, 3H), 3.29 (d, J = 9.2, 1H), 2.25 (s, 3H), 1.25 (s, 
3H), 1.01 (s, 3H); 
13
C NMR (126 MHz, DMSO) δ 157.9, 156.7, 154.8, 150.4, 145.2, 134.9, 
126.7, 125.4, 121.2, 119.7, 119.0, 113.1, 111.7, 110.7, 109.8, 97.0, 81.9, 76.6, 69.4, 66.2, 59.8, 
53.8, 27.1, 21.6, 6.9; IR (film) νmax 3402 (br), 2359, 2341, 1714, 1647, 1609, 1252, 1132, 1086, 
1074, 991, 960 cm
-1
; HRMS (ES
+
) m/z: [M + H] calcd for C27H30N3O8  524.2033; found 
524.2038. 
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3-(4-(4-(dimethylamino)phenyl)-1H-1,2,3-triazol-1-yl)-7-hydroxy-8-methyl-2H-chromen-2-
one (12a). Compound 12a was prepared following General Procedure A with azide 7a (150 mg, 
0.69 mmol) and 4-ethynyl-N,N-dimethylaniline (105 mg, 0.72 mmol) and was purified by 
column chromatography (SiO2, 90:9:1 CH2Cl2:EtOAc:Acetone) to afford a yellow amorphous 
solid (99 mg, 40%): 
1
H NMR (500 MHz, d6-Acetone) δ 9.42 (s, 1H), 8.59 (s, 1H), 8.41 (s, 1H), 
7.69 (d, J = 8.9, 2H), 7.51 (d, J = 8.5, 1H), 6.92 (d, J = 8.5, 1H), 6.71 (d, J = 8.8, 2H), 2.87 (s, 
6H), 2.20 (s, 3H); 
13
C NMR (126 MHz, d6-Acetone) δ 160.7, 157.2, 153.8, 151.5, 148.6, 135.8, 
128.4, 127.4(2C), 120.8, 120.0, 119.5, 114.0, 113.3(2C), 112.5, 112.1, 40.5(2C), 8.2; IR (film) 
νmax 3350 (br), 2922, 2440, 2388, 1703, 1682, 1612, 1603, 1583, 1362, 1315, 1294, 1261, 1236, 
1196, 1167, 1086, 1065, 935 cm
-1
; HRMS (ES
+
) m/z: [M + H] calcd for C20H19N4O3  363.1457; 
found 363.1441. 
 
3-(4-(4-(dimethylamino)phenyl)-1H-1,2,3-triazol-1-yl)-8-methyl-2-oxo-2H-chromen-7-yl 
acetate (12b). Compound 12b was prepared following General Procedure A with azide 7b (150 
mg, 0.58 mmol) and 4-ethynyl-N,N-dimethylaniline (101 mg, 0.70 mmol) and was purified by 
column chromatography (SiO2, 19:1 CH2Cl2:EtOAc) to afford a yellow amorphous solid (95 mg, 
42%): 
1
H NMR (500 MHz, DMSO) δ 8.84 (s, 1H), 8.75 (s, 1H), 7.85 (d, J = 8.3, 1H), 7.78 (d, J 
= 8.9, 2H), 7.28 (d, J = 8.5, 1H), 6.82 (d, J = 9.0, 2H), 2.96 (s, 6H), 2.39 (s, 3H), 2.25 (s, 3H); 
13
C NMR (126 MHz, DMSO) δ 168.5, 155.7, 151.9, 151.4, 150.2, 147.2, 134.7, 127.3, 
126.3(2C), 122.5, 119.9, 119.7, 118.3, 117.5, 116.1, 112.1(2C), 40.0(2C), 20.5, 8.8; IR (film) 
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νmax 3028, 2922, 2897, 2359, 2341, 1761, 1720, 1618, 1605, 1506, 1450, 1427, 1360, 1344, 
1213, 1194, 1171, 1167, 1136, 1084, 1061, 1026, 943, 908 cm
-1
; HRMS (ES
+
) m/z: [M + H] 
calcd for C22H21N4O4  405.1563; found 405.1564. 
 
7-((2S,3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-dimethyltetrahydro-2H-pyran-2-yloxy)-3-
(4-(4-(dimethylamino)phenyl)-1H-1,2,3-triazol-1-yl)-8-methyl-2H-chromen-2-one (12c).  
Compound 12c was prepared following General Procedure B with coumarin 12a (75 mg, 0.21 
mmol) and was purified by column chromatography (SiO2, 49:1 CH2Cl2:MeOH) to afford a 
yellow amorphous solid (39 mg, 35% over two steps): 
1
H NMR (500 MHz, DMSO) δ 8.78 (s, 
1H), 8.65 (s, 1H), 7.77 (d, J = 8.5 1H), 7.76 (d, J = 8.9, 2H), 7.26 (d, J = 8.9, 1H), 6.81 (d, J = 
9.0, 2H), 5.59 (d, J = 2.5, 1H), 5.36 (d, J = 4.7, 1H), 5.05 (d, J = 6.2, 1H), 4.02 (ddd, J = 3.3, 6.3, 
9.4, 1H), 3.94 – 3.90 (m, 1H), 3.50 (s, 3H), 3.29 (d, J = 9.2, 1H), 2.95 (s, 6H), 2.25 (s, 3H), 1.25 
(s, 3H), 1.01 (s, 3H); 
13
C NMR (126 MHz, DMSO) δ 157.9, 156.1, 151.7, 150.2, 147.1, 136.0, 
127.8, 126.3(2C), 120.4, 120.1, 117.6, 113.0, 112.3, 112.0(2C), 111.1, 98.3, 83.3, 78.0, 70.7, 
67.5, 61.1, 40.0(2C), 28.5, 22.8, 8.2; IR (film) νmax 3421 (br), 2341, 2332, 1717, 1699, 1609, 
1558, 1506, 1456, 1420, 1362, 1261, 1088, 987, 966 cm
-1
; HRMS (ES
+
) m/z: [M + H] calcd for 
C28H33N4O7  537.2349; found 537.2361. 
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(3aR,7R,7aR)-7-methoxy-6,6-dimethyl-2-oxotetrahydro-3aH-[1,3]dioxolo[4,5-c]pyran-4-yl 
2,2,2-trichloroacetimidate (17). As previously described in reference 69. 
 
 
3-(4-(3',6-dimethoxybiphenyl-3-yl)-1H-1,2,3-triazol-1-yl)-7-hydroxy-8-methyl-2H-chromen-
2-one (13a). Compound 13a was prepared following General Procedure A with azide 7a (150 
mg, 69 mmol) and alkyne 18 (173 mg, 0.76 mmol) and was purified by column chromatography 
(SiO2, 2:2:1 Hexanes:CH2Cl2:EtOAc) to afford a yellow amorphous solid (101 mg, 32%): 
1
H 
NMR (500 MHz, DMSO) δ 10.86 (s, 1H), 8.99 (d, J = 1.0, 1H), 8.63 (d, J = 1.3, 1H), 7.94 (d, J 
= 8.5, 1H), 7.86 (d, J = 2.3, 1H), 7.62 (d, J = 8.6, 1H), 7.36 (t, J = 7.9, 1H), 7.24 (d, J = 8.7, 1H), 
7.13 – 7.10 (m, 1H), 7.10 – 7.08 (m, 1H), 6.98 (d, J = 8.5, 1H), 6.94 (dd, J = 2.3, 8.0, 1H), 3.83 
(s, 3H), 3.80 (s, 3H), 2.23 (s, 3H); 
13
C NMR (126 MHz, DMSO) δ 160.5, 158.9, 156.4, 156.1, 
152.6, 146.2, 139.1, 137.1, 130.1, 129.0, 127.8, 127.5, 125.9, 122.7, 121.7, 121.4, 118.7, 115.1, 
89 
113.1, 112.5, 112.2, 110.9, 110.3, 55.6, 55.0, 7.9; IR (film) νmax 3379 (br), 2937, 2833, 2588, 
2357, 1717, 1701, 1605, 1583, 1477, 1456, 1425, 1387, 1315, 1298, 1273, 1258, 1238, 1167, 
1142, 1090, 1047, 1018 cm
-1
; HRMS (ES
+
) m/z: [M + H] calcd for C26H22N3O5  456.1559; found 
456.1555. 
 
3-(4-(3',6-dimethoxybiphenyl-3-yl)-1H-1,2,3-triazol-1-yl)-8-methyl-2-oxo-2H-chromen-7-yl 
acetate (13b) Compound 13b was prepared following General Procedure A with azide 7b (135 
mg, 0.52 mmol) and alkyne 18 (130 mg, 0.55 mmol) and was purified by column 
chromatography (SiO2, 2:1:1 Hexanes:CH2Cl2:EtOAc) to afford a white amorphous solid (72 
mg, 28%): 
1
H NMR (500 MHz, DMSO) δ 9.08 (s, 1H), 8.78 (s, 1H), 7.98 (dd, J = 2.3, 8.5, 1H), 
7.89 (d, J = 2.3, 1H), 7.85 (d, J = 8.3, 1H), 7.39 – 7.33 (m, 1H), 7.29 (d, J = 8.5, 1H), 7.24 (d, J = 
8.7, 1H), 7.12 (dd, J = 1.0, 7.6, 1H), 7.11 – 7.08 (m, 1H), 6.94 (dd, J = 1.7, 8.3, 1H), 3.83 (s, 
3H), 3.80 (s, 3H), 2.39 (s, 3H), 2.25 (s, 3H); 
13
C NMR (126 MHz, DMSO) δ 168.7, 158.9, 156.2, 
155.6, 152.0, 151.4, 146.4, 139.0, 135.1, 130.2, 129.0, 127.6, 127.3, 126.1, 122.6, 122.4, 121.7, 
121.3, 119.8, 118.4, 116.0, 115.1, 112.5, 112.3, 55.7, 55.0, 20.6, 8.8; IR (film) νmax 3439, 2964, 
2837, 2357, 2253, 2127, 1771, 1720, 1645, 1605, 1497, 1454, 1439, 1421, 1385, 1369, 1302, 
1269, 1244, 1198, 1167, 1134, 1049, 1007, 932, 906 cm
-1
; HRMS (ES
+
) m/z: [M + H] calcd for 
C28H24N3O6  498.1665; found 498.1653. 
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7-((2S,3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-dimethyltetrahydro-2H-pyran-2-yloxy)-3-
(4-(3',6-dimethoxybiphenyl-3-yl)-1H-1,2,3-triazol-1-yl)-8-methyl-2H-chromen-2-one (13c). 
Compound 13c was prepared following General Procedure B with coumarin 13a (70 mg, 0.154 
mmol) and was purified by column chromatography (SiO2, 49:1 CH2Cl2:MeOH) to afford a pale 
yellow amorphous solid (29.2 mg, 30% over two steps): 
1
H NMR (500 MHz, DMSO) δ 9.02 (s, 
1H), 8.69 (s, 1H), 7.96 (dd, J = 2.3, 8.5, 1H), 7.88 (d, J = 2.3, 1H), 7.79 (d, J = 8.8, 1H), 7.37 (t, 
J = 7.9, 1H), 7.27 (d, J = 9.0, 1H), 7.25 (d, J = 8.7, 1H), 7.12 (d, J = 7.9, 1H), 7.11 – 7.09 (m, 
1H), 6.97 – 6.93 (m, 1H), 5.60 (d, J = 2.5, 1H), 5.35 (d, J = 4.7, 1H), 5.04 (d, J = 6.2, 1H), 4.03 
(ddd, J = 3.2, 6.3, 9.3, 1H), 3.95 – 3.91 (m, 1H), 3.84 (s, 3H), 3.81 (s, 3H), 3.51 (s, 3H), 3.30 (d, 
J = 9.2, 1H), 2.27 (s, 3H), 1.27 (s, 3H), 1.03 (s, 3H); 
13
C NMR (126 MHz, DMSO) δ 158.9, 
158.0, 156.1, 151.8, 146.3, 139.1, 136.3, 130.1, 129.0, 127.9, 127.6, 126.0, 122.7, 121.7, 121.4, 
120.2, 115.1, 113.1, 112.4, 112.3, 112.0, 111.2, 103.2, 98.3, 83.2, 78.0, 70.8, 67.5, 61.1, 55.6, 
55.0, 28.4, 22.8, 8.3; IR (film) νmax 3431 (br), 3173, 3065, 2976, 2935, 2835, 2359, 1801, 1724, 
1609, 1580, 1501, 1479, 1458, 1441, 1425, 1387, 1321, 1259, 1173, 1142, 1113, 1090, 1022, 
987, 966 cm
-1
; HRMS (ES
+
) m/z: [M + H] calcd for C34H36N3O9  630.2449; found 630.2418. 
 
(E)-7-hydroxy-8-methyl-3-(4-styryl-1H-1,2,3-triazol-1-yl)-2H-chromen-2-one (14a). 
Compound 14a was prepared following General Procedure A with azide 7a (120 mg, 0.55 mmol) 
and alkyne 19
70-71
 (71 mg, 0.55 mmol) and was purified by column chromatography (SiO2, 1:1 
Hexanes:EtOAc) to afford an orange amorphous solid (87.1 mg, 46%): 
1
H NMR (400 MHz, 
DMSO) δ 10.85 (s, 1H), 8.73 (s, 1H), 8.64 (s, 1H), 7.66 – 7.61 (m, J = 3.3, 7.9, 3H), 7.44 – 7.37 
(m, 3H), 7.36 – 7.28 (m, 2H), 6.98 (d, J = 8.5, 1H), 2.23 (s, 3H); 
13
C NMR (126 MHz, DMSO) δ 
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160.3, 156.4, 152.6, 145.2, 136.5, 136.5, 130.0, 128.8(2C), 127.9, 127.8, 126.5(2C), 122.8, 
118.8, 116.8, 113.2, 110.9, 110.3, 7.9; IR (film) νmax 3414 (br), 2922, 2850, 2359, 2332, 1717, 
1701, 1610, 1589, 1420, 1313, 1261, 1236, 1088, 1055, 955 cm
-1
; HRMS (ES
+
) m/z: [M + H] 
calcd for C20H16N3O3 346.1192; found 346.1183. 
 
(E)-8-methyl-2-oxo-3-(4-styryl-1H-1,2,3-triazol-1-yl)-2H-chromen-7-yl acetate (14b).  
Compound 14b was prepared following General Procedure A with azide 7b (100 mg, 0.39 
mmol) and alkyne 19
70-71
 (49.5 mg, 0.39 mmol) and was purified by column chromatography 
(SiO2, 1:1 EtOAc:Hexanes) to afford a yellow amorphous solid (91 mg, 61%): 
1
H NMR (500 
MHz, DMSO) δ 8.80 (s, 1H), 8.79 (s, 1H), 7.85 (d, J = 8.3, 1H), 7.64 (d, J = 7.3, 2H), 7.30-7.49 
(m, 5H), 7.28 (d, J = 8.5, 1H), 2.39 (s, 3H), 2.25 (s, 3H); 
13
C NMR (126 MHz, DMSO) δ 168.7, 
155.6, 152.0, 151.2, 145.4, 136.5, 134.4, 130.2, 128.8(2C), 128.0, 127.2, 126.5(2C), 122.7, 
122.4, 119.8, 118.3, 116.6, 116.1, 20.5, 8.8; IR (film) νmax 3061, 2926, 2359, 2341, 2127, 1763, 
1738, 1718, 1630, 1605, 1520, 1454, 1420, 1369, 1236, 1200, 1161, 1117, 1082, 1040, 1009, 
989, 962, 924, 905 cm
-1
; HRMS (ES
+
) m/z: [M + H] calcd for C22H18N3O4 388.1297; found 
388.1288. 
 
7-((2S,3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-dimethyltetrahydro-2H-pyran-2-yloxy)-8-
methyl-3-(4-styryl-1H-1,2,3-triazol-1-yl)-2H-chromen-2-one (14c). Compound 14c was 
prepared following General Procedure B with coumarin 14a (90 mg, 0.250 mmol) and was 
purified by column chromatography (SiO2, 49:1 CH2Cl2:MeOH) to afford a pale yellow solid 
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(34.5 mg, 26% over two steps): 
1
H NMR (500 MHz, DMSO) δ 8.76 (s, 1H), 8.70 (s, 1H), 7.78 
(d, J = 8.7, 1H), 7.64 (d, J = 7.6, 2H), 7.49 – 7.24 (m, 6H), 5.60 (d, J = 2.2, 1H), 5.40 (d, J = 4.7, 
1H), 5.09 (d, J = 6.3, 1H), 4.02 (ddd, J = 3.2, 6.3, 9.4, 1H), 3.92 (dt, J = 3.8, 7.5, 1H), 3.50 (s, 
3H), 3.29 (d, J = 9.2, 1H), 2.25 (s, 3H), 1.25 (s, 3H), 1.01 (s, 3H); 
13
C NMR (126 MHz, DMSO) 
δ 158.1, 156.1, 151.6, 145.2, 136.5, 135.6, 130.1, 128.8(2C), 128.0, 127.9, 126.5(2C), 122.7, 
120.2, 116.7, 113.0, 112.1, 111.2, 98.3, 83.2, 78.0, 70.8, 67.5, 61.1, 28.5, 22.9, 8.1; IR (film) νmax 
3422 (br), 3171, 3057, 2980, 2935, 2359, 2341, 1799, 1717, 1609, 1497, 1450, 1423, 1385, 1366, 
1256, 1167, 1113, 1086, 1041, 987, 966 cm
-1
; HRMS (ES
+
) m/z: [M + H] calcd for C28H30N3O7 
520.2084; found 520.2070. 
 
3-(4-(1H-indol-2-yl)-1H-1,2,3-triazol-1-yl)-7-hydroxy-8-methyl-2H-chromen-2-one (15a). 
Compound 15a was prepared following General Procedure A with azide 7a (120 mg, 0.55 mmol) 
and alkyne 20
72
 (118 mg, 0.55 mmol) with the addition of TBAF (1M, 553 µL, 0.55 mmol). 15a 
was purified by column chromatography (SiO2, 3:1:1 Hexanes:CH2Cl2:EtOAc) to afford a 
yellow amorphous solid (73 mg, 37%): 
1
H NMR (500 MHz, DMSO) δ 11.80 (s, 1H), 10.87 (s, 
1H), 9.02 (s, 1H), 8.70 (s, 1H), 7.65 (d, J = 8.5, 1H), 7.57 (d, J = 8.0, 1H), 7.43 (dd, J = 0.8, 8.1, 
1H), 7.14 – 7.10 (m, 1H), 7.04 – 7.00 (m, 1H), 6.99 (d, J = 8.5, 1H), 6.94 (d, J = 1.3, 1H), 2.24 
(s, 3H); 
13
C NMR (126 MHz, DMSO) δ 160.4, 156.3, 152.6, 140.8, 136.6, 136.4, 128.5, 128.1, 
127.8, 121.7, 121.5, 120.2, 119.5, 118.7, 113.2, 111.5, 110.9, 110.4, 99.0, 8.03; IR (film) νmax 
3258 (br), 2922, 2851, 2357, 2320, 1706, 1645, 1626, 1601, 1582, 1556, 1373, 1333, 1298, 1281, 
1229, 1204, 1163, 1124, 1108, 1081, 999, 960, 916 cm
-1
; HRMS (ES
+
) m/z: [M + H] calcd for 
C20H15N4O3  359.1144; found 359.1131. 
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3-(4-(1H-indol-2-yl)-1H-1,2,3-triazol-1-yl)-8-methyl-2-oxo-2H-chromen-7-yl acetate (15b). 
Compound 15b was prepared following General Procedure A with azide 7b (56 mg, 0.20 mmol) 
and alkyne 20
72
 (45 mg, 0.2 mmol) with the addition of TBAF (1M, 211 µL, 0.20 mmol). 15b 
was purified by column chromatography (SiO2, 3:1:1 Hexanes:CH2Cl2:EtOAc) to afford a 
yellow/green amorphous solid (28.3 mg, 35%): 
1
H NMR (500 MHz, DMSO) δ 11.82 (s, 1H), 
9.10 (s, 1H), 8.84 (s, 1H), 7.87 (d, J = 8.4, 1H), 7.56 (d, J = 7.7, 1H), 7.42 (dd, J = 0.8, 8.1, 1H), 
7.28 (d, J = 8.5, 1H), 7.12 (ddd, J = 1.2, 7.1, 8.2, 1H), 7.04 – 7.00 (m, 1H), 6.97 (d, J = 1.3, 1H), 
2.39 (s, 3H), 2.25 (s, 3H); 
13
C NMR (126 MHz, DMSO) δ 168.7, 155.7, 152.0, 151.4, 141.0, 
136.6, 134.4, 128.3, 128.1, 127.3, 122.3, 121.7, 121.4, 120.1, 119.8, 119.4, 118.3, 116.0, 111.3, 
99.2, 20.6, 8.8; IR (film) νmax 3362, 3165, 3049, 2962, 2359, 2341, 1763, 1724, 1605, 1456, 
1412, 1369, 1337, 1311, 1231, 1198, 1169, 1130, 1084, 1032, 1013, 968, 926 cm
-1
; HRMS (ES
+
) 
m/z: [M + H] calcd for C22H17N4O4  401.1250; found 401.1260. 
 
3-(4-(1H-indol-3-yl)-1H-1,2,3-triazol-1-yl)-7-hydroxy-8-methyl-2H-chromen-2-one (16a). 
Compound 16a was prepared following General Procedure A with azide 7a (165 mg, 0.76 mmol) 
and alkyne 21 (162 mg, 0.76 mmol) with the addition of TBAF (1M, 800 µL, 0.76 mmol). 16a 
was purified by column chromatography (SiO2, 3:1 to 1:1 Hexanes:EtOAc) to afford a yellow 
amorphous solid (38 mg, 14%): 
1
H NMR (500 MHz, DMSO) δ 11.44 (s, 1H), 10.87 (s, 1H), 8.82 
(s, 1H), 8.63 (s, 1H), 8.08 (d, J = 7.8, 1H), 7.93 (d, J = 2.6, 1H), 7.62 (d, J = 8.5, 1H), 7.46 (d, J 
= 7.9, 1H), 7.21 – 7.16 (m, 1H), 7.14 (ddd, J = 1.2, 7.1, 8.0, 1H), 6.97 (d, J = 8.5, 1H), 2.23 (s, 
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3H); 
13
C NMR (126 MHz, DMSO) δ 160.3, 156.6, 152.6, 142.8, 136.8, 136.4, 127.7, 124.7, 
123.6, 121.7, 120.0, 119.9, 119.6, 119.0, 113.1, 111.8, 110.9, 110.4, 105.4, 7.9; IR (film) νmax 
3342 (br), 2307, 1703, 1600, 1583, 1416, 1317, 1286, 1261, 1236, 1215, 1091, 1059 cm
-1
; 
HRMS (ES
+
) m/z: [M + H] calcd for C20H15N4O3 359.1141; found 359.1127. 
 
3-(4-(1H-indol-3-yl)-1H-1,2,3-triazol-1-yl)-8-methyl-2-oxo-2H-chromen-7-yl acetate (16b). 
Compound 16b was prepared following General Procedure A with azide 7b (100 mg, 0.39 
mmol) and alkyne 21 (82 mg, 0.39 mmol) with the addition of TBAF (1M, 385 µL, 0.39 mmol). 
16b was purified by column chromatography (SiO2, 3:1:1 Hexanes:CH2Cl2:EtOAc) to afford a 
red/brown amorphous solid (80.1 mg, 35%): 
1
H NMR (500 MHz, DMSO) δ 11.46 (s, 1H), 8.88 
(s, 1H), 8.78 (s, 1H), 8.08 (d, J = 7.7, 1H), 7.96 (d, J = 2.6, 1H), 7.85 (d, J = 8.5, 1H), 7.46 (d, J 
= 7.9, 1H), 7.28 (d, J = 8.5, 1H), 7.20 – 7.16 (m, 1H), 7.16 – 7.11 (m, 1H), 2.39 (s, 3H), 2.25 (s, 
3H); 
13
C NMR (126 MHz, DMSO) δ 13C NMR (126 MHz, DMSO) δ 168.7, 155.7, 151.9, 
151.4, 143.1, 136.3, 134.6, 127.3, 124.7, 123.8, 122.6, 121.8, 119.8, 119.8, 119.7, 119.7, 118.4, 
116.0, 111.8, 105.2, 20.4, 8.9; IR (film) νmax 3400, 3344, 2962, 2930, 2876, 1755, 1715, 1693, 
1643, 1605, 1520, 1454, 1371, 1261, 1200, 1155, 1078, 1009, 908 cm
-1
; HRMS (ES
+
) m/z: [M + 
H] calcd for C22H17N4O4 401.1250; found 401.1240. 
 
3-(4-(1H-indol-3-yl)-1H-1,2,3-triazol-1-yl)-7-((2S,3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-
dimethyltetrahydro-2H-pyran-2-yloxy)-8-methyl-2H-chromen-2-one (16c). Compound 16c 
was prepared following General Procedure B with coumarin 16a (100mg, 0.28 mmol) and was 
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purified by column chromatography (SiO2, 49:1 CH2Cl2:MeOH) to afford a yellow/green 
amorphous solid (47.1 mg, 32%):  
1
H NMR (500 MHz, DMSO) δ 11.45 (s, 1H), 8.84 (s, 1H), 
8.70 (s, 1H), 8.08 (d, J = 7.8, 1H), 7.95 (d, J = 2.6, 1H), 7.79 (d, J = 8.7, 1H), 7.48 – 7.45 (m, 
1H), 7.27 (d, J = 8.9, 1H), 7.21 – 7.16 (m, 1H), 7.16 – 7.12 (m, 1H), 5.59 (d, J = 2.5, 1H), 5.37 
(d, J = 4.7, 1H), 5.06 (d, J = 6.2, 1H), 4.02 (ddd, J = 3.3, 6.2, 9.4, 1H), 3.95 – 3.90 (m, 1H), 3.50 
(s, 3H), 3.29 (d, J = 9.2, 1H), 2.27 (s, 3H), 1.26 (s, 3H), 1.02 (s, 3H); 
13
C NMR (126 MHz, 
DMSO) δ 158.0, 156.3, 151.6, 142.9, 136.4, 135.9, 127.8, 124.7, 123.7, 121.8, 120.5, 119.9, 
119.7, 113.0, 112.1, 111.8, 111.2, 111.1, 105.4, 98.2, 83.1, 77.8, 70.6, 67.4, 60.9, 28.4, 22.7, 8.4; 
IR (film) νmax  3423 (br), 2982, 2935, 1715, 1628, 1609, 1522, 1456, 1375, 1258, 1109, 1084, 
966 cm
-1
; HRMS (ES
+
) m/z: [M + H] calcd for C28H29N4O7 533.2036; found 533.2014. 
Preparation of Alkynes: 
 
(3',6-dimethoxybiphenyl-3-yl)methanol (18b). To 18a
73
 (500 mg, 1.80 mmol) in CH2Cl2 (8 
mL), di-isobutyl aluminum hydride (1.0 M in CH2Cl2, 4.20 mL, 4.20 mmol) was added at -78°C, 
was warmed to rt and stirred for 4 h. An equal volume of saturated, aqueous potassium sodium 
tartrate was added and stirred for 2 h at rt. The reaction contents were partitioned between water 
and CH2Cl2 and were extracted with CH2Cl2 (2 x 25 mL). The combined organic layers were 
washed with saturated aqueous NaCl, dried (Na2SO4), filtered, and concentrated. The residue 
was purified by column chromatography (SiO2, 3:1 Hexanes:EtOAc) to give 18b as a yellow 
viscous liquid (405 mg, 91%): 
1
H NMR (500 MHz, CDCl3) δ 7.36 – 7.31 (m, 3H), 7.13 – 7.10 
(m, 1H), 7.09 (dd, J = 1.9, 2.5, 1H), 6.98 (d, J = 9.0, 1H), 6.89 (ddd, J = 0.9, 2.6, 8.3, 1H), 4.67 
(d, J = 4.8, 2H), 3.84 (s, 3H), 3.82 (s, 3H); 
13
C NMR (126 MHz, CDCl3) δ 159.2, 156.1, 139.6, 
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133.2, 130.6, 130.1, 129.0, 127.7, 122.0, 115.2, 112.6, 111.3, 65.1, 55.7, 55.3; IR (film) νmax 
3348 (br), 2999, 2935, 2908, 2874, 2833, 1607, 1576, 1504, 1481, 1462, 1454, 1435, 1412, 1312, 
1275, 1265, 1242, 1225, 1167, 1144, 1040, 1028 cm
-1
; HRMS (ES
+
) m/z: [M + H] calcd for 
C15H17O3 245.1178; found 245.1168. 
 
3',6-dimethoxybiphenyl-3-carbaldehyde (18c). To 18b (400 mg, 1.66 mmol) in CH2Cl2 (10 
mL), Dess-Martin periodinane (843 mg, 2.0 mmol) was added at 0°C. The solution was then 
stirred upon warming to rt for 4 h. A 1:1 solution of aqueous saturated NaHCO3:Na2S2O3 (20 
mL) was then added and stirred until two layers were present. The partitioned layers were 
extracted with CH2Cl2 (2 x 25 mL), the combined organic layers were then washed with 
saturated NaHCO3, followed by saturated NaCl, dried (Na2SO4), and concentrated. The residue 
was purified by column chromatography (SiO2, 3:1 Hexanes:EtOAc) to give 18c as a yellow 
viscous liquid (400 mg, 99%): 
1
H NMR (500 MHz, CDCl3) δ 9.95 (s, 1H), 7.87 – 7.90 (m, 2H), 
7.36 (t, J = 7.9, 1H), 7.13 – 7.09 (m, 2H), 7.08 (dd, J = 1.6, 2.4, 1H), 6.93 (ddd, J = 0.9, 2.6, 8.3, 
1H), 3.92 (s, 3H), 3.86 (s, 3H); 
13
C NMR (126 MHz, CDCl3) δ 190.9, 161.5, 159.3, 138.4, 132.4, 
131.4, 131.2, 129.9, 129.2, 121.9, 115.3, 113.1, 111.1, 56.0, 55.3; IR (film) νmax 3366, 3072, 
3003, 2939, 2910, 2837, 2727, 2359, 2035, 1680, 1597, 1582, 1501, 1481, 1456, 1439, 1418, 
1371, 1310, 1290, 1267, 1254, 1219, 1169, 1142, 1130, 1051, 1036, 1020, 945, 918 cm
-1
; HRMS 
(ES
+
) m/z: [M + H] calcd for C15H15O3 243.1017; found 243.1005. 
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5-ethynyl-2,3'-dimethoxybiphenyl (18).  Following the procedure by Mueller et al.,
74
 to 
aldehyde 18c (800 mg, 3.30 mmol) in MeOH (30 mL), K2CO3 (0.91 g, 6.6 mmol) was added 
followed by the addition of dimethyl-1-diazo-2-oxopropylphosphonate (595 µL, 4.0 mmol). 
After stirring for 12 h at rt, the reaction was diluted with Et2O (100 mL) and organics washed 
with saturated NaHCO3 and dried (MgSO4). The residue was purified by column 
chromatography (SiO2, 9:1 Hexanes:EtOAc) to give 18 as a yellow viscous liquid (152 mg, 
77%): 
1
H NMR (500 MHz, CDCl3) δ 7.51 – 7.47 (m, 2H), 7.35 (t, J = 7.9, 1H), 7.10 (dd, J = 0.8, 
7.6, 1H), 7.09 – 7.06 (m, 1H), 6.95 – 6.90 (m, 2H), 3.85 (d, J = 8.6, 6H), 3.04 (s, 1H); 
13
C NMR 
(126 MHz, CDCl3) δ 159.3, 156.9, 138.8, 134.6, 132.7, 130.7, 129.0, 122.0, 115.2, 114.3, 112.9, 
111.1, 83.5, 76.0, 55.7, 55.3; IR (film) νmax 3285, 3051, 3001, 2959, 2939, 2906, 2835, 2529, 
2359, 2104, 1601, 1580, 1501, 1479, 1462, 1439, 1394, 1317, 1248, 1217, 1165, 1051, 1038, 
1024, 903 cm
-1
; HRMS (ES
+
) m/z: [M + H] calcd for C16H15O2 239.1072; found 239.1067. 
 
3-((trimethylsilyl)ethynyl)-1H-indole (21). Compound 21a
75
 (100 mg, 0.41 mmol) was 
dissolved in degassed THF (3 mL). PdCl2(PPh3)2 (14.4 mg, 0.02 mmol), CuI (3.9 mg, 0.02 
mmol), DBU (246 µL, 1.6 mmol) then ethynyltrimethylsilane (69.7 µL, 0.49 mmol) were added 
in that order. The reaction was stirred at 55°C under argon for 12 h. The reaction mixture was 
then diluted with EtOAc (10 mL) and filtered through celite. The organic layer was then washed 
with DI H2O (2 x 10 mL) and saturated NaCl and dried (Na2SO4). The solvents were removed in 
vacuuo and the residue was purified by column chromatography (SiO2, 10:1 Hexanes:EtOAc) to 
afford a brown solid (45.4 mg, 52%): 
1
H NMR (500 MHz, CDCl3) δ 8.15 (s, 1H), 7.77 – 7.73 
98 
(m, 1H), 7.43 (d, J = 2.6, 1H), 7.38 – 7.35 (m, 1H), 7.25 – 7.19 (m, 2H), 0.29 (s, 9H); 
13
C NMR 
(126 MHz, CDCl3) δ 134.7, 128.3, 128.1, 122.8, 120.5, 119.8, 111.0, 98.6, 98.3, 95.5, 0.0(3C); 
IR (film) νmax 3408, 3061, 2957, 2897, 2359, 2341, 2332, 2150, 1531, 1456, 1416, 1340, 1325, 
1248, 1238, 1128, 1097, 1070, 1009 cm
-1
; HRMS (ES
+
) m/z: [M + H] calcd for C13H15NSi 
214.1052; found 214.1045.  
Anti-proliferation Assay. MCF-7 and SKBr-3 cells were maintained in a 1:1 mixture of 
Advanced DMEM/F12 (Gibco) supplemented with non-essential amino acids, L-glutamine (2 
mM), streptomycin (500 g/mL), penicillin (100 units/mL), and 10% FBS. Cells were grown to 
confluence in a humidified atmosphere (37 °C, 5% CO2), seeded (2000/well, 100 L) in 96-well 
plates, and allowed to attach overnight. Compound or geldanamycin at varying concentrations in 
DMSO (1% DMSO final concentration) was added, and cells were returned to the incubator for 
72 h.  At 72 h, the number of viable cells was determined using an MTS/PMS cell proliferation 
kit (Promega) per the manufacturer’s instructions. Cells incubated in 1% DMSO were used as 
100% proliferation, and values were adjusted accordingly. IC50 values were calculated from 
separate experiments performed in triplicate using GraphPad Prism. 
Western Blot Analysis. MCF-7 cells were grown to confluence as described above, seeded in 10 
cm culture dishes (1x10
6 
cells/dish) and allowed to attach overnight. Compound was added at 
varying concentrations in DMSO (1% DMSO final concentration) and the cells were incubated 
with drug for 24 h. Cells were harvested in cold PBS and lysed in mammalian protein extraction 
reagent (MPER, Pierce) lysis buffer containing protease inhibitors (Roche) on ice for 1 h. 
Lysates were clarified at 14,000g for 10 min at 4° C. Protein concentrations were determined 
using the Pierce BCA protein assay kit per the manufacturer’s instructions. Equal amounts of 
protein (2.5-10 μg) were electrophoresed under reducing conditions (10% acrylamide gel), 
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transferred to a polyvinylidene fluoride membrane (PVDF), and immunoblotted with the 
corresponding specific antibodies. Membranes were incubated with an appropriate horseradish 
peroxidase-labeled secondary antibody, developed with a chemiluminescent substrate, and 
visualized. 
Antibodies. The following antibodies were used for Western Blotting: mouse anti-Hsp90 
(Stressgen/Enzo Life Sciences), rabbit anti-Raf-1 (SantaCruz), rabbit anti-Her2 (Invitrogen), and 
rabbit anti-Actin (SantaCruz). 
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Chapter III 
Biological Evaluation of Isoform Selective Hsp90 Inhibitors and Characterization of 
Isoform Dependent Client Proteins 
I. Introduction 
In humans, there are four Hsp90 isoforms: Hsp90α and Hsp90β reside primarily in the 
cytoplasm and are stress-inducible and constitutively expressed, respectively.
1
 Glucose regulated 
protein 94 (Grp94) is localized to the endoplasmic reticulum, while tumor necrosis factor 
receptor associated protein1 (Trap1) is the mitochondrial-resident chaperone (Figure 27). 
Distinguishing the role played by each Hsp90 isoform has been a significant challenge, 
especially those manifested by the two cytosolic isoforms, which are structurally very similar.
1-2
 
The responsibility of each cytosolic isoform appears to overlap with some client proteins. 
However, recent evidence has emerged that suggests co-chaperones and client proteins interact 
with each isoform in a unique manner.
2
 Delineating the roles and responsibilities of each isoform 
Figure 27. Comparison of the hHsp90 isoforms. A.) Overall structural comparison between the four 
hHsp90 isoforms, including important structural features. B.) Amino acid similarity/identity between 
the four hHsp90 isoforms.  
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has become a major goal for this field, as such information will provide insight into some of the 
clinically observed toxicities and detriments manifested by Hsp90 inhibitors that exhibit pan-
inhibition. In addition, isoform selective inhibitors may help elucidate the role of each isoform as 
well as understand the clinical implications of inhibiting a single isoform. This chapter describes 
the evaluation of the human ether a-go-go (hERG) channel as an Hsp90α isoform-dependent 
client, the progress towards elucidating other isoform-dependent clients and the development of 
an assay to identify Grp94 inhibitors. 
A. Hsp90 α/β 
 The cytosolic Hsp90 isoforms, Hsp90α and Hsp90β, have been the most widely studied 
chaperones. Many of the client proteins for Hsp90α/β have been identified and much is known 
about the structure and function of these isoforms. Several crystal structures and co-crystal 
structures of the N-terminal domain (NTD) exist, which have provided valuable insights into the 
mechanism for ATP binding and hydrolysis. Hsp90α and Hsp90β, encoded by the HSP90AA1 
and HSP90AB1 genes respectively, are 86% identical and 93% similar in amino acid sequence, 
while the highly conserved NTD is 95% identical between the two isoforms. The vast array of 
over 200 client proteins that depend upon Hsp90α/β include numerous protein kinases, 
transcription factors, mutated signaling proteins and cell cycle regulators. An up-to-date list of 
these client proteins is maintained by Didier Picard at the University of Geneva.
3-4
 It has been 
difficult to biochemically distinguish the roles manifested by each Hsp90 isoform due to the high 
structural similarity, significant antibody cross reactivity, and the presence of Hsp90α/β 
heterodimers.  
Only a few Hsp90 isoform–dependent client proteins have been identified this far. Prior 
studies have demonstrated that the cellular inhibitor of apoptosis protein 1 (c-IAP1) depends 
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upon Hsp90β,
5
 while some intermediates in the major histocompatibility complex (MHC) class I, 
but not MHC class II, pathway depend solely upon Hsp90α.
6-7
 Phenotypic screens have also been 
used to identify the unique roles played by each cytosolic Hsp90 isoform. For example, Hsp90β 
appears to be critical for embryonic development, as an Hsp90β null mutation results in 
embryonic lethality.
8
 Meanwhile, Hsp90α is overexpressed in many cancer cells and has been 
linked to cancer cell invasiveness, which is directly related to  matrix metalloproteinase 2 
activity.
9
 Chadli et al. provided rationale to support Hsp90 isoform dependence of co-
chaperones.
10
 In their studies, they found the general cell UNC45 (GCUNC45) binds 
preferentially to Hsp90β and was capable of stalling the chaperone machinery during the 
progression/activation of the progesterone receptor. In this example, the specific co-chaperone 
required for client protein activation/folding determines the isoform dependence. In a yeast 
model system in which the endogenous Hsp90 was replaced with either hHsp90α or hHsp90β as 
the sole Hsp90, differences in activation of client proteins and sensitivity to Hsp90 inhibitors 
were observed.
11-12
 Using RNA interference (RNAi) and other genetic manipulation strategies, it 
has become possible to investigate the roles manifested by each cytosolic isoform. It is expected 
that the list of isoform dependent client proteins and co-chaperones will grow exponentially over 
the coming years.  
B. Grp94 
 Glucose-regulated protein 94 (Grp94), also called gp96 and endoplasmin, resides in the 
lumen of the endoplasmic reticulum (ER), is encoded by the HSP90B1 gene in humans and is 
not present in most unicellular organisms, including yeast, most fungi, and most bacteria.
1,13
 The 
expression of Grp94 is controlled by different mechanisms and transcription factors as compared 
to Hsp90α/β. Grp94 is not overexpressed following heat shock, but following ER stress, such as 
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redox stress, calcium imbalance, and hypoxia, Grp94 is upregulated as part of the unfolded 
protein response (UPR).
13
 Grp94 is 42-43% identical and 59-60% similar in primary sequence to 
the two cytosolic isoforms, Hsp90α/β (Figure 27B). The overall structure of Grp94 resembles 
that of Hsp90α/β, as Grp94 contains the same four domains: NTD, charged linker, MD, and CTD 
(Figure  27).
1
 Grp94 contains a Bergerat fold in the NTD that binds ATP and other compounds 
known to bind Hsp90α/β, such as geldanamycin and radicicol, and is 55% identical and over 
70% similar to the Hsp90α/β NTD.
14-17
 However, the NTD of Grp94 is longer than the NTD of 
Hsp90α/β because of a 21-residue sequence in the NTD that targets Grp94 to the ER, which is 
subsequently cleaved to produce the mature form of Grp94. In addition, a 5-amino acid insertion 
proximal to the ATP binding site provides a unique hydrophobic cleft that allows binding of the 
adenosine analogue, N-ethylcarboxamidoadenosine (NECA), which does not bind to Hsp90α/β.
18
 
This unique pocket was proposed to allow for the development of isoform-selective Hsp90 
inhibitors, as described below.  
 The charged linker of Grp94 is comprised of an E/D-rich sequence that is capable of 
binding Ca
2+ 
ions, followed by a positively charged poly-K stretch.
19-20
 The analogous region in 
Hsp90α/β does not bind Ca
2+
 ions, as the positively and negatively charged residues are 
interspersed and prevent formation of the negatively charged cleft that is capable of binding the 
positively charged divalent metal. The middle domain (MD) of Grp94 is highly homologous to 
the MD contained within Hsp90 α/β and provides similar functionalities, namely client and co-
chaperone binding and cooperation with the NTD for nucleotide binding and hydrolysis.  
 The C-terminal domain (CTD) of Grp94 contains the required dimerization domain, 
similar to Hsp90 α/β. In contrast to the MEEVD motif in Hsp90α/β which is recognized by TPR-
containing proteins, Grp94 contains the ER-retention sequence, KDEL, which is recognized by 
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KDEL receptors. In general, Grp94 is similar in overall structure to Hsp90 α/β but contains a few 
unique structural elements specific to its function in the ER. 
 Grp94 functions as a molecular chaperone in the ER and plays a role in the maturation 
and degradation of a specific subset of client proteins. Grp94 also participates in the 
translocation of defective, misfolded proteins from the ER to the cytosol for degradation. 
Generally, client proteins that depend upon Grp94 for maturation are secreted, membrane-
localized, glycosylated proteins that contain disulfide bonds. Grp94-dependent client proteins 
include: Toll-like receptors, integrins, IFG-I, IGF-II, IFN-γ, and IRS-1, many of which are 
important in intercellular communication.
13,21
 In addition, Grp94 is an essential gene and appears 
to be crucial for embryonic development, stem cell maintenance, host defense and cell 
adhesion.
22-25
 Unlike Grp94, little is known about the function and clientele of the mitochondria-
resident chaperone, Trap-1. 
C. Trap-1  
 Tumor necrosis factor receptor-associated protein-1 (Trap1) resides in the mitochondria 
and is the least structurally conserved of the four human isoforms sharing only 26% identity and 
45% similarity with Hsp90α.
26-29
 The overall domain structure of Trap1 is similar to the other 
isoforms, with a few notable exceptions. Trap1 does not have a charged linker domain nor the 
MEEVD motif. However, Trap1 does contain a 60-residue N-terminal mitochondrial-targeting 
sequence that is cleaved after translocation to the mitochondria.
25
 Trap1 displays weak ATPase 
activity and is inhibited by that natural products, geldanamycin and radicicol.
30
 Functionally, less 
is known about the responsibilities of Trap1. However, Trap1 plays a role in cytoprotection, 
specifically from mitochondrial apoptosis and aids in the maintenance of mitochondrial 
maintenance.
31-33
 It has been suggested that Trap1 is overexpressed in human cancers owing to 
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its cytoprotective nature.
34
 Trap1 appears to inhibit mitochondrial apoptosis, suppress reactive 
oxygen species formation, and aid in the acquisition of resistance mechanisms to 
chemotherapies.
25,34
   
Delineating the roles played by and clientele dependent upon each Hsp90 isoform has 
become a significant goal in the Hsp90 field. Advances in biochemical methods have allowed the 
study of individual isoforms. However, small molecule isoform-selective inhibitors would 
further progress this deconvolution process, as all known Hsp90 inhibitors demonstrate pan-
inhibition, which does not provide a means to study individual isoforms. 
II. The hERG Channel is Dependent upon the Hsp90α Isoform for Maturation and 
Trafficking 
All currently described Hsp90 inhibitors manifest pan-inhibition and since cardiotoxicity 
represents a major hurdle for Hsp90 inhibitor development, we investigated whether the hERG 
channel was an isoform-dependent Hsp90 client protein. The α-subunit of the voltage gated 
potassium channel, the human ether-a-gogo-related gene product, hERG, constitutes a major 
component of the ion channel responsible for repolarization of cardiac action potential.
35-36
 
Ficker et al. demonstrated previously that hERG depends upon Hsp90 for its functional 
maturation and that pharmacological inhibition of Hsp90 had deleterious effects on the hERG-
related membrane potential.
37-38
 Defects in the hERG channel or off-target pharmacological 
inhibition of the hERG channel can cause long-QT syndrome, resulting in ventricular 
arrhythmias and even death.
36,39
 There are three primary classes of compounds that disrupt hERG 
function; 1) compounds that bind directly to and inhibit the hERG channel (hERG blockers), 2) 
compounds that inhibit the functional trafficking of hERG, or 3) compounds that exhibit both 
hERG blocking and hERG trafficking inhibitory abilities.
40-41
 Hsp90 inhibitors have been shown 
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to disrupt hERG function and cause a reduction in hERG-related membrane currents in in vitro 
studies. It has previously been demonstrated that the Hsp90 inhibitor, geldanamycin, inhibits 
hERG trafficking, presumably through an Hsp90-dependent mechanism.
37
 Given the intense 
pharmaceutical interest in the development of Hsp90 inhibitors as therapies for cancer and other 
diseases, the importance of identifying the isoform dependency of this client protein is clear, as 
pan-inhibition may result in undesired effects. 
A. hERG Interacts Solely with Hsp90α 
 The K+ channel encoded by hERG gene plays a major role in the repolarization of 
cardiac myocytes following normal action potential.
35
 Although pharmacological inhibition of 
hERG itself is a therapeutic target for the treatment of some cardiac arrhythmias, more often 
undesired inhibition of hERG is an off-target effect that results in cardiotoxicity and leads to the 
ultimate failure of  pre-clinical or clinical candidates.
36
 hERG has been previously identified as 
an Hsp90/Hsp70–dependent client protein, and studies have shown that inhibition of Hsp90 with 
geldanamycin resulted in proteasome-mediated degradation of hERG which prevented 
maturation of a fully functional hERG channel.
37-38
 In addition, the Hsp90 co-chaperones Hsp-
organizing protein (Hop), Hdj-2, and BCL-associated athanogene 2 (Bag-2), as well as the 38-
kDa FK506 binding protein (FKBP38) and calnexin were found to interact with hERG, 
presumably to aid in hERG maturation.
42
 Based on these observations, we sought to determine 
whether hERG was dependent upon a sole Hsp90 isoform, which would provide rationale to 
support the development of Hsp90 isoform-selective inhibitors that avoid such detriments. 
 Using the method of Ficker et al.
37
 co-immunoprecipitation studies were performed to 
evaluate the interaction of hERG with each of the Hsp90 isoforms. hERG expressing HEK 
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(HEK-hERG) cell lysates were chemically crosslinked and immunoprecipitated utilizing 
antibodies that recognize Hsp90α, Hsp90β, or hERG (Figure 28).
43
   
hERG channels exist 
as either a functional, 
fully glycosylated 
mature form (fg) or an 
immature core-
glycosylated protein 
(cg), and both species 
can be detected by 
Western Blot 
analysis.
44-46
 As 
previously determined, 
Hsp90 only interacts 
with the core glycosylated hERG (Figure 28).
37
 In addition, as evidenced in Figure 28, hERG 
only interacts with a single Hsp90 isoform, namely Hsp90α. The hERG-Hsp90α interaction can 
be captured by co-immunoprecipitation with either an anti-hERG or anti-Hsp90α antibody 
(Figure 28A/B). Due to the harsh conditions of the chemical crosslinking and the existence of 
Hsp90α/β heterodimers, some cross-reactivity in terms of the co-immunoprecipitation antibodies 
of Hsp90α and Hsp90β was observed. 
 In order to identify other proteins involved in this interaction, we performed co-
immunoprecipitations with anti-hERG antibody, separated the complexes on SDS-PAGE, 
excised protein bands and subjected the proteins to tryptic digest and mass spectrometry. Using 
 
Figure 28. hERG co-immunoprecipitates with Hsp90α and not Hsp90β. 
A.) Cross-linked cell lysates were immunoprecipitated with an anti-
hERG, anti-Hsp90α, or anti Hsp90β antibody, immunocomplexes were 
collected with Protein G beads. Proteins were eluted, uncrosslinked, 
separated by SDS-PAGE, and analyzed by Western Blotting B.) Same as 
(A) with longer exposure western blot of middle panel hERG blot (fg = 
fully glycosylated; cg = core glycosylated). Adapted from Ref. 43. 
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this approach we identified Hsp90α in the hERG-associated complex. Since Hsp90α and Hsp90β 
are overall 86% identical, it is important to note that we observed overlapping peptides derived 
from both isoforms, however the only unique peptides identified were from Hsp90α. In addition 
to the chaperones and co-chaperones previously identified to interact in the hERG complex,
42
 
additional proteins were found (Table 8). The Hsp/c70 co-chaperone, Hsc70-interacting protein 
(Hip), was found in this complex and typically directs Hsc70 to the Hsp90 complex with the help 
of the Hsp organizing protein (Hop).  Two additional peptidyl-prolyl cis-trans isomerases were 
also identified, FK506 binding protein 51 (FKBP51) and Cyclophilin A (CypA). FKBP51 has 
previously been identified in Hsp90 complexes, specifically those that contain the steroid 
hormone receptors.
47
 Hsp90 associated immunophilins typically bind to the C-terminus of Hsp90 
and mediate interactions between Hsp90 and other co-chaperones.  
Table 8. hERG interacting proteins (N=3).
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Protein
1
 
Accession 
Number (NCBI) 
No. Unique 
Peptides 
Sequence Coverage (%) 
hERG Q12809.1 9 11 
Hsp90α P07900 6 22 
Hsc70
* 
P11142 13 29 
Hsp70 P08107 21 40 
Calnexin
* 
P27824 3 7 
FKBP51 Q02790 3 12 
Hip P50502 2 7 
Hop
* 
P31948 6 16 
Cyclophilin A P62937 7 47 
14-3-3 P62258 9 44 
1
Confidence level of 95% or greater 
*
Also identified in Ref. 42 
 
CypA and Hsp90 have been shown to be necessary for cell membrane translocation of toxins 
from both Bacillus anthracis and Clostridium difficile, however, the involvement of CypA in 
Hsp90-mediated client protein maturation has not been reported.
48-49
 Another tetratricopeptide 
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repeat-containing protein, 14-3-3 protein epsilon (14-3-3) was also identified. Its role in client 
protein maturation is undocumented, however TPR-domain containing proteins typically mediate 
protein-protein interactions. 
B. Hsp90α and Hsp90β Knockdown have Differential Effects on hERG Trafficking 
To investigate the relationship between each of the cytosolic Hsp90 isoforms and hERG 
maturation, we analyzed the effects of either Hsp90α or Hsp90β knockdown using RNA 
interference with siRNAs targeted to each isoform. Under control conditions (scrambled siRNA), 
both the fully glycosylated and core glycosylated hERG proteins were observed (Figure 29). 
Previously, it was shown that Hsp90 inhibitors, such as geldanamycin and radicicol, cause both a 
dose-dependent reduction in the hERG-associated current amplitudes in patch clamp experiments 
and in the trafficking efficiency of hERG, or the ratio of fg hERG over total hERG (fg+cg) 
Figure 29. Hsp90α knockdown reduces hERG trafficking. A.) Control, Hsp90α, and Hsp90β targeted 
siRNA were transfected into hERG-HEK cells. The effect of siRNA was analyzed by Western Blot 
Analysis 48 h. post transfection. Actin represents a loading control. B.) Equation for trafficking 
efficiency. C.) Densitometry analysis of Western Blots from A (N=3); *, p < 0.02; **, p < 0.01 versus 
control siRNA values; From Ref. 43. 
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(Figure 29B).
37
 Knockdown of Hsp90α (60% reduction) caused approximately a 70% reduction 
in the trafficking efficiency of hERG and a 55% reduction in the total amount of hERG (Figure 
29C). Conversely, the hERG trafficking efficiency and total amount of hERG remained 
unchanged after Hsp90β knockdown (60% reduction).  
For further confirmation, we sought to demonstrate a direct relationship between the 
amount of functional Hsp90α and the trafficking efficiency of hERG. Using a tetracycline-
induced promoter linked to the expression of either an Hsp90α or Hsp90β targeted shRNA, this 
relationship was investigated (Figure 30). Figure 30 demonstrates the direct relationship 
between the amount of Hsp90α and the trafficking efficiency of the hERG channel. Decreasing 
amounts of Hsp90α in these cells causes a “dose-dependent” decrease in the amount of fully 
glycosylated, functional hERG after both 24 and 48 hours (Figure 30A/C/E and 30B/D/F). In 
addition, we observed a reduction in the total amount of hERG (fg+cg) in these cells following 
shRNA-mediated Hsp90α reduction (Figure 30A/C/E/G). Conversely, reduction in the amount 
of Hsp90β had no effect on the glycosylation state, i.e. functional activity, or total hERG (Figure 
30E/F/H). These data further demonstrate the isoform–dependent nature of the hERG channel 
for Hsp90α. 
115 
 
Figure 30. Hsp90α levels directly affect hERG trafficking efficiency.  Western blot analysis of cell 
lysates from HEK-hERG cells that either express Hsp90α or Hsp90β targeted shRNA after 
doxycyline treatment for (A) 24 h. or (B) 48 h. treatment. C.) and D.) Densitometry analysis of 
Western blots from A and B (Hsp90α knockdown) respectively. E.) and F.) Densitometry analysis of 
Western blots from A and B (Hsp90β knockdown) respectively.  Western blot analysis of cell lysates 
from HEK-hERG cells expressing G) Hsp90α targeted shRNA or H.) Hsp90β targeted shRNA after 
48 h. doxycycline treatment; From Ref. 43. 
 
116 
C. Implications for Hsp90 Inhibitor Development 
As pharmacological inhibition of hERG can lead to the ultimate failure of pre-clinical 
drug candidates, it is important to understand the different mechanisms by which hERG function 
can be affected.
36
 Drug-like molecules can bind directly to and inhibit hERG. However, it has 
also been demonstrated that Hsp90 inhibitors halt the functional maturation of hERG and can 
therefore inhibit hERG function by preventing trafficking to the membrane.
40-41
 Hsp90 inhibitors 
appear to prevent the glycosylation of hERG and halt translocation from the ER to the cell 
surface, which results in non-functional hERG accumulation in the cytosol.
37
 Since small 
molecule Hsp90 inhibitors are of great interest to the pharmaceutical industry, it is important to 
outline the liabilities associated with Hsp90 inhibition. These results clearly demonstrate that the 
cardiotoxic liability associated with pan-Hsp90 inhibition may be avoidable by the development 
of Hsp90 inhibitors that avoid Hsp90α. 
In addition, these results suggest that deconvolution of the Hsp90-isoform proteome is 
needed in order to more thoroughly understand the consequences of Hsp90 inhibition. It has been 
difficult to biochemically distinguish the roles manifested by each Hsp90 isoform due to the high 
structural similarity, significant antibody cross reactivity, and the presence of Hsp90α/β 
heterodimers. Furthermore, only a few Hsp90 isoform–dependent client proteins have been 
identified. In conclusion, we have shown herein that the hERG channel depends solely on 
Hsp90α, providing rationale for the design of isoform selective Hsp90 inhibitors. Furthermore, 
understanding the responsibilities manifested by each Hsp90 isoform will be crucial to the 
development of Hsp90 inhibitors and will allow for the development of Hsp90 inhibitors that 
produce fewer adverse effects. 
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III. Development of Grp94 Selective Inhibitors and Assays to Evaluate Grp94-inhibitory 
Activity 
Hsp90 contains an atypical nucleotide N-terminal binding pocket, which allows for the 
development of selective inhibitors.
50
 Several of these Hsp90 N-terminal inhibitors, e.g., 17-
AAG (Phase I-III), SNX-5422 (Phase I), CNF2024 (Phase II) and NVP-AUY922 (Phase I/II) 
have been evaluated clinical trials for various indications, including but not limited to melanoma, 
multiple myeloma, 
refractory solid tumors, and 
breast cancer (Figure 31).
51
 
Unfortunately, 
cardiovascular, ocular, 
and/or hepatotoxicities have 
been observed.
51-53
 Pan- 
Hsp90 inhibition may be the 
cause for these effects, as 
clinical inhibitors are known to target all four human isoforms; Hsp90α, Hsp90β, Trap1 and 
Grp94. Little is known about the client protein selectivity manifested by each of the four 
isoforms, and this gap in understanding may underlie the toxicity concerns that have arisen in 
clinical trials. Despite the clinical significance of Hsp90 inhibition, little investigation towards 
the development of isoform-selective inhibitors has been pursued to delineate isoform-dependent 
substrates, or as an opportunity to reduce the potential side effects that result from pan-inhibition.  
Grp94 co-crystal structures have recently been determined, and demonstrate this isoform 
to exhibit a unique secondary binding pocket that may provide an opportunity to develop 
 
Figure 31. Clinically evaluated N-terminal Hsp90 inhibitors. 
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isoform-selective inhibitors.
14-18,54-55
 Unlike TRAP-1, several substrates dependent upon Grp94 
have been identified and include Toll-like receptors (TLR1, TLR2, TLR4 and TLR9), integrins 
(CD11a, CD18, CD49d, α4, β7, αL and β2), IGF-I and –II and immunoglobulins.
13,21,23-24,56-62
 
Since these clients play key roles in cell-to-cell communication and adhesion, Grp94-selective 
inhibitors may disrupt malignant progression by preventing metastasis, migration, 
immunoevasion and/or cell adhesion.
24,56,60,62-66
  Interestingly, many of these Grp94-dependent 
clients have also been identified as key contributors to inflammatory disorders such as 
rheumatoid arthritis, diabetes and asthma.
21,24,59,67
 Therefore, the ability to develop a Grp94-
selective inhibitor may not only provide a new paradigm for Hsp90 inhibition, but may also 
provide new opportunities for the treatment of diseases other than cancer.  
The biological roles manifested by Grp94 have been primarily elucidated through the use 
of RNAi induced Grp94 knockdown, immunoprecipitation experiments, or through pan- 
inhibition of all four Hsp90 isoforms.  A selective small molecule inhibitor of Grp94 would 
provide an alternative and potentially powerful method for further elucidation of the roles 
manifested by Grp94, as well as the identity of other Grp94-dependent processes/substrates. 
Recently, the co-crystal structures 
of the chimeric inhibitor, radamide 
(RDA), bound to the N-terminal 
domain of both the yeast ortholog 
of cytosolic Hsp90 (yHsp82N, 
PDB: 2FXS) and the canine 
ortholog of Grp94 (cGrp94N∆41, 
Figure 32. Natural product Hsp90 inhibitors, GDA and 
RDC, along with their chimera, RDA. 
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PDB: 2GFD) were described.
17
 Utilizing a structure-based approach that relied upon these co-
crystal structures, a new class of inhibitors that target Grp94 has been developed.
68
 
A. Design of a Grp94 Inhibitor 
The design and synthesis of Grp94-selective inhibitors was carried out by Adam 
Duerfeldt, a former graduate student in the Blagg Laboratory, and is fully described in his 
doctoral dissertation.
69
 Briefly, Grp94-selective inhibitors were designed using a structure-based 
approach with the co-crystal structures of radamide (RDA, Figure 32), an N-terminal chimeric 
Figure 33. Structure-based design of Grp94-selective inhibitors. RDA bound to both A.) yHsp82 and 
B.) canine Grp94; C.) Sequence alignment of Grp94 and other Hsp90 isoforms highlighting Grp94 5-
amino acid insertion; From Ref. 18; D.) Modeling studies with proposed Grp94 inhibitors; and E.) 
Design of Grp94 inhibitors from N-terminal chimera, RDA. 
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compound, bound to both cytosolic Hsp90 from yeast (yHsp82) and Grp94 from canine 
(cGrp94N∆41).
17,70-71
  Analyses of the two co-crystal structures (Figure 33A/B) revealed the 
resorcinol ring to bind similarly in both isoforms, making a direct hydrogen bond with the 
conserved aspartic acid residue (Asp79 in yHsp82 and Asp149 in cGrp94N∆41) involved in ATP 
binding.  However, the quinone moiety was found to bind yHsp82N in a linear, trans-amide 
conformation, which was distinct from one conformation observed in the cGrp94N∆41 co-crystal 
structure. Upon binding cGrp94N∆41, two opposing conformations of RDA were observed (50% 
occupancy each):  One conformation exhibited a cis-amide orientation and projected the quinone 
moiety into a hydrophobic pocket that exists solely in Grp94 due to a five amino acid insertion 
into the primary sequence (Figure 33C). The second conformation of RDA observed in the 
RDA∙cGrp94N∆41 co-crystal structure presented the amide in a trans-configuration and 
projected the quinone toward the outside of the binding pocket, similar to that observed for RDA 
in the yHsp82N co-crystal structure.21 Interestingly, RDA was found to exhibit an 
approximately 2-fold higher binding affinity for full-length Grp94 than yHsp82.  
Further analyses of the RDA∙yHsp82N co-crystal structure revealed the quinone to 
mediate an intricate hydrogen-bonding network, whereas its interaction with cGrp94N∆41 was 
limited. For example, in the RDA∙yHsp82N structure, direct hydrogen bonds between the RDA 
quinone and Lys98 and Lys44 were observed.  In contrast, no direct hydrogen bonds were 
observed between cGrp94N∆41 and the cis-amide quinone, suggesting that functionalities on the 
quinone ring may be dispensable for Grp94 binding, but obligatory for cytosolic Hsp90 binding.  
In addition, this Grp94 hydrophobic pocket contains aromatic amino acids (Phe199, Tyr200 and 
Trp223) that are likely to facilitate π-stacking interactions, and could be utilized for the design of 
inhibitors that exhibit increased selectivity and affinity for Grp94 over cytosolic Hsp90.  
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Figure 35. Binding of compounds 22–26 to 
Grp94. Compounds 22–26 (25M) were 
incubated with cGrp94 and FITC-GDA (tracer) 
for 5 h and then fluorescence polarization values 
were measured. DMSO serves as a negative 
control (vehicle) while GDA (500 nM) served as 
the positive control; From Ref. 68. 
Although the primary sequences and ATP-binding pockets are highly homologous (>70% 
similar, 55% identical), this minor disparity was exploited for the rational design of Grp94 
inhibitors.
72
 Based on these observations, inhibitors containing a more hydrophobic and aromatic 
surrogate of the quinone linked to the resorcinol through a cis-amide bioisostere were 
hypothesized to inhibit Grp94 selectively (Figure 33D/E). The first generation analogues 
included an imidazole ring as the cis-amide isostere linked to both the resorcinol from RDA and 
an aryl ring, proposed to fill the aromatic-rich hydrophobic 
pocket, with varying linker lengths between the imidazole and 
benzene (Figure 34). Once the design and synthesis of a Grp94-
selective inhibitor was achieved, an assay capable of 
determining Grp94 inhibitory activity was needed.  
B. Development of a Grp94 Inhibitor Assay 
Upon preparation of compounds 22–26, 
we sought to determine the ability of these 
compounds to bind to Grp94. Using 
fluorescence polarization competition assays 
with recombinant cGrp94 and FITC-GDA, the 
ability of each compound to bind Grp94 and 
displace FITC-GDA was determined (Figure 
35).
73
 As evidenced in Figure 35, compounds 
22 and 23 were the only analogues capable of 
binding Grp94 and displacing FITC-GDA. 
Although FP can be used to determine the ability of these compounds to bind Grp94, it has 
Figure 34. Proposed Grp94 
inhibitors. 
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previously been demonstrated that Hsp90 inhibitors bind preferentially to the Hsp90 
heteroprotein complex.
74
 Therefore, we decided to investigate these compounds further in a cell-
based system. 
 
Once it was established that these compounds bind recombinant Grp94, biological studies 
commenced to validate our hypothesis that imidazoles containing a phenyl moiety provide Grp94 
inhibition. Unlike cytosolic Hsp90 inhibitors that exhibit anti-proliferative effects, RNAi 
experiments have shown that in culture, cell viability is unhampered by knockdown of Grp94.
24
 
Thus, a functional assay was necessary to determine Grp94 inhibition. Grp94 is required for the 
functional maturation and trafficking of select TLRs.
24,57
 Non-functional Grp94 causes TLR 
retention in the ER. Furthermore, mice deficient in Grp94 had deficient TLR signaling and did 
not produce proinflammatory cytokines after treatment with TLR agonists and also could not 
 
Figure 36. Development of a Grp94 assay. A.) Grp94’s (gp96) role in TLR maturation and 
trafficking; From Ref. 74; B.) Depiction of the Toll trafficking assay. 
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mount an immune response against Listeria monocytogenes infection.
57,75
 We reasoned that TLR 
trafficking could be used as a measure of Grp94 inhibition in in vitro assays and could be 
monitored with either fluorescence microscopy or flow cytometry following immunostaining of 
the extracellular TLR (Figure 36). HEK293 cells were stably transfected to express Grp94 
directed or scrambled shRNA. Both cell lines were then transfected with a plasmid encoding 
expression of the Toll protein, the Drosophila homologue of the interleukin 1 receptor and the 
founding member of the TLR family. Grp94 knockdown prevented presentation of the Toll 
receptor at the cell surface (Figure 37) as indicated by immunostaining and fluorescence 
microscopy. In order to investigate this inhibition of trafficking, cells were permeabilized with 
Triton X to effect intracellular staining for Toll. Results clearly indicated that the Toll receptor 
was expressed in the absence of Grp94, but unable to be trafficked to the cell membrane. 
Western blot analyses of lysates from Grp94 knockdown cells indicated a difference in the 
glycosylation pattern of the Toll protein, consistent with ER-retention and providing evidence for 
 
Figure 37. Toll trafficking depends upon Grp94. A.) Representative fluorescence confocal 
microscopy images of HEK293 cells stably transfected to express either scrambled shRNA or 
Grp94-targeted shRNA and transfected to express the Toll receptor (green) (blue = DAPI, 100x 
TIRF oil immersion; B.) Western blot analysis of cells treated as in A; Adapted from Ref. 68. 
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impaired trafficking to the cell membrane (Figure 37).
76-79
 This may indicate that Grp94 
interacts with a chaperone or partner protein that is involved in the glycosylation of its clients.  
Once functional knockdown of Grp94 was established, and a reduced cell surface 
expression of Toll observed, this assay served as readout for Grp94 inhibition. HEK293 cells 
were transfected with the same Toll-expressing plasmid, and subsequently exposed to compound 
for 24 h. prior to surface staining. The extent of surface expression was then quantified by 
measuring fluorescence intensity at the cell surface with Cell Profiler.
80
 A dose-response curve 
Figure 38. Fluorescence microscopy images and data of Toll trafficking inhibition. A.) Table of 
activities for compounds 22–26 to inhibit the trafficking of toll (error bars = +/- SEM for at least 100 
different cell populations; B.) dose-response curve for Toll-trafficking inhibition of compound 23; and 
C.) Representative epifluorescence microscopy images of HEK293 cells transfected to express the Toll 
receptor (green) and then treated with increasing concentration of compound 23 for 24 h. prior to 
staining (blue = DAPI, 60x, air objective. Adapted from Ref. 68. 
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for each of the compounds that inhibited at least 50% of Toll trafficking at 5 M was generated 
to obtain IC50 values (Figure 38). Representative fluorescent microscopic images and a dose-
response curve are shown for the most active compound, 23, in Figure 38. In parallel with 
fluorescence microscopy studies, flow cytometry was also used to quantify Toll surface 
expression. In a similar manner to fluorescence microscopy studies, HEK293 cells were 
transfected with the plasmid encoding Toll expression and were subsequently treated with 
compound for 24 h. Cells were 
fixed and stained for Toll surface 
expression using an anti-Toll 
antibody in conjunction with a 
fluorescently tagged secondary 
antibody (Figure 39). Due to a 
very limited dynamic range in 
fluorescence signal between the 
Grp94 deficient (94KD) and 
Grp94 expressing cells (94S), 
only 35 to 60 fluorescence units, 
flow cytometry was not further 
pursued as a method to quantify Toll trafficking inhibition.  
Once we established an assay to monitor Grp94 inhibition, we sought to ensure that 
compound 23 demonstrates selectivity for Grp94 versus cytosolic Hsp90 (Hsp90α and Hsp90β). 
The effect of compound 23 on both cell proliferation and the stability of Hsp90-obligate clients, 
 
Figure 39. Toll trafficking inhibition as determined by flow 
cytometry; mean fluorescence intensity determined only for 
intact, whole cells as determined by forward scatter vs. side 
scatter plots; S, scrambled shRNA; KD, Grp94 shRNA; 
cRDA, cis-radamide. 
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two well-established methods for the evaluation of Hsp90α/β inhibitors was pursued, in addition 
to other Grp94-dependent processes. 
C. Subsequent Biological Evaluation of a Grp94 Inhibitor 
As previously mentioned, it has been shown that Grp94 is not essential for tissue culture 
cell viability.
23-24
 In contrast, loss of functional Hsp90α or Hsp90β results in cell death. 
Therefore, we investigated the anti-proliferative effects of compounds 22–26 against two breast 
cancer cells, MCF7 (ER+) and SKBR3 (Her2 overexpressing, ER-), and against the non-
transformed HEK293 cells. None of the compounds evaluated manifested anti-proliferative 
activity at 100M, indicating these compounds do not target Hsp90α or Hsp90β. To support 
these findings, western blot analyses of Hsp90α/β client proteins were performed from HEK293 
cell lysates. Prototypical pan-Hsp90 inhibitors induce proteasome-mediated degradation of 
Hsp90α/β client substrates.
81
 As shown in Figure 40, compound 23 does not induce the 
degradation of Raf or Akt, two well-documented Hsp90α/β-dependent client proteins until 100 
M concentration.
82-84
 Compound 23 inhibits the presentation of the Grp94-dependent Toll 
 
Figure 40. Western blot analysis of 23 from HEK293 cell lysates (7.5 g total protein) after treatment 
with indicated concentration of compound for 24 h. GDA, a known pan-Hsp90 inhibitor is shown as a 
positive control (500 nM), DMSO is shown as a negative, and Actin serves as a loading control; 
Adapted from Ref. 68. 
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receptor at approximately 
30 nM and does not 
affect cytoplasmic 
proteins until 100 M in 
HEK293 cells, providing 
evidence for Grp94 
selective inhibition. To 
further understand the 
implications of Grp94-
selective inhibition, 
compound 23 was 
analyzed in other Grp94-dependent processes. 
Inhibition of Hsp90 is also known to induce expression of Hsp70 and this response is 
useful as a diagnostic tool.
85-86
 A parallel response exists when Grp94 expression is ablated by 
RNAi, or when its activity is inhibited by Radicicol (RDC) or 17-AAG: a transcriptional 
response is initiated that leads to upregulation of expression of BiP, the ER member of the Hsp70 
family. In collaboration with the Yair Argon Laboratory, we assessed the ability of 23 to cause 
BiP up-regulation, in comparison to pan-Hsp90 inhibitors. As shown in Figure 41, treatment of 
C2C12 cells with 0-75 µM of compound 23 did not lead to up-regulation of BiP, while 
treatments with 10µM RDC did cause BiP up-regulation. Only at concentrations above 200 µM 
did compound 23 resemble RDC and induce BiP expression. However, at these concentrations, 
the compound also destabilized Akt, a hallmark of inhibition of cytosolic Hsp90 (Figure 41).  
The inability of 23 to upregulate BiP at the 0-75 µM concentration range was surprising, because 
Figure 41. Induction of BiP Expression by treatment with 23.  NIH-
3T3 cells were treated with 10 µM of RDC or 0-50 µM of 23. After 18 
h. cells were harvested for SDS-PAGE and analyzed by 
immunoblotting. Grp94, BiP and PDIA6 were detected with the 
monoclonal anti-KDEL antibody, Akt by rabbit anti-serum. 14-3-3 
served as loading control. Numbers below BiP, Grp94, and Akt bands 
are the relative expression levels, determined by densitometry; *, an 
unknown KDEL-containing band; From Ref. 68. 
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this transcriptional response has previously been shown to be a property of Grp94 ablation and 
not Hsp90. 
IGF-II is a second well-defined Grp94-dependent client protein and active Grp94 is 
required for the secretion of IGF-II.
61
 It has been previously demonstrated that pan-Hsp90 
inhibitors, such as 17-AAG, prevent the secretion of IGF-II in serum-starved C2C12 myoblast 
cells.
23,61-62
 Also performed by the Argon Laboratory, serum-starved C2C12 cells were treated 
with increasing concentrations of compound 23 and the secretion of IGF-II was measured by 
ELISA (Figure 42A). Approximately 60% reduction of IGF-II was observed at 10 M of 23, 
while little effect on cell viability was observed (Figure 42B). The effect on IGF-II secretion is 
consistent with previous observations using pan-Hsp90 inhibitors, while the lack of effect on cell 
viability by 23 indicates that this compound is working through a Grp94-dependent mechanism 
and does not exhibit pan-inhibition.   
 
Figure 42. Inhibition of IFG-II secretion by 23.  A.) C2C12 cells were induced to differentiate by 
serum-starvation in the presence of the indicated concentrations of 23. Supernatants were collected 48 
h. later and IFG-II levels measured by ELISA. B.) Toxicity of compound 23 () and RDC () against 
C2C12 cells. The viability of cells treated as in A was measured at each of the indicated 
concentrations by the XTT assay; From Ref. 68. 
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Prior studies have shown that occupation of the Grp94 N-terminal ATP binding pocket 
by inhibitors results in an altered conformation of this domain.
87-88
 Anti-Grp94 (9G10) is an 
 
antibody that recognizes the acidic region (residues 290–350) in the second domain of Grp94.
89
 
Occupation of the ATP binding site causes a conformational switch in this region and prevents 
the 9G10 antibody from recognizing Grp94.
88
 Therefore, lysates of C2C12 cells treated with 
increasing concentrations of compound 23 were immunoprecipitated to assess whether it induces 
a conformational switch in Grp94. As observed in Figure 43, compound 23 induces a 
conformational switch in Grp94, as the 9G10 antibody is unable to recognize and 
immunoprecipitate the Grp94 in cells treated with 23. This result parallels the IGF-II secretion 
data shown in Figure 42, suggesting that an alteration in Grp94 conformation is incompatible 
with IGF-II secretion. Interestingly, this activity of Grp94 inhibitors appears to be cell-specific, 
 
Figure 43. Compound 23 alters Grp94 conformation. C2C12 cells were treated with the indicated 
concentrations of 23 or RDC overnight and cell lysates were immunoprecipitated with the 
conformation-specific antibody 9G10 and subsequently were immunoblotted for Grp94; lower panel, 
immunoblot of whole cell lysates with 9G10; HC=heavy chain; N=3; From Ref. 68. 
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as analogous experiments performed in CHO cells failed to show an effect on the conformation 
of Grp94 (data not shown).   
Previous studies have demonstrated that Gp93, the Drosophila ortholog of Grp94 is an 
essential gene.
58
 In the Drosophila model, maternal Gp93 is sufficient to support embryogenesis 
in Gp93 homozygous null embryos. In the absence of zygotic expression of Gp93, however, 
larvae display a pronounced growth defect, commensurate with disrupted gut epithelial 
morphology, decreased gut nutrient uptake, and marked aberrations in copper cell structure and 
function. As a consequence, loss of Gp93 expression is larval lethal in Drosophila.  In 
collaboration with the Chris Nicchitta Laboratory, the effects of compound 23 on Drosophila 
larval growth were determined. First instar wild type (w1118) larvae were placed onto fly food 
supplemented with either no supplement (A), 0.1% (B), 0.3% (C), or 0.5% (D) DMSO (vehicle 
 
Figure 44. Effect of compound 23 on Drosophila larval growth; From Ref. 68. 
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controls) or fly food supplemented with 250 g/ml (E), 500 g/ml (F), 750 g/ml (G) or 1 mg/ml 
(H) compound 23. As is evident from the micrographs of representative larvae, dietary uptake of 
23 was associated with a dramatic growth phenotype (Figure 44). In parallel experiments, larval 
gut tissue was obtained from each of the feeding conditions and gut epithelial morphology 
evaluated by fluorescence microscopy. No grossly discernible effects on copper cell structure 
were observed, indicating that under these feeding conditions, the inhibition of Gp93 function 
was incomplete (data not shown). Pharmacokinetic studies of compound absorption and 
metabolism may provide addition insights into this partial phenotypic behavior.  
D. Summary of and Implications for Grp94 Inhibition 
Hsp90 inhibitors have been the subject of intense pharmaceutical research, not only for 
cancer, but also neurodegeneration.
90-98
 All Hsp90 inhibitors that have reached clinical trials bind 
to the Hsp90 N-terminal ATP-binding pocket and demonstrate pan-Hsp90 inhibition, i.e. they 
inhibit all human Hsp90 isoforms simultaneously.
51-52,99
 Toxicities and off-target effects 
resulting from Hsp90 inhibition may be a consequence of pan-inhibition. Therefore, the design 
of Hsp90 isoform-selective inhibitors may provide a valuable pharmacological tool to dissect the 
roles of each isoform and may lead to more clinically useful inhibitors. 
 Comparing the crystal structures of several known Hsp90 inhibitors bound to either 
cytosolic Hsp90 or to the ER-resident Grp94 provided a rational design platform for the 
development of Grp94 inhibitors. Using structure-based drug design, five compounds were 
identified as potential leads that contain a phenyl ring appended to an imidazole ring, which 
serves as a cis-amide bioisostere. The predisposed orientation of the phenyl ring was postulated 
to allow interactions with the unique Grp94 π-rich pocket. Since Grp94 has previously been 
shown to be responsible for the trafficking of TLRs to the cell membrane,
57
 this activity was 
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used as a functional assay for Grp94 inhibition. Of the five compounds evaluated, compound 23 
manifested the best activity in this assay (35 nM). In subsequent, direct readout assays, including 
an in-cell conformational assay, compound 23 affected Grp94 itself at the same concentration as 
that needed to inhibit chaperone activity. 
Once the Grp94 inhibitory activity of compound 23 was established by these parameters, 
we evaluated the isoform selectivity of the compound. Inhibitors of cytosolic Hsp90 (Hsp90α/β) 
manifest antiproliferative activity in cell culture. At concentrations wherein the assays observed 
activity for compound 23, there were no cytotoxic effects against any cell line tested. In addition, 
compound 23 exhibited no effect on the prototypical Hsp90α/β client kinases, Akt or Raf, until 
concentrations 100x greater than the IC50 for Grp94 inhibition. Therefore, compound 23 appears 
to manifest considerable selectivity for Grp94 versus Hsp90α/β, perhaps explaining its low 
toxicity. Lastly, compound 23 stunted the growth of Drosophila larvae in a dose-dependent 
manner, suggesting that it may be a useful Grp4 inhibitor in vivo. Future studies with 23 will 
help dissect the roles played by Grp94 and will shed light into the validity of Grp94 as a 
therapeutic target. 
IV. Conclusions and Future Work 
 Delineating the roles manifested by each Hsp90 isoform and the identification of 
isoform-selective Hsp90 inhibitors have become major themes of research for the Blagg 
Laboratory. Throughout the work described above, we have been able to elucidate the Hsp90 
isoform-dependency of the hERG subunit of the K
+
 channel. Namely, hERG relies on Hsp90α, 
and not Hsp90β or Grp94, for its maturation and functional trafficking. This finding provides 
rationale for the development of Hsp90 inhibitors that do not target Hsp90α. In addition, it is one 
of the first examples demonstrating the single isoform dependency of an Hsp90 client protein. In 
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addition, we have been able to identify a rationally designed Grp94 inhibitor, namely compound 
23. This compound not only will aid in the elucidation of Grp94-dependent processes, but it will 
also provide an avenue to explore Grp94 as a therapeutic target. Overall, these contributions 
highlight the necessity to fully understand the individual roles of each Hsp90 isoform. 
 The identification of subsequent isoform-dependent client proteins is underway. The 
prostate cancer cell line, PC3, has been engineered to express either Hsp90α or Hsp90β shRNA. 
Using these cell lines, it is possible to determine the isoform dependency of other Hsp90 client 
proteins (Figure 45). It is evident that several proteins are degraded in the absence of Hsp90α, 
i.e. Raf, c-Src, Survivin, hERG, GAPDH, and HSF1. However, CXCR4 appears to depend upon 
Hsp90β, as it is degraded upon Hsp90β depletion. The same dependencies of both ERK5 and c-
Figure 45. The elucidation of Hsp90 isoform-dependent client proteins in PC3 cells engineered to 
express either Hsp90α or Hsp90β shRNA. 
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Srv (v-Src) were observed in a yeast-based system in which the endogenous yeast Hsp90s had 
been replaced with either hHsp90α or hHsp90β as the sole Hsp90 present.
12
 Subsequent studies 
are underway to expand the list of known isoform-dependent client proteins. 2-Dimensional 
difference gel electrophoresis (2D-DIGE) is underway in the George Vielhauer Laboratory at 
The University of Kansas Medical Center using this same PC3-based system. In addition, stable 
isotope labeling by amino acids in cell culture (SILAC) is currently in progress wherein the wild 
type, Hsp90α- and Hsp90β-deficient cell lines were differentially labeled with stable isotope 
combinations of lysine and arginine.
100
 Effects over the entire Hsp90-ome will subsequently be 
identified using mass spectrometry and bioinformatic techniques. Together, these powerful 
experimental methods will provide a comprehensive list of Hsp90 isoform-dependent clients, 
providing insights into the clinical relevance of inhibiting each Hsp90 isoform as well as 
delineating the toxicities observed with pan-Hsp90 inhibition.  
V. Materials and Methods 
A. The hERG Channel is Dependent upon the Hsp90α Isoform for Maturation and 
Trafficking 
Antibodies. The following antibodies were used for Western Blotting and/or co-
immunoprecipitation: rabbit anti-Hsp90α (Neomarkers), goat anti-Hsp90β (SantaCruz), goat 
anti-hERG (SantaCruz), rabbit anti-Grp94 (SantaCruz) and rabbit anti-Actin (SantaCruz). 
Cell Lines. The HEK-hERG
101
 (HEK 293 stably transfected with human hERG WT) cell line 
was a kind gift from Eckhard Ficker (MetroHealth Medical Center/Case Western Reserve 
University). The HEK-hERG cell line was maintained in DMEM supplemented with 10% FBS, 
streptomycin, penicillin, and geneticin at 37ºC, 5% CO2. Inducible knockdown of Hsp90 or 
Hsp90 in the HEK-hERG cell line was accomplished using a tetracycline inducible shRNA 
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construct containing a hairpin sequence specific for either the Hsp90α or Hsp90β isoform. These 
constructs were made by subcloning the isoform specific hairpin sequences from pGIPZ vectors 
(Open Biosystems, Lafayette, CO) into pTRIPZ vectors using MluI and XhoI restriction sites. 
The mature shRNA sequences were 5ʹ–AGGAAGAATTTGGTCAAAA–3ʹ and 5ʹ–
ACTAAGAAGATCAAAGAGA–3ʹ for Hsp90 and Hsp90 respectively. Resulting clones 
where sequenced verified using pTRIPZ sequencing primers 5ʹ–GGAAAGAATCAAGGAGG–
3ʹ. The resulting pTRIPZ plasmids containing Hsp90 isoform specific shRNA were packaged 
into third generation lentivirus particles. Cells were cultured as above but with the addition of 2.5 
g/mL puromycin to select for stable, transduced cells. Induction of shRNA expression with 
tetracycline dose was monitored by the increase in TurboRFP fluorescence which is driven by 
the tetracycline response element (TRE). shRNA expression was induced with the addition of 1-
24 g/mL doxycyline. 
siRNA and Transfection. Cells were plated in 24-well plates at 9.0x10
5
 cells/mL (0.5 mL/well) 
in antibiotic free DMEM supplemented with 10% FBS. After 24 h., media was replaced with 0.2 
mL OptiMEM (Invitrogen) and transfected with 43 uL of transfection mix containing 50 pmol 
siRNA and 2 uL oligofectamine (Invitrogen). Proteins were harvested 48 h. post transfection. 
Hsp90α siRNA was purchased from Ambion while Hsp90β siRNA was from SantaCruz 
Biotechnology.  
Western Blot Analysis. The various HEK cells were harvested in cold PBS and lysed in 
mammalian protein extraction reagent (MPER, Pierce) lysis buffer containing protease inhibitors 
(Roche) on ice for 1 h. Lysates were clarified at 14,000g for 10 min at 4° C. Protein 
concentrations were determined using the Pierce BCA protein assay kit per the manufacturer’s 
instructions. Equal amounts of protein (2.5-10 μg) were electrophoresed under reducing 
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conditions (6.5% acrylamide gel), transferred to a polyvinylidene fluoride membrane (PVDF), 
and immunoblotted with the corresponding specific antibodies. Membranes were incubated with 
an appropriate horseradish peroxidase-labeled secondary antibody, developed with a 
chemiluminescent substrate, and visualized. 
Immunoprecipitation. Using a method analogous to Ficker et al.
37
 and Nanduri et al.
38
, cells 
were plated in 10 cm cell culture dishes and allowed to grow to 80% confluency. Cells were then 
washed once with phosphate-buffered saline (PBS) and then crosslinked by incubation with 1.5 
mM dithiobis(succinimidyl propionate, DSP, Pierce) in PBS for 15 min at room temperature. 
DSP was quenched by the addition of pH 7.5 Tris (final concentration 10 mM). Cells in 
PBS/DSP/Tris were scraped into conical tubes, pelleted, and washed with PBS. Cells were 
harvested in lysis buffer containing 0.1% NP40, 50 mM Tris (pH 7.5), 150 mM NaCl, 20 mM 
MoO4, and protease inhibitors (Roche). Lysates were clarified and protein concentration was 
determined using BCA assay. For co-immunoprecipitation, 300 g total protein was diluted to 
500 L total volume in lysis buffer and incubated with 2g of either anti-hERG, anti-Hsp90α or 
anti-Hsp90β antibody overnight at 4ºC with rocking. Immunocomplexes were captured with 35 
L of DynaBeads Protein G (Invitrogen) for 2 h. with rocking at 4ºC. Protein G Bead-complexes 
were washed three times with lysis buffer and eluted with sample buffer. Samples were then 
boiled and subjected to SDS-PAGE and Western Blot analysis.  
Tryptic Digest and Mass Spectrometry. Lysates were co-immunoprecipitated as above except 
with 1 mg total protein, 6 ug anti-hERG antibody, and 100 L DynaBeads Protein G in 1.5 mL 
total volume. After wash steps, samples were boiled and subjected to SDS-PAGE. Acrylamide 
gels were stained, bands excised, destained and washed using the Silver Stain Kit for Mass 
Spectrometry (Pierce). Excised bands were further washed (0.2 M NH4HCO3, 50% acetonitrile) 
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and then dried. Gel pieces were suspended in 0.2 M NH4HCO3 and 10 mM DTT (final 
concentration) was added and heated at 60ºC for 15 mins. 20 mM iodoacetamide (final 
concentration) was then added and gel bands incubated for 30 mins at 25ºC in the dark. Gel 
bands were then washed (0.2 M NH4HCO3, 50% acetonitrile), shrunk in 100% acetonitrile, and 
dried. Gel bands were re-swelled in 0.2 M NH4HCO3 containing 0.5 g trypsin and 0.2 M 
NH4HCO3 with 10% acetonitrile was added to keep gel pieces submerged. Digest was terminated 
after 16 h. of incubation at 37ºC by the addition of 0.1% trifluoroacetic acid (final 
concentration). Supernatants were then subjected to LC-MS/MS at the University of Kansas 
Analytical Proteomics Lab. Results were analyzed using Scaffold software which integrates 
results from Mascot, Sequest and X!Tandem search engines. 
Densitometry and Statistical Analysis. Western Blot films were digitally captured using a 
standard flatbed scanner (HP). The digital blots were then converted to 16-bit black and white 
images using ImageJ software. Densitometric measurements were then performed in ImageJ 
using the “Gels” tool. Peak areas were used as a measure of protein levels. Statistical analysis 
was performed using GraphPad Prism5, statistical significance was determined using a paired, 
two-tailed t-test. 
B. Development of Grp94 Selective Inhibitors and Assays to Evaluate Grp94-inhibitory 
Activity 
Cell Culture. HEK293 cells were maintained in DMEM supplemented with non-essential amino 
acids, L-glutamine (2 mM), streptomycin (500 µg/mL), penicillin (100 units/mL), and 10% FBS. 
Cells were grown to confluence in a humidified atmosphere (37 °C, 5% CO2). Stable Grp94-
siRNA knockdown cell lines were generated as folllows: the shRNA sequence 5′-
GGCUCAAGGACAGAUGAUGtt-3′ was cloned into the A pSilencer 2.0-U6 vector  (Ambion) 
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and positive clones confirmed by sequencing. The pSilencer 2.0-U6-GRP94 siRNA vector and a 
control, non-targeting pSilencer 2.0-U6 siRNA vector (scrambled, control) were transfected into 
HEK293 cells using Lipofectamine 2000 and the manufacturers protocol. Cell cultures were 
selected thirty six hours post-transfection by addition of 1 g/mL puromycin to the media. 
Puromycin resistant clones (both Grp94 siRNA and non-targeting siRNA) were subsequently 
expanded and screened for knockdown efficiency by immunoblotting, using Grp94 antibody 
DU120. Clones displaying greater than 90% knockdown were selected. Puromycin-resistant 
clones from the non-targeting siRNA were obtained in parallel and screened for normal Grp94 
expression, also by immunoblotting with DU120.  
Fluorescence Polarization. Assay buffer (25L, 20 mM HEPES pH 7.3, 50 mM KCl, 5 mM 
MgCl2, 1 mM DTT, 20 mM Na2MoO4, 0.01% NP-40, and 0.5 mg/mL BSA) containing com-
pounds 22–26 or GDA were plated in 96-well plates (black well, black bottom) to provide final 
concentrations of 25 M or 500 nM, re-spectively (1% final DMSO concentration).
73
 
Recombinant cGrp94 and FITC-GDA were then added (50 L and 25 L) to give final 
concentrations of 60 nM and 5 nM, respectively. Plates were incubated with rocking for 5 h at 4 
°C. Fluorescence polarization values were then read using excitation and emission filters of 485 
nm and 528 nm, respectively. Percent FITC-GDA bound was determined by using the DMSO 
millipolarization unit (mP) as the 100% bound value and the mP value of free FITC-GDA as the 
0% bound value. 
Toll-Trafficking Assay – Fluorescence Microscopy. HEK293 cells were plated in 6-well cell 
culture treated plates in Dulbecco's Modified Eagle Medium (1x DMEM) supplemented with 
10% fetal bovine serum containing no antibiotics and were maintained at 37 °C, 5% CO2, and 
95% relative humidity. After 24 h, the cells (95% confluence) were transfected with pcDNA6B-
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Toll-Flag using Lipofectamine2000 according the manufacturer’s instructions. Cells were 
transfected for 16 h, then were trypsinized and plated in 96-well microscopy-quality, black 
walled plates that had been pre-treated with attachment factor. After 3 h. incubation at 37 °C to 
allow the cells to attach, compound at varying concentrations in DMSO (1% DMSO final 
concentration) was added and cells were returned to incubator for 24 h. After 24 h, the media 
was removed and cells were fixed in freshly made 4% paraformaldehyde in Dulbecco’s 
Phosphate Buffered Saline (DPBS) for 10 min at 25 °C. Cells were washed twice with DPBS 
then stained with Wheat Germ Agglutinin-Texas Red (5 µg/mL in DPBS, 60 min, 25°C). Cells 
were washed twice with DPBS, blocked in 5% bovine serum albumin (BSA, 10 min, 25 °C) 
followed by staining for 16 h with an anti-Toll antibody (1:200 in 5%BSA/DPBS, 4°C, Santa 
Cruz, sc-33741). Cells were washed twice with DPBS and stained with an anti-rabbit-
AlexaFluor488 antibody (1:300 in DPBS, 25 °C, Invitrogen, A-11008) for 3 h at 25 °C. Cells 
were then washed twice with DPBS after which DAPI was added (1 µM in DPBS). Cells were 
imaged using an inverted Olympus IX-81 microscope with a 60X long working distance air 
objective using appropriate filter sets for the various tags (AlexaFluor488, Texas Red, DAPI). 
Images were processed using SlideBook5.0 and analyzed using CellProfiler and CellProfiler 
Analyst. 
Flow Cytometry. HEK293 cells were plated in 6-well plates and transfected as described above 
in Toll-Trafficking Assay. For drug treated cells, 18 h post transfection, fresh media was added 
(5 mL) and cells were dosed in the 6-well plate with compound in DMSO (1% DMSO final 
concentration). Cells were incubated with compound for 24 h at 37 °C. To collect the cells, 
media was aspirated and cells were scraped into 1 mL of cold PBS. Wells were washed with an 
additional 1 mL cold PBS and combined with corresponding cells. Cells were centrifuged at 
140 
1000 rpm for 5 min. at 4°C and PBS was removed. All washing and staining steps performed at 
4 °C, while all centrifugation steps performed at 1000 rpm for 5 min at 4 °C. Cells were fixed 
with 4% paraformaldehyde in PBS at 4 °C for 30 min. Cells were then washed twice with wash 
buffer (WB 0.5% BSA in PBS) followed by three washes with blocking buffer (BB, 1% FBS and 
0.5% BSA in PBS) for 5 min at 4 °C each. Cells were then stained with an anti-Toll antibody 
(100 L of 5.0 g/mL in BB) for 40 min at 25 °C. Cells were washed twice with BB and were 
stained with an AlexaFluor488-conjugated secondary antibody (100 L of 5.0 g/mL in BB) for 
40 min at 25 °C in the dark. Cells were washed twice with WB, suspended in 1 mL of WB, 
passed through a mesh strainer to obtain a homogenous cell solution and analyzed by flow 
cytometry. 
Western Blotting. HEK293 cells were plated in 6-well plates and treated with various 
concentrations of drug, GDA in DMSO (1% DMSO final concentration), or vehicle (DMSO) for 
24 h. Cells were harvested in cold PBS and lysed in mammalian protein extraction reagent 
(MPER, Pierce) and protease inhibitors (Roche) on ice for 1 h. Lysates were clarified at 14,000 g 
for 10 min at 4 ºC. Protein concentrations were determined with the Pierce BCA assay kit per the 
manufacturer’s instructions. Equal amounts of protein were electrophoresed under reducing 
conditions, transferred to a PVDF membrane, and immunoblotted with the corresponding 
specific antibodies. Membranes were incubated with an appropriate horseradish peroxidase-
labeled secondary anti-body, developed with chemiluminescent substrate, and visualized. 
Grp94 Immunoprecipitation. Detergent lysates of the indicated cells were immunoprecipitated 
with 9G10 monoclonal anti-Grp94 (StressGen, Vancouver, BC) followed by protein G-
Sepharose (Sigma Chemicals or Pierce) as described in Ref. 102. 
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Chapter IV 
Exploration of Curcumin as a Novel Hsp90 Inhibitor 
I. Introduction 
Curcumin (27, Figure 46) is the biologically 
active natural product found in turmeric and yellow 
curry, and has demonstrated activity for the treatment 
of inflammatory diseases, Alzheimer’s, and cancer.
1
 Curcumin was first isolated from the 
rhizome of Curcuma longa L. (Zingiberaceae) and has been used as a botanical medicine by 
inhabitants of both India and China.
2
 Traditionally, curcumin was used for the treatment of 
wounds, inflammation, and tumors.
3
 More recently, it was identified as an anti-tumor agent and 
was shown to exhibit beneficial activity towards the treatment of Alzheimer’s disease.
4
 In 
regards to curcumin’s anticancer activity, several studies have demonstrated that curcumin 
manifests potent anti-proliferative activity against numerous cancer cell lines, but is not toxic to 
small and large animals at high doses.
5-6
 As a result of this exceptional selectivity, curcumin has 
entered several clinical trials for the treatment of cancer.
7-8
 Previous studies have shown that 
curcumin can inhibit topoisomerase II at concentrations of 50 g/mL.
9
 More recently it was 
shown to inhibit NAD(P)H:quinone oxidoreductase 1 (NQO1) and lead to the degradation of p53 
at 40 M.
10
 However, there are a large number of other proteins whose activities curcumin has 
been shown to alter for which no rational explanation has been provided.
11
  
 Curcumin’s anti-inflammatory activity has been ascribed to result from its ability to 
decrease prostaglandin E2 synthase (PGE2), thus reducing prostaglandins responsible for 
inflammation.
12
 In addition, curcumin has been shown to inhibit pathways that modulate 
inflammatory cascades, including the nuclear transcription factor-κB (NF-κB), activator protein-
Figure 46. Structure of curcumin. 
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1 (AP-1) and c-Jun, all of which are important mediators of cellular response to environmental 
stress, pro-inflammatory kinases, mitogen stimulation, and apoptotic stimuli.
13
 In regards to 
curcumin’s use for the treatment of Alzheimer’s disease, curcumin has been shown to decrease 
amyloid pathology, decrease aggregated Amyloid β (Aβ), and protect neuronal cells from Aβ 
induced toxicity.
4,14
 Furthermore, curcumin has been shown to increase levels of the 70 kDa heat 
shock protein (Hsp70), which has been implicated for the refolding and solubilization of these 
protein aggregates.
15-16
 The antioxidant activity afforded by curcumin has been described to 
result from decreased nitric oxide synthase (NOS) activity.
17
 Data obtained from previous studies 
support the use of curcumin for the treatment of these diseases, several of which are currently in 
preclinical development.  
 Curcumin promotes apoptosis in colon, liver, breast, prostate, and leukemia cancer cell 
lines.
18
 Curcumin has been shown to suppress the expression of cyclin D, endothelial growth 
factor receptor (EGFR), and cause degradation of the p53 tumor suppressor. In addition, 
curcumin disrupts cell signaling pathways involving phosphokinase B (Akt), nuclear factor κB 
(NF-κB), c-myc, and phospho-Akt (pAkt).
17
 Angiogenic growth factor production, tumor 
necrosis factor 1-β (TNF-1β), and interleukin 1 (IL-1) have also been shown to be decreased at 
low micromolar concentrations of curcumin.  
Additional proteins affected by administration of curcumin include the aryl hydrocarbon 
receptor (AHR), survivin, glutathione S-transferase (GST), telomerase (hTERT and hTR 
assembly), estrogen receptor (ER), androgen receptor (AR), bcr-Abl kinase, calmodulin, cyclin-
dependent kinase 4 (CDK4), STAT3, Bcl-2,  and others (Table 9). Although it is plausible that 
curcumin could individually disrupt all of these processes, it can be reasoned that curcumin was 
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more likely inhibiting a single target that was responsible for mediating cascades in which the 
above proteins were involved. 
Table 9. Client proteins of Hsp90 also affected by curcumin. 
Protein 
Curcumin 
Reference 
Hsp90 
Reference 
PGE
2
 synthase 12 19 
NF-κB 20 21 
AP-1 22 23 
c-Jun 24 25 
iNOS 17 26 
Hsp70 15 27 
Cyclin D 28 29 
EGFR 30 31 
p53 10 32 
Akt 33 34 
p-Akt 35 36 
c-Myc 37 38 
TNF-1α 39 40 
IL-1 41 40 
AHR 42 43 
Survivin 35 44 
ER 45 46 
AR 47 48 
Telomerase 49 50 
Bcr-Abl 51 52 
CDK-4 28 53 
Bcl-2 54 55 
Calmodulin 56 57 
GST 58 59 
STAT3 60 61 
 
The Hsp90-family of gene products function as molecular chaperones, which are 
ubiquitously expressed and required for the viability of all eukaryotic cells. While Hsp90 
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functions to facilitate the refolding of denatured proteins, Hsp90 is more widely appreciated for 
its obligatory role in facilitating the post-translational maturation of numerous proteins that 
regulate a plethora of signal transduction pathways.
62
 More than 100 Hsp90-dependent client 
proteins have been identified, including those that are involved in inflammatory response such as 
STAT3, NF-kB, PGE2, AP-1, and c-Jun.
63
  Among these Hsp90 clients, many are proteins 
directly related to oncogenesis,
64
 and numerous Hsp90 clients are represented in all six hallmarks 
of cancer.
65-66
 Recent studies by Dou and coworkers provided evidence that increased levels of 
Hsp90 and/or Hsp70 can refold phosphorylated Tau aggregates and protect neuronal cells from 
Aβ induced toxicity.
16
 Hsp90 and Hsp70 are induced upon cellular exposure to stress stimuli or 
Hsp90 inhibitors, which dissociate Hsp90 from Hsp90/HSF1 (heat shock factor 1) complexes, 
allowing the assembly of HSF1 trimers. HSF1 trimers serve as transcriptional activators by 
binding to the heat shock response elements and leads to the induction of Hsp’s.
27
 Results from 
previous studies demonstrated that exposure of neuronal cells to Hsp90 inhibitors led to 
increased expression of Hsps and the rapid clearance of phosphorylated Tau and protection from 
Aβ induced toxicity in a manner dependent upon the concentration of the previously identified 
Hsp90 inhibitor, geldanamycin.
16
 
The notable similarities between the pharmacological properties and physiological effects 
of curcumin and geldanamycin led to a search of the literature to determine whether additional 
relationships existed.  As a result, it became clear that Hsp90 had previously been shown to 
mediate the activities of cyclin D, EGFR, p53, AKT, NF-kB, Bcl-2, c-myc, TNF-α, AHR, 
survivin, GST, telomerase, ER, AR, bcr-Abl kinase, CDK4, calmodulin, Bcl-2, TNF-α, STAT3, 
and interleukin-1, which have all been shown to be affected by curcumin (Table 9). Prior to 
joining the Blagg Laboratory, the hypothesis that curcumin’s inhibitory activity resulted from 
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Hsp90 inhibition was evaluated. In addition, several other research groups simultaneously 
recognized the similarities between curcumin’s biological activity and those manifested by 
Hsp90 inhibition.
67-68
 
II. Evaluation of Curcumin as an Hsp90 Inhibitor 
The mechanism for conformational maturation of Hsp90’s diverse set of client proteins is 
complex, and involves the interaction of Hsp90 with a number of co-chaperones and partner 
proteins and the binding/hydrolysis of ATP.
62
 To test the hypothesis that many of the 
physiological effects of curcumin are manifested through its ability to inhibit Hsp90, the effects 
of curcumin on Hsp90 activity was investigated previously in the Blagg Laboratory. 
Subsequently, it was determined that curcumin bound recombinant Hsp90, inhibited its 
chaperone function, induced a concentration-dependent depletion of Hsp90-dependent client 
proteins in malignant cells, and induced Hsp90 levels in cells, all which correlated directly with 
its ability to inhibit cell growth.  
A. Curcumin Binds Purified Recombinant Hsp90.  
Addition of purified, 
recombinant Hsp90 to a buffered 
aqueous solution of curcumin resulted 
in a three-fold increase in curcumin 
fluorescence at 523 nm when excited 
by light at 422 nm, indicating a direct 
binding interaction between curcumin 
and Hsp90. Titration of Hsp90 with 
curcumin (Figure 47) showed saturable binding with an apparent Kd of 2.3 M. 
Figure 47. Titration of purified recombinant Hsp90 with 
curcumin. 
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 B. Curcumin Inhibits Hsp90-dependent Refolding of Heat Denatured Luciferase.  
Heat denatured firefly 
luciferase has been utilized as a 
model substrate for measuring the 
protein folding activity of the Hsp90 
multiprotein complex,
69
 because 
measurement of the luminescence 
produced by restoration of its 
enzymatic activity provides a highly 
sensitive and reproducible assay for 
the Hsp90’s chaperone activity. 
Rabbit reticulocyte lysate provides a 
quasi-physiological model system in which to study the activity of Hsp90, as it contains Hsp90 
and all the requisite co-chaperones and partner proteins necessary for the refolding denatured 
luciferase.
70
 Because different sources of rabbit reticulocyte lysate can contain varying levels of 
the individual components of Hsp90 protein folding machinery,
70
 two lysates were analyzed in 
this study. When increasing concentrations of curcumin were added to these assays, a 50% 
decrease in the amount of refolded luciferase was observed at 10 M and 38 M (i.e. EC50, 
Figure 48), similar to data obtained from the Hsp90 binding studies. Control experiments 
indicated that curcumin had no effect on the activity of native luciferase. Thus, the results 
indicate that curcumin has the capacity to inhibit the refolding of an Hsp90-dependent client 
protein.  
Figure 48. Effect of curcumin on Hsp90-dependent 
refolding of luciferase in rabbit reticulocyte lysate. 
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C. Curcumin Inhibits the Maturation of Hsp90-dependent Proteins in MCF-7 Breast 
Cancer Cells.  
Hsp90 inhibitors, such as geldanamycin, exert their activity by competitive inhibition of 
Hsp90’s ATP-driven reaction cycle,
71
 as the ability to bind and hydrolyze ATP is required for 
Hsp90 to facilitate the maturation of its client. In the presence of Hsp90 inhibitors, the 
multiprotein complex formed between Hsp90, its co-chaperones and clients becomes 
destabilized, and, the heteroprotein complex is unable to proceed through the normal protein 
folding process. Consequently, these unproductive complexes become substrates for ubiquitin 
ligase, which leads to ubiquitination of the client and hydrolysis of the substrate via the 
proteasome.
72
 
To determine whether curcumin similarly caused the degradation of well-documented 
Hsp90 client proteins in transformed cells, increasing concentrations of curcumin were incubated 
with MCF-7 breast cancer cells for 24 h and equal concentrations of protein from these lysates 
were probed for the disappearance of Hsp90 client proteins, Akt, Raf-1, and Her2 (erbB2). Since 
actin is not an Hsp90 dependent protein, its level remains unaffected by Hsp90 inhibitors and 
ensures no decrease in overall protein levels is observed.
73
 Western blot analyses of these 
 
Figure 49. Western blot analyses of several Hsp90 client proteins from MCF-7 cell lysates after 
treatment with varying concentrations of curcumin.  
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proteins indicated that all three client proteins were rapidly degraded between at 5 and 30 M of 
curcumin, without affecting actin levels (Figure 49). Furthermore, Hsp90 levels were increased. 
Similar studies have previously shown that curcumin also causes the induction of Hsp70.
15
 Both 
of these results are likely due to curcumin-induced disassembly of the Hsp90/HSF1 complex, as 
geldanamycin similarly causes the induction of Hsp synthesis by disrupting the interaction of 
Hsp90 with HSF1.
74-75
 Therefore, these results indicate that curcumin, like other Hsp90 
inhibitors, stimulates the turnover of Hsp90-dependent clients in transformed cells. 
D. Curcumin Inhibits Proliferation at a Concentration that Mirrors its Ability to Prevent 
Folding of Hsp90-dependent Substrates.  
MCF-7 cells were incubated with varying concentrations of curcumin and the anti-
proliferative activity was determined. Curcumin exhibited anti-proliferative activity with an IC50 
of 6 M, approximately the same concentration needed to bind purified recombinant Hsp90 
ATPase, inhibit the renaturation of heat denatured luciferase, cause the degradation of Hsp90 
client proteins Akt, Raf-1, and Her2 in MCF-7 cells, and induce the expression of Hsp90. These 
results strongly support the hypothesis that the anti-proliferative effect of curcumin on MCF-7 
breast cancer cells is due to curcumin-induced disappearance of Hsp90-dependent client proteins. 
III. Design, Synthesis and Evaluation of Electron Rich Curcumin Analogues 
 In total, there are over 100 previously reported “biological targets” for curcumin, ranging 
from transcription factors to various enzymes and receptors.
76
 Although initial studies indicate 
that curcumin manifests these properties through Hsp90 inhibition, it is not known whether these 
activities are due to covalent modification of Hsp90 and other targets through its Michael 
acceptor properties or general promiscuity resulting from the moderately simple scaffold. It has 
been postulated that conversion of the α, β,-unsaturated 1,3-diketone moiety into an electron rich 
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ring system would lessen the potential for nucleophilic addition.
77
 Therefore, it was proposed 
that modification of the 1,3-diketone into a comparatively electron rich isoxazole moiety that 
contains two adjacent hydrogen bond acceptors in similar proximity to the original ketones 
would accomplish this objective. Furthermore, since the 1,3-diketone can tautomerize into the 
corresponding enol,
78
 it was proposed that a pyrazole aromatic nucleus would represent an 
electron rich mimetic of this hydrogen-bonding network and also serve to suppress nucleophilic 
addition to the adjacent, conjugated olefins. Identification of previously reported curcumin 
analogues that exhibit increased anti-proliferative,
79-80
 anti-malarial,
81
 antioxidant, and anti-
inflammatory activity
82
 as well as improved anti-neurodegenerative properties provided the basis 
for the heteroaromatic species reported herein.
83-84
 
A. Synthesis of 1,3-Diketone Analogues 
Chemistry developed by Lin et al. was utilized and expanded upon to prepare 1,3-
diketone analogues for the purpose of determining structure–activity relationships (Scheme 4).
79-
80
 A complex was formed between boric anhydride and 2,4-pentanedione, facilitating a 1,5-bis-
aldol condensation with 3,4-dimethoxybenzaldehyde to afford dimethylcurcumin, 30. Similar 
methodology was used to derive compounds 31, 32, and 33 from their respective 3,4-
disubstituted benzaldehydes and 3-substituted pentanediones. Compounds 34, 35, and 36 were 
obtained from dimethylcurcumin (30) via Michael addition with methyl propiolate, ethyl 
propiolate, and propiolamide, respectively. Reduction of the α,β,-unsaturated ethyl ester 35 with 
di-isobutyl aluminum hydride at –78 °C produced the allylic alcohol 37, in good yield.
85
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B. Synthesis of Pyrazole and Isoxazole Analogues 
The completed diketone species were used to prepare pyrazole analogues through an 
acid-catalyzed condensation with hydrazine hydrochloride, while stirring at reflux for forty 
hours. The isoxazole analogues were prepared in similar fashion enlisting hydroxylamine 
hydrochloride (Scheme 5). After discovering the instability of allylic alcohol 37 to these 
cyclization conditions, an alternative pathway was utilized in which the α,β-unsaturated ethyl 
ester analogue (35) was first cyclized, and subsequently reduced with sodium borohydride to 
give the cyclized allylic alcohol, 46.
85
 
Scheme 4. Preparation of 1,3-diketone curcumin analogues; From Ref. 85. 
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C. Electrophilicity of Curcumin and Analogues 
To compare the electrophilicity of curcumin to the electron rich pyrazole and isoxazole 
analogues, 1,4 conjugate addition of benzyl mercaptan to the benzylic olefins was monitored 
over time by 
1
H NMR. After incubating an equimolar mixture of curcumin and benzyl mercaptan 
for 1 hour, new aliphatic protons began to appear at δ2.96 and δ4.17 (Figure 50), indicative of 
conjugate addition.  Additionally, the appearance of a multiplet at δ3.57 was attributed to the α-
methylene group adjacent to sulfur in the conjugated product.  Furthermore, two singlets 
appeared at δ3.76 and δ3.83 corresponding to the disulfide product of benzyl mercaptan and the 
desymmetrization of the curcumin scaffold, respectively. 
Scheme 5. Synthesis of pyrazole and isoxazole curcumin analogues; From Ref. 
85. 
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Quantitative addition to the olefin was not observed due to competing disulfide formation, 
however, integration of the emerging aliphatic protons with respect to the aromatic methoxy 
protons (Table 10) indicated 53% addition after 24 hours.  Additionally, mass spectrometry data 
provided evidence that addition of benzyl mercaptan to curcumin resulted in both mono- and di-
conjugate-addition products, as masses were observed for both products.  
 
 
 
 
Figure 50. 
1
H NMR spectra for the addition of benzyl mercaptan to curcumin (a) 10 min (b) 1 h (c) 5 
h (d) 14 h (e) 24 h after addition; From Ref. 85.  
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Table 10. Relative integration
a
 of protons resulting from 1,4-conjugate addition to curcumin; From Ref 
85. 
Elapsed Time δ 2.96 (d, J = 7.7, α-CH2) δ 4.16 (t, J = 7.8, β-CH) 
10 min 0.08 0.03 
1 h 0.22 0.12 
5 h 0.37 0.21 
14 h 0.91 0.56 
24 h 1.06 0.62 
a
Integration relative to aromatic OCH3 substituents (6H) 
 
In contrast, when the related isoxazole (47) and pyrazole analogues were incubated with 
benzyl mercaptan for 48 hours, no change in the 
1
H NMR was observed (Figure 51 and 
Materials and Methods), indicating that these species were not reactive to nucleophilic attack by 
 
 
Figure 51. 
1
H NMR spectra for the addition of benzyl mercaptan to compound 47 after the time 
indicated; From Ref. 85. 
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benzyl mercaptan as curcumin itself. This observation can be explained by the electron rich and 
heteraromatic nature of the pyrazole and isoxazole rings as compared to the diketone species.
86
 
The benzylic olefin is less susceptible to Michael addition due to decreased electrophilicity and 
because the mechanism by which such a transformation occurs involves a non-aromatic 
intermediate. The electron-rich and heteroaromatic properties of the pyrazole and isoxazole rings 
appear to make these compounds less electrophilic and thus, less promiscuous than curcumin as 
a “general” alkylating agent within the cell. 
D. Biological Evaluation of Curcumin and Analogues 
The data shown in Table 11 represents the growth inhibitory activity of curcumin and its 
analogues against MCF-7(ER+) and SKBr-3(ER-, HER2 over-expressing) breast cancer cell 
lines. The results indicate that compounds 30, 33, 34, 35 and 37 represent the most potent 
analogues, manifesting submicromolar to low micromolar IC50 values against both cell lines. 
Upon analysis of the anti-proliferation data for these analogues, it is evident that in most cases, 
IC50 values for the parent dione are better than the pyrazole and isoxazole analogues. This can be 
attributed to the promiscuity of the α,β,-unsaturated ketone, as well as conformational differences 
between the 6-membered hydrogen bonding network created by the enol form of the diketone 
species and the rigid, more conformationally constrained 5-membered ring derivatives. 
Additionally, the pyrazole analogues exhibited lower IC50 values than the corresponding 
isoxazole analogues, highlighting the potential significance of a hydrogen bond donor on the 
pyrazole ring and its related nature to the corresponding enol form of the diketone species. 
Another interesting observation is the IC50 values between analogues with 3,4-dimethoxy 
substitution on each of the aromatic rings and the analogues with the 3-methoxy-4-hydroxy 
substitution, which is similar to the natural product. The diketone species with a 3,4-dimethoxy 
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substitution generally manifested lower IC50 values than the analogues that contain phenols. In 
contrast, the pyrazole and isoxazole derivatives possessed the opposite trend, as the phenolic 
analogues exhibited lower IC50 values than the analogues with dimethoxy substitution. This can 
be attributed to the electronic effect induced by the pyrazole and isoxazole rings, which impacts 
the hydrogen bond capability and pKa of the phenols as compared to the diketo species.
87
  
Table 11. Anti-proliferative activities of curcumin and analogues;
a
 From Ref. 85. 
Compound 
MCF-7  
(IC50, µM)
b 
SKBR3  
(IC50, µM) 
27 5.58 ± 0.97 2.11 ± 0.09 
30 1.07 ± 0.05 0.955 ± 0.145 
31 1.96 ± 0.35 4.38 ± 1.18 
32 >100 >100 
33 1.09 ± 0.03 1.02 ± 0.05 
34 0.512 ± 0.004 0.564 ± 0.020 
35 1.28 ± 0.14 1.96 ± 0.65 
36 5.35 ± 0.28 9.83 ± 1.12 
37 0.796 ± 0.067 1.24 ± 0.58 
38 4.19 ± 1.59 0.258 ± 0.034 
39 12.7 ± 0.3 1.58 ± 0.46 
40 6.01 ± 0.39 5.60 ± 1.24 
41 10.1 ± 0.7 11.7 ± 0.5 
42 8.16 ± 3.73 >100 
43 49.5 ± 2.9 >100 
44 11.4 ± 0.5 5.99 ± 0.61 
45 39.9 ± 2.6 52.6 ± 7.8 
46 >100 >100 
47 1.76 ± 0.39 4.00 ± 0.13 
48 59.5 ± 6.5 >100 
49 13.2 ± 1.6 13.9 ± 1.9 
50 >100 >100 
51 55.7 ± 5.7 42.5 ± 12.2 
a
Values represent mean ± standard error for at least 
two separate experiments performed in triplicate 
b
IC50 is defined as the concentration of compound 
necessary to inhibit cellular growth by 50% 
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Finally, the difference in IC50 values between the diketo species with substitutions at the α 
position indicates that an unsaturated and oxygen-containing moiety generally lowers the IC50 
value, as observed with compounds 34 and 37. Compound 32, containing 3,4-dimethoxy 
substitution and a saturated R
2
 substituent (Scheme 5) displayed no anti-proliferative activity at 
the concentrations tested. Further SAR is required to elucidate the origin of this effect as no other 
compounds in this library shared this group of functionalities. It should be noted that similar 
compounds bearing the unsaturated amide substituent also manifested decreased activity, 
indicating that nitrogen-bearing substituents may be detrimental to their anti-proliferative 
activity. In summary, it was observed that the most active analogues were those that contained a 
3,4-dimethoxy aromatic substitution and unsaturated, oxygen-containing substituents flanking 
the α position, which exhibited low to sub micromolar IC50 values. 
 Once the anti-proliferative activity of each analogue was determined, we sought to 
investigate if the analogues with attenuated electrophilicity still manifested Hsp90 inhibitory 
activity, as monitored by client protein degradation. MCF-7 cells were treated with varying 
concentrations of compound 47 for 24 h. and Western blot analyses were performed for Raf, Akt, 
and Her2, three known 
Hsp90 client proteins 
(Figure 52). As evident 
in Figure 52, compound 
47 induces the 
degradation of Her2, Raf, 
and Akt, which is 
indicative of Hsp90-
 
Figure 52. Western blot analysis for compound 47 from MCF-7 cell 
lysates after treatment with compound for 24 h. GDA (500 nM) and 
DMSO serve as positive and negative controls, respectively. Actin is 
shown as a loading control.  
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inhibitory activity, consistent with observations made for curcumin (Figure 49). 
IV. Conclusions and Future Work 
 A library of curcumin analogues has been synthesized in an effort to elucidate structure–
activity relationships, as well as to determine the relevance of curcumin’s Michael acceptor 
properties and its ability to act as an anti-cancer agent. Anti-proliferative data from two breast 
cancer cell lines were obtained, which led to identification of several compounds that exhibit 
increased growth inhibitory activity versus the natural product. Furthermore, it was determined 
that the Michael acceptor properties were not critical to retention of inhibitory activity for 
curcumin and analogues. In fact, both the isoxazole and pyrazole analogues displayed only 
slightly lower activities than the related diketone species, with the pyrazole species manifesting 
slightly better activity than the related isoxazole. These studies highlighted the importance of the 
hydrogen-bonding network demonstrated by curcumin in its enol form, which corresponds 
favorably to pyrazoles H-bond donor/acceptor moieties. Diminished electrophilicity, while 
maintaining anti-proliferative activity, makes these non-toxic curcumin analogues potentially a 
viable target for future drug development. It will be crucial to follow-up these studies by 
investigating the effects of non-electrophilic curcumin analogues on various Hsp90 functions. 
V. Materials and Methods 
 
(1E,16E)-1,7-Bis(3,4-dimethoxyphenyl)hepta-1,6-diene-3,5-dione (30). 2,4-Pentanedione 
(0.32 mL, 3.0 mmol) and boric anhydride (0.15 g, 2.1 mmol) were dissolved in EtOAc (3.0 mL). 
The solution was stirred for 30 min at 40 ºC before 3,4-Dimethoxybenzaldehyde (1.0 g, 6.0 
mmol) and tributyl borate (1.64 mL, 6.0 mmol) were added and stirred for 30 min at 40 ºC. n-
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Butylamine (0.45 mL, 4.5 mmol) was dissolved in EtOAc (3.0 mL), and added dropwise over 15 
min. The reaction mixture stirred for 24 h at 40 ºC, at which point it was quenched by the 
addition of 4N HCl (10 mL). The mixture was stirred at 60 ºC for 30 min, and then the aqueous 
layer extracted with EtOAc (3 x 50 mL). The combined organic layers were washed with 
saturated aqueous NaHCO3 and saturated aqueous NaCl, dried (Na2SO4), filtered, and 
concentrated. The residue was purified by flash chromatography (SiO2, 2:3 EtOAc in hexanes, 
then 3:2 EtOAc in hexanes) to afford 30 (438.1 mg, 37%) as a yellow amorphous solid:  
1
H 
NMR (CDCl3, 500 MHz) δ 3.86 (d, J = 6.20 Hz, 12H), 5.76 (s, 1H), 6.43 (d, J = 15.8 Hz, 2H), 
6.81 (d, J = 8.35 Hz, 2H), 7.01 (d, J = 1.85 Hz, 2H), 7.08 (dd, J = 1.90 Hz, 8.30 Hz, 2H), 7.54 (d, 
J = 15.8 Hz, 2H); 
13
C NMR (CDCl3, 125 MHz) δ 55.9 (2C), 56.0 (2C), 77.3, 101.4 (2C), 109.6 
(2C), 111.1 (2C), 122.0, 122.7, 128.0 (2C), 140.4 (2C), 149.2 (2C), 151.0 (2C), 183.3 (2C); IR 
(film) vmax 3001, 2959, 2934, 2912, 2837, 1624, 1582, 1556, 1512, 1462, 1454, 1441, 1421, 
1339, 1300, 1263, 1232, 1198, 1159, 1136, 1022, 966 cm
-1
; HRMS (ES
+
) m/z: [M + H] calcd for 
C23H24O6 397.1651; found 397.1640. 
 
(E)-Ethyl 7-(4-hydroxy-3-methoxyphenyl)-4-((E)-3-(4-hydroxy-3-methoxyphenyl)acryloyl)-
5-oxohept-6-enoate (31). Compound 31 was prepared following the same procedure used in the 
preparation of compound 30. The residue was purified by flash chromatography (SiO2, 5:3:2 
Hexanes:EtOAc:CH2Cl2) to afford 31 (490.0 mg, 32%) as an orange amorphous solid: 
1
H NMR 
(CDCl3, 500 MHz) δ 1.18 (t, J = 9.5 Hz, 3H), 2.48 (t, J = 8 Hz, 2H), 2.87 (t, J = 9.5 Hz, 2H), 
3.90 (s, 6H), 4.06 (q, J = 7.15Hz, 2H), 5.82 (s, 2H), 6.87 (s, 1H), 6.88-6.89 (m, 2H), 6.92 (s, 1H), 
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7.02 (d, J = 2 Hz, 2H), 7.10 (d, J = 8.25 Hz, 2H), 7.64 (d, J = 15.3 Hz, 2H); 
13
C NMR (CDCl3, 
125 MHz) δ 14.2, 21.7, 36.6, 56.0 (2C), 60.7, 109.5, 110.1 (2C), 114.9 (2C), 117.8 (2C), 122.9 
(2C), 128.0 (2C), 142.2 (2C), 146.8 (2C), 147.9 (2C), 173.0, 182.9 (2C); IR(film) νmax 3400, 
3074, 2961, 2926, 2852, 2400, 1722, 1663, 1618, 1587, 1514, 1454, 1429, 1393, 1377, 1275, 
1207, 1186, 1161, 1124, 1101, 1032, 976, 945 cm
-1
; HRMS (ES
+
) m/z: [M + Na] calcd for 
C26H28O8 491.1682; found 491.1677. 
 
(E)-Ethyl-7-(3,4-dimethoxyphenyl)-4-((E)-3-(3,4-dimethoxyphenyl)acryloyl)-5-oxohept-6-
enoate (32). Compound 32 was prepared following the same procedure used in the preparation 
of compound 30. The residue was purified by flash chromatography (SiO2, 5:3:2 
Hexanes:EtOAc:CH2Cl2) to afford 32 (351.1 mg, 23%) as a yellow amorphous solid: 
1
H NMR 
(CDCl3, 500 MHz) As a mixture of tautomers: δ 1.26 (t, J = 7.2 Hz, 3H), 1.26 (t, J = 7.2 Hz, 
3H), 2.36 (t, J = 6.9Hz, 2H), 2.40 (t, J = 6.9, 2H), 2.57 (t, J = 7.4Hz, 2H), 2.97 (t, J = 7.3Hz, 2H), 
3.93 (12H), 3.97 (12H), 4.15 (q, J = 7.1Hz, 2H), 4.15 (q, J = 7.1Hz, 2H), 4.26 (t, J = 7.1Hz, 1H), 
6.73 (d, J = 15.9Hz, 2H), 6.87 (d, J = 8.3Hz, 2H), 6.90 (d, J = 8.3Hz, 2H), 7.01 (d, J = 15.3Hz, 
2H), 7.07 (d, J = 1.8Hz, 2H), 7.14 (d, J = 1.7Hz, 2H), 7.16 (dd, J1 = 8.4Hz, J2 = 1.8Hz, 2H), 7.20 
(dd, J1 = 8.4Hz, J2 = 1.6Hz, 2H), 7.67 (d, J = 15.9Hz, 2H), 7.74 (d, J = 15.3Hz, 2H); 
13
C NMR 
(CDCl3, 125 MHz) As a mixture of tautomers δ 14.1, 14.2, 23.3, 29.7, 31.6, 36.6, 56.0 (4C), 60.6 
(2C), 63.5, 108.9, 109.6, 109.9, 110.2, 110.4, 111.0 (2C), 111.1 (2C), 118.0, 121.7 (2C), 122.7 
(2C), 123.9, 126.9 (2C), 127.1 (3C), 128.4 (2C), 142.1, 145.0,  149.2 (4C), 151.1 (2C), 151.8 
(2C), 172.9 (2C), 182.9, 190.9, 194.9 (2C); IR (film) νmax 3061, 2959, 2930, 2853, 2617, 2357, 
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2029, 1732, 1681, 1666, 1639, 1593, 1574, 1556, 1514, 1504, 1454, 1444, 1421, 1377, 1339, 
1308, 1263, 1231, 1186, 1161, 1138, 1109, 1022, 984, 945 cm
-1
; HRMS (ES
+
) m/z: [M + Na] 
calcd for C28H32O8 519.1995; found 519.1944. 
 
(1E,6E)-1,7-Bis(3,4-dimethoxyphenyl)-4-methylhepta-1,6-diene-3,5-dione (33). Compound 
33 was prepared following the same procedure used in the preparation of compound 30. The 
residue was purified by flash chromatography (SiO2,1:1Hexanes:EtOAc) to afford 33 (573.7 mg, 
44%) as a dark yellow amorphous solid: 
1
H NMR (CDCl3, 400 MHz) As a mixture of tautomers: 
δ 1.51(d, J = 6.9Hz, 3H), 2.19(s, 3H), 3.92-3.96(24H), 6.72(d, J = 15.9Hz, 2H), 6.89(d, J = 
8.4Hz, 2H), 6.99(d, J = 15.3Hz, 2H), 7.06(d, J = 1.68, 2H), 7.10(s, 2H), 7.16(dd, J1 = 8.5, J2 = 
1.9, 2H), 7.19(d, J = 8.2, 2H), 7.43(s, 1H), 7.48(dd, J1 = 8.1, J2=2.2, 1H), 7.65(d, J = 16.0Hz, 
2H), 7.70(d, J = 15.4, 2H);  
13
C NMR (CDCl3, 125 MHz) As a mixture of tautomers δ 12.1 29.7, 
55.9 (4C), 56.0 (4C), 59.0, 105.7, 109.9, 110.0, 110.1, 110.4, 111.0, 111.0, 111.1, 111.2, 116.6, 
118.7 (2C), 121.4 (2C), 122.5, 123.7, 124.4, 127.1 (2C), 128.5, 141.3, 144.7, 146.2 (2C), 149.2 
(2C), 149.2 (2C), 151.0 (2C), 151.7, 152.0, 182.5, 191.0, 196.1, 196.8; IR(Film) νmax 3412, 3059, 
2999, 2959, 2928, 2853, 2839, 2613, 2598, 2536, 2359, 2035, 1713, 1668, 1591, 1514, 1464, 
1454, 1443, 1421, 1377, 1340, 1308, 1265, 1238, 1198, 1161, 1140, 1107, 1045, 1024, 982, 947, 
924 cm
-1
; HRMS (ES
+
) m/z: [M + H] calcd for C24H26O6 411.1808; found 411.1800. 
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(2E,6E)-Methyl-7-(3,4-dimethoxyphenyl)-4-((E)-(3,4-dimethoxyphenyl)acryloyl)-5-
oxohepta-2,6-dienoate (34).  Compound 30 (500.0 mg, 1.26 mmol) was dissolved in THF (6.0 
mL) and stirred at rt before NaH (45.4 mg, 60% wt in mineral oil, 1.17 mmol) was added. The 
solution was stirred for 30 min at rt. In a separate flask, methyl propiolate (0.17 mL, 1.95 mmol) 
was dissolved in THF (9.0 mL) and stirred at room temperature. Contents from the first flask 
were slowly added via cannula to the methyl propiolate solution over 10 min, and subsequently 
stirred at rt for 24 h. The reaction was quenched by addition of 5% sulfuric acid (25 mL) and the 
aqueous layer extracted with EtOAc (3 x 50 mL). The combined organic layers were washed 
with saturated aqueous NaHCO3 and saturated aqueous NaCl, dried (Na2SO4), filtered, and 
concentrated. The residue was purified by flash chromatography (SiO2, 2:3 EtOAc in hexanes, 
then 3:2 EtOAc in hexanes) to afford 34 (291.0 mg, 53%) as an orange amorphous solid: 
1
H 
NMR (CDCl3, 500 MHz) δ 3.85 (s, 3H), 3.96 (d, J = 1.65, 12H), 6.00 (d, J = 11.7 Hz, 1H), 6.92 
(d, J = 11.7 Hz, 2H), 7.00 (d, J = 11.6 Hz, 2H), 7.09 (s, 2H), 7.22 (d, J = 6.15 Hz, 2H), 7.79 (d, J 
= 11.6 Hz, 2H), 7.93 (d, J = 11.7 Hz, 1H); 
13
C NMR (CDCl3, 125 MHz) δ 51.8, 56.02 (2C), 
56.04 (2C), 109.9, 110.0 (2C), 110.5 (2C), 111.2 (2C), 118.8, 121.9, 123.0, 128.0 (2C), 139.3 
(2C), 143.0, 149.3 (2C), 151.5 (2C), 167.3, 183.8 (2C); IR (film) νmax 2999, 2949, 2935, 2910, 
2837, 2604, 2359, 1715, 1614, 1597, 1580, 1508, 1437, 1420, 1342, 1308, 1261, 1225, 1190, 
1161, 1138, 1022, 1001, 982, 964, 932 cm
-1
; HRMS (ES
+
) m/z: [M + Na] calcd for C27H28O8 
503.1682; found 503.1667.  
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(2E,6E)-Ethyl-7-(3,4-dimethoxyphenyl)-4-((E)-3-(3,4-dimethoxyphenyl)acryloyl)-5-
oxohepta-2,6-dienoate (35).  Compound 35 was prepared following the same procedure used in 
the preparation of compound 34. The residue was purified by flash chromatography (SiO2, 1:199 
MeOH in CH2Cl2, then 1:66 MeOH in CH2Cl2) to afford 35 (636.0 mg, 94.4%) as a red 
amorphous solid: 
1
H NMR (CDCl3, 500 MHz) δ 1.35 (t, J = 7.16 Hz, 3H), 3.95 (s, 12H), 4.30 (q, 
J = 7.12 Hz, 2H), 5.98 (d, J = 15.64 Hz, 1H), 6.91 (d, J = 8.34 Hz, 2H), 7.00 (d, J 15.42 Hz, 2H), 
7.09 (d, J = 1.84 Hz, 2H), 7.21 (dd, J = 1.84, 8.34 Hz, 2H), 7.78 (d, J = 15.42 Hz, 2H), 7.91 (d, J 
= 15.64 Hz, 1H); 
13
C NMR (CDCl3, 125 MHz) δ 14.6, 56.17 (2C), 56.24 (2C), 60.8, 110.2 (3C), 
110.5 (2C), 111.4 (2C), 119.2, 122.7, 123.3, 128.3 (2C), 139.2 (2C), 143.1, 149.5 (2C), 151.6 
(2C), 167.1, 183.9 (2C); IR (film) vmax 3061, 2978, 2961, 2935, 2907, 2872, 2837, 2598, 2033, 
1715, 1614, 1595, 1580, 1512, 1464, 1443, 1421, 1367, 1308, 1265, 1161, 1140, 1097, 1024, 
976cm
-1
; HRMS (ES
+
) m/z: [M + Na] calcd for C28H30O8 517.1838; found 517.1826. 
 
(2E,6E)-7-(3,4-Dimethoxyphenyl)-4-((E)-3-(3,4-dimethoxyphenyl)acryloyl)-5-oxohepta-2,6-
dienamide (36).  Concentrated aqueous ammonia (6.5 mL) was cooled in a dry ice-isopropyl 
alcohol bath. Methyl propiolate (2.0 mL, 22.4 mmol) was added dropwise, and after 10 min, the 
organic layer was extracted with EtOAc (3 x 5 mL), dried over Na2SO4, and concentrated, 
affording crystalline propiolamide (quantitative). Compound 30 (600.0 mg, 1.52 mmol) was 
dissolved in THF (10.0 mL) and stirred at rt before NaH (54.52 mg, 60% wt in mineral oil, 1.36 
mmol) was added. The solution was stirred for 30 min at rt. In a separate flask, propiolamide 
(209.3 mg, 3.03 mmol) was dissolved in THF (6.0 mL) and stirred at rt. Contents from the first 
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flask were slowly added via cannula to the propiolamide solution over 10 min, and subsequently 
stirred at rt for 24 h. The reaction was quenched by addition of 5% sulfuric acid (25 mL) and the 
aqueous layer extracted with EtOAc (3 x 50 mL).  The combined organic layers were washed 
with saturated aqueous NaHCO3 and saturated aqueous NaCl, dried (Na2SO4), filtered, and 
concentrated. The residue was recrystallized from EtOAC/hexanes to afford 36 (557.7 mg, 88%) 
as an orange amorphous solid: 
1
H NMR (CDCl3, 500 MHz) δ 3.94 (d, J = 1.9 Hz, 12H), 5.45 (s, -
NH2), 5.95 (d, J = 15.2 Hz, 1H), 6.90 (d, J = 8.4 Hz, 2H), 6.98 (d, J = 15.4 Hz, 2H), 7.07 (d, J = 
1.9 Hz, 2H), 7.21 (dd, J = 1.9, 8.4 Hz, 2H), 7.76 (d, J = 15.4 Hz, 2H), 7.90 (d, J = 15.2 Hz, 1H); 
13
C NMR (CDCl3, 125 MHz) δ 55.9 (2C), 56.0 (2C), 110.1 (3C), 110.3 (2C), 111.1 (2C), 118.8, 
122.9, 124.1, 128.0 (2C), 137.2 (2C), 142.6, 149.2 (2C), 151.3 (2C), 166.9, 183.4 (2C); IR (film) 
vmax 3412, 3323, 3292, 3215, 2999, 2943, 2837, 1663, 1614, 1597, 1582, 1510, 1466, 1441, 
1421, 1385, 1342, 1308, 1263, 1225, 1161, 1140, 1111, 1020, 1001, 978, 966cm
-1
; HRMS (ES
-
) 
m/z: [M – H] calcd for C26H27NO7 464.1709; found 464.1731.   
 
(1E,6E)-1,7-Bis(3,4-dimethoxyphenyl)-4-((E)-3-hydroxyprop-1-enyl)hepta-1,6-diene-3,5-
dione (37). Compound 35 (500.0 mg, 1.0 mmol) was dissolved in CH2Cl2 (10.0 mL) and cooled 
to -78 ºC before 
i
Bu2AlH (3.0 mL, 1M in CH2Cl2, 3.0 mmol) was added drop wise. After 30 min, 
the solution was warmed to rt and stirred for an additional 1.5 h. The solution was quenched 
using saturated aqueous sodium potassium tartrate (Rochelle’s salt) and the aqueous layer 
extracted with CH2Cl2 (3 x 50 mL). The combined organic layers were washed with saturated 
aqueous NaCl, dried (Na2SO4), and concentrated. The residue was purified by flash 
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chromatography (SiO2, 1:5:9:10 MeOH:CH2Cl2:EtOAc:hexanes) to afford 37 (301.3 mg, 66%) 
as a red amorphous solid: 
1
H NMR (CDCl3, 500 MHz) δ 3.92 (d, J = 3.9 Hz, 12H), 4.40 (d, J = 
4.6 Hz, 2H), 5.88 (dt, J = 5.7, 15.6 Hz, 1H), 6.58 (dt, J = 1.4, 15.6 Hz, 1H), 6.87 (d, J = 8.3 Hz, 
2H), 6.97 (d, J = 15.6 Hz, 2H), 7.05 (d, J = 1.8 Hz, 2H), 7.16 (dd, J = 1.8, 8.4 Hz, 2H), 7.67 (d, J 
= 15.6 Hz, 2H); 
13
C NMR (CDCl3, 125 MHz) δ 55.94, 55.98, 56.0 (2C), 63.6, 110.4, 111.0 (2C), 
111.1 (2C), 111.5 (2C), 119.7, 122.5, 124.2, 128.4 (2C), 136.5 (2C), 141.2, 149.2 (2C), 151.0 
(2C), 182.5 (2C); IR (film) vmax 3458, 3443, 2997, 2926, 2874, 2853, 2835, 1620, 1595, 1580, 
1556, 1510, 1464, 1454, 1435, 1421, 1337, 1306, 1261, 1192, 1159, 1138, 1094, 1022, 959, 
930cm
-1
; HRMS (ES
-
) m/z: [M – H] calcd for C26H28O7 451.1757; found 451.1766.   
 
4,4'-(1E,1'E)-2,2'-(1-H-Pyrazole-3,5-diyl)bis(ethene-2,1-diyl)bis(2-methoxyphenol) (38).  
Compound 27 (300.0 mg, 0.81 mmol) was dissolved in absolute EtOH (5.0 mL). Hydrazine 
hydrochloride (66.9 mg, 0.984 mmol) was added followed by a catalytic amount of glacial acetic 
acid (1.0 mL). The solution stirred at reflux for 40 h.  The crude reaction mixture was 
concentrated in vacuuo and re-dissolved in EtOAc (200 mL). The organic layer was washed with 
saturated aqueous NaHCO3 and saturated NaCl, dried (Na2SO4), filtered, and concentrated in 
vacuuo. The residue was purified by column chromatography (SiO2, 5:3:2 
hexanes:EtOAc:CH2Cl2) to afford compound 38 (262.0 mg, 87%) as a dark orange amorphous 
solid: 
1
H NMR (CDCl3 w/MeOD, 500 MHz) δ 3.79 (s, 6H), 6.43 (s, 1H), 6.72 (s, 2H), 6.73 (s, 
1H), 6.75 (s, 1H), 6.85 (dd, J1 = 8.2Hz, J2 = 1.8Hz, 2H), 6.90(d, J = 8.3 Hz, 2H), 6.92(d, J = 
6.4Hz, 2H); 
13
C NMR (CDCl3 w/MeOD, 125 MHz) δ 55.4 (2C), 98.8, 108.6 (2C), 114.8 (2C), 
115.3 (2C), 120.1 (2C), 127.6 (2C), 128.8 (2C), 130.5 (2C), 146.1 (2C), 147.3 (2C); IR (film) 
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νmax 3383, 2359, 2341, 2332, 1593, 1558, 1512, 1456, 1429, 1277, 1259, 1231, 1211, 1155, 1122 
cm
-1
; HRMS(ES
+
) m/z: [M+H] calcd for C21H20N2O4 365.1505; found 365.1484. 
 
3,5-Bis(3,4-dimethoxystyryl)-1-H-pyrazole (39). Compound 39 was prepared following the 
same procedure used in the preparation of compound 38. The residue was purified by flash 
chromatography (SiO2, 2:3:5 (CH2Cl2, EtOAc, hexanes)) to afford 39 (54.0 mg, 90%) as a 
yellow-orange amorphous solid: 
1
H NMR (CDCl3, 500 MHz) δ 3.85 (d, J = 15.5 Hz, 12H), 6.62 
(s, 1H), 6.74 (d, J = 8.10 Hz, 2H), 6.95 (m, 6H), 7.05 (d, J = 16.5 Hz, 2H); 
13
C NMR (CDCl3, 
125 MHz) δ 55.6 (2C), 55.8 (2C), 99.4, 99.9 (2C), 108.5 (2C), 111.0 (2C), 115.8 (2C), 119.9 
(2C), 129.6 (2C), 130.6 (2C), 149.0 (2C), 149.1 (2C); IR (film) vmax 3331, 3177, 3126, 3078, 
3065, 2999, 2959, 2934, 2910, 2835, 1599, 1583, 1558, 1514, 1464, 1441, 1420, 1331, 1311, 
1265, 1196, 1157, 1138, 1103, 1024, 960cm
-1
; HRMS (ES
+
) m/z: [M + H] calcd for C23H24N2O4 
393.1814; found 393.1801.  
 
Ethyl 3-(3,5-bis(4-hydroxy-3-methoxystyryl)-1-H-pyrazol-4-yl)propanoate (40). Compound 
40 was prepared following the same procedure used in the preparation of compound 38. The 
residue was purified by flash chromatography (SiO2, 5:3:2 Hexanes:EtOAc:CH2Cl2) to afford 40 
(63.5 mg, 81%) as a yellow-orange amorphous solid: 
1
H NMR (CDCl3, 500 MHz) δ 1.23 (t, J = 
7.1 Hz, 3H), 2.57 (t, J = 7.8 Hz, 2H), 3.01 (t, J = 7.8 Hz, 2H), 3.83 (s, 6H), 4.12 (q, J = 7.2 Hz, 
2H), 6.82 (d, J = 16.6 Hz, 2H), 6.85 (d, J = 8.3 Hz, 2H), 6.89 (d, J = 1.5 Hz, 2H), 6.93 (dd, J1 = 
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8.2 Hz, J2 = 1.6 Hz, 2H), 7.06 (d, J = 16.5 Hz, 2H); 
13
C NMR (CDCl3, 125 MHz) δ 14.2, 18.8, 
35.5, 55.8 (2C), 60.6, 108.4 (2C), 113.9, 114.6 (2C), 115.3 (2C), 120.5 (2C), 129.4 (2C), 130.1 
(2C), 144.0 (2C), 145.9 (2C), 146.8 (2C), 173.0; IR(Film) νmax 3323, 3041, 3034, 2957, 2924, 
2851, 2320, 1724, 1661, 1593, 1556, 1514, 1464, 1429, 1375, 1277, 1238, 1205, 1159, 1124, 
1099, 1068, 1034, 962 cm
-1
; HRMS (ES
+
) m/z: [M + H] calcd for C26H28N2O6 465.2026; found 
465.2005. 
 
Ethyl 3-(3,5-bis(3,4-dimethoxystyryl)-1-H-pyrazol-4-yl)propanoate (41). Compound 41 was 
prepared following the same procedure used in the preparation of compound 38.  The residue 
was purified by flash chromatography (SiO2, 5:3:2 Hexanes:EtOAc:CH2Cl2) to afford 41 (43.0 
mg,73%) as a yellow-orange amorphous solid: 
1
H NMR (CDCl3, 500 MHz) δ 1.23 (t, J = 7.1 Hz, 
3H), 2.58 (t, J = 7.7 Hz, 2H), 3.03 (t, J = 7.8 Hz, 2H), 3.87 (12H), 4.12 (q, J = 4.1Hz, 2H), 6.77 
(m, 2H), 6.85 (m, 2H), 6.93 (d, J = 8.25Hz, 2H), 6.97 (s, 2H), 7.07 (m, 2H); 
13
C NMR (CDCl3, 
125MHz) 14.2, 18.8, 35.6, 55.9 (4C), 60.6, 108.2 (2C), 111.1, 114.3 (2C), 115.4 (2C), 120.1 
(2C), 129.3 (2C), 129.7 (2C), 129.9 (2C), 149.1 (2C), 149.1 (2C), 173.0; IR (Film) νmax 3333, 
3173, 3078, 3030, 2957, 2924, 2851, 1728, 1666, 1601, 1583, 1556, 1514, 1464, 1443, 1420, 
1373, 1335, 1265, 1234, 1159, 1138, 1095, 1068, 1026, 962 cm
-1
; HRMS (ES
+
) m/z: [M + H] 
calcd for C28H32N2O6 493.2339; found 493.2321. 
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3,5-Bis(3,4-dimethoxystyryl)-4-methyl-1-H-pyrazole (42). Compound 42 was prepared 
following the same procedure used in the preparation of compound 38. The residue was purified 
by flash chromatography (SiO2, 2:3:5 (CH2Cl2, EtOAc, hexanes)) to afford 42 (60.8 mg, 58%) as 
a yellow-orange amorphous solid: 
1
H NMR (CDCl3, 500 MHz) δ 2.22 (s, 3H), 3.82 (s, 6H), 3.82 
(s, 6H), 6.73 (d, 2H, J = 8.8Hz), 6.81 (d, 2H, J = 16.5Hz), 6.92 (m, 4H), 6.97 (d, 2H, J = 
16.5Hz); 
13
C NMR (CDCl3, 125 MHz) δ 9.1, 55.8 (2C), 55.9 (2C), 108.6, 108.7 (2C), 111.1 
(2C), 112.2 (2C), 115.1 (2C), 119.9 (2C), 129.5 (2C), 130.1 (2C), 149.1 (2C), 149.1 (2C); 
IR(Film) νmax 3416, 3240, 3229, 3111, 2999, 2957, 2932, 2835, 2359, 1636, 1601, 1514, 1464, 
1420, 1333, 1265, 1238, 1159, 1138, 1024, 960 cm
-1
; HRMS (ES
+
) m/z: [M + H] calcd for 
C24H26N2O4 407.1971; found 407.1954.  
 
(E)-Methyl 3-(3,5-bis(3,4-dimethoxystyryl)-1-H-pyrazol-4-yl)acrylate (43). Compound 43 
was prepared following the same procedure used in the preparation of compound 38.  The 
residue was purified by flash chromatography (SiO2, 1:1 Hexanes:EtOAc) to afford 43 (43.3 
mg,15%) as a yellow-orange amorphous solid: 
1
H NMR (CDCl3, 500 MHz) δ 3.76 (s, 3H), 3.83 
(s, 6H), 3.84 (s, 6H), 6.15 (d, J = 16.0Hz, 1H), 6.75 (d, J = 8.1Hz, 2H), 6.86 (d, J = 16.3Hz, 2H), 
6.93 (d, J = 2.5Hz, 2H), 6.95 (d, J = 1.7Hz, 2H), 7.09 (d, J = 16.3, 2H), 7.81 (d, J = 16.0Hz, 2H); 
13
C NMR (CDCl3, 125 MHz) δ 51.7, 56.0 (4C), 109.0 (2C), 111.1, 113.0 (2C), 113.5 (2C), 117.8 
(2C), 120.6 (2C), 129.3 (2C), 132.6 (2C), 135.2 (2C), 149.2 (2C), 149.7 (2C), 167.9; IR (Film) 
νmax3317, 2923, 2849, 2837, 1701, 1624, 1601, 1582, 1514, 1464, 1437, 1420, 1310, 1265, 1198, 
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1159, 1138, 1024, 960, 933 cm
-1
; HRMS (ES
+
) m/z: [M + H] calcd for C27H28N2O6 477.2026; 
found 477.1993. 
 
(E)-Ethyl-3-(3,5-bis(3,4-dimethoxystyryl)-1-H-pyrazol-4-yl)acrylate (44). Compound 44 was 
prepared following the same procedure used in the preparation of compound 38. The residue was 
purified by flash chromatography (SiO2, 1:7.5:15:26.5 MeOH:CH2Cl2:EtOAc:hexanes) to afford 
44 (37.5 mg, 76%) as a yellow-orange amorphous solid: 
1
H NMR (CDCl3, 500 MHz) δ 1.35 (t, J 
= 7.15 Hz, 3H), 3.93 (d, J = 8.30 Hz, 12H), 4.29 (q, J = 7.15 Hz, 2H), 6.23 (d, J = 16.0 Hz, 1H), 
6.86 (d, J = 8.20 Hz, 2H), 6.96 (d, J = 16.3 Hz, 2H), 7.04 (d, J = 1.80 Hz, 2H), 7.06 (dd, J = 
1.80, 8.25 Hz, 2H), 7.17 (d, J = 16.3 Hz, 2H), 7.89 (d, J = 16.0 Hz, 2H); 
13
C NMR (CDCl3, 125 
MHz) 14.4, 55.90 (2C), 55.92 (2C), 60.5, 108.9 (2C), 111.1 (2C), 113.0, 113.6, 118.3 (2C), 
120.5 (2C), 129.2 (2C), 132.4 (2C), 134.9 (2C), 149.06, 149.11 (2C), 149.6 (2C), 167.5; IR 
(film) vmax 3321, 2995, 2957, 2935, 2835, 1701, 1684, 1624, 1601, 1583, 1558, 1514, 1464, 
1443, 1420, 1394, 1367, 1308, 1263, 1240, 1159, 1140, 1094, 1026, 962cm
-1
; HRMS (ES
+
) m/z: 
[M + H] calcd for C28H30N2O6 491.2182; found 491.2168. 
 
(E)-3-(3,5-Bis(3,4-dimethoxystyryl)-1-H-pyrazol-4-yl)acrylamide (45). Compound 45 was 
prepared following the same procedure used in the preparation of compound 38. The residue was 
purified by flash chromatography (SiO2, 1:99 MeOH in CH2Cl2) to afford 45 (41.7 mg, 84%) as 
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a yellow-orange amorphous solid: 
1
H NMR (CDCl3, 500 MHz) δ 3.92 (s, 12H), 5.62 (s, -NH2), 
6.34 (d, J = 15.6 Hz, 1H), 6.87 (d, J = 8.2 Hz, 2H), 6.92 (d, J = 16.4 Hz, 2H), 7.03 (d, J = 16.4 
Hz, 2H), 7.04 (d, J = 1.7 Hz, 2H), 7.10 (dd, J = 1.7, 8.2 Hz, 2H), 7.60 (d, J = 15.6 Hz, 1H); 
13
C 
NMR (CDCl3, 125 Hz) δ 55.88 (2C), 55.98 (2C), 105.4 (2C), 109.6 (2C), 111.0 (2C), 111.1(2C), 
111.2, 117.1 (2C), 120.1, 122.3 (2C), 127.4 (2C), 142.5 (2C), 149.1 (2C), 150.8, 168.0; IR (film) 
vmax3339, 3325, 3198, 3186, 2999, 2957, 2935, 2912, 2835, 1717, 1668, 1634, 1595, 1514, 1464, 
1441, 1420, 1394, 1337, 1308, 1265, 1186, 1159, 1140, 1024, 978, 968; HRMS (ES
+
) m/z: [M + 
H] calcd for C26H27N3O5 462.2029; found 462.2010. 
 
(E)-3-(3,5-Bis(3,4-dimethoxystyryl)-1-H-pyrazol-4-yl)prop-2-en-1-ol (46). Compound 44 
(80.0 mg, 0.16 mmol) was dissolved in anhydrous MeOH (5.0 mL) and stirred at rt. NaBH4 (61.7 
mg, 1.6 mmol) was added and the solution stirred at reflux. After 1 h, additional NaBH4 (61.7 
mg, 1.6 mmol) was added, and the solution stirred at reflux for 15.5 h. The reaction was 
quenched by the addition of H2O, resulting in the formation of a white solid.  The precipitate was 
dissolved by the addition of 10% HCl (10 mL) and the aqueous layer was extracted with CH2Cl2 
(3 x 20 mL). The combined organic layers were washed with saturated aqueous NaHCO3 and 
saturated aqueous NaCl, dried (Na2SO4), filtered, and concentrated. The residue was purified by 
flash chromatography (SiO2, 1:7.5:15:26.5 MeOH:CH2Cl2:EtOAc:hexanes) to afford 46 (41.0 
mg, 83%) as a yellow-orange amorphous solid: 
1
H NMR (CDCl3, 500 MHz) δ 3.84 (s, 2H), 3.87 
(d, J = 9.7 Hz, 12H), 6.21 (d, J = 16.0 Hz, 1H), 6.76 (d, J = 8.45 Hz, 2H), 6.89 (d, J = 16.3 Hz, 
2H), 6.92 (m, 4H), 7.16 (d, J = 16.3 Hz, 2H), 7.87 (d, J = 16.0 Hz, 1H); 
13
C NMR (CDCl3, 125 
Hz) δ 51.7, 55.84 (2C), 55.87 (2C), 108.8 (2C), 111.0 (2C), 112.9, 113.3, 117.6 (2C), 120.6 (2C), 
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129.1 (2C), 132.6 (2C), 135.2 (2C), 149.0, 149.6 (2C), 167.9 (2C); IR (film) vmax 3315, 3153, 
3059, 2999, 2949, 2935, 2835, 1713, 1626, 1601, 1583, 1514, 1464, 1441, 1421, 1312, 1265, 
1198, 1161, 1140, 1097, 1026, 960, 933cm
-1
; HRMS (ES
+
) m/z: [M + H] calcd for C26H28N2O5 
449.2076; found 449.2096. 
 
4,4'-(1E,1'E)-2,2'-(Isoxazole-3,5-diyl)bis(ethene-2,1-diyl)bis(2-methoxyphenol) (47). 
Compound27 (250 mg, 0.69 mmol) was dissolved in absolute EtOH (5.0 mL). Hydroxylamine 
hydrochloride (56.6 mg, 0.83 mmol) was added followed by a catalytic amount of glacial acetic 
acid(750 µL). The solution stirred at reflux for 40 h. The crude reaction mixture was 
concentrated in vacuuo and re-dissolved in EtOAc (200 mL). The organic layer was washed with 
saturated aqueous NaHCO3 and saturated NaCl, dried (Na2SO4), filtered, and concentrated in 
vacuuo. The residue was purified by column chromatography (SiO2, 5:3:2 
hexanes:EtOAc:CH2Cl2) to afford 47 (218.0 mg, 89%) as a dark orange amorphous solid: 
1
H 
NMR (d-DMSO, 500 MHz) δ 3.89 (s, 6H), 6.85 (d, J = 8.1Hz, 1H), 6.87 (d, J = 8.1Hz, 1H), 6.92 
(s, 1H), 7.10 (dd, J1 = 8.3Hz, J2 = 1.9Hz, 1H), 7.13 (d, J = 12.4Hz, 1H), 7.13 (dd, J1 = 8.3Hz, J2 = 
1.8Hz, 1H), 7.16 (d, J = 12.3Hz, 1H), 7.33-7.37 (m, 4H), 9.45 (s, 1H), 9.51 (s, 1H); 
13
C NMR 
(CDCl3, 125 MHz) δ 55.6, 55.6, 97.8, 109.9, 110.2, 110.3, 112.6, 115.5, 115.5, 121.3, 121.7, 
126.9, 127.3, 134.7, 136.4, 147.8, 147.9, 147.9, 148.1, 162.2, 168.3; IR (film) νmax 3402, 2961, 
2924, 2851, 2359, 2341, 2332, 1645, 1605, 1593, 1562, 1514, 1464, 1433, 1375, 1279, 1231, 
1207, 1188, 1159, 1122, 1032, 960 cm
-1
; HRMS (ES
+
) m/z: [M + H] calcd for C21H19NO5 
366.1342; found 366.1348. 
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3,5-Bis(3,4-dimethoxystyryl)isoxazole (48).  Compound 48 was prepared following the same 
procedure used in the preparation of compound 47. The residue was purified by flash 
chromatography (SiO2, 2:3:5 (CH2Cl2, EtOAc, hexanes)) to afford 48 (54.0 mg, 90%) as a 
yellow-orange amorphous solid: 
1
H NMR (CDCl3, 500 MHz) δ 3.85 (d, J = 2.55 Hz, 6H), 3.88 
(d, J = 4.20 Hz, 6H), 6.37 (s, 1H), 6.77 (d, J = 16.35, 1H), 6.81 (dd, J = 3.75, 8.20 Hz, 2H), 6.94 
(d, J = 16.4 Hz, 1H), 7.03 (m, 5H), 7.23 (d, J = 16.4 Hz, 1H); 
13
C NMR (CDCl3, 125 Hz) δ 
55.89, 55.93, 55.98, 56.0, 97.8, 108.6, 108.9, 111.0, 111.1, 114.2 (2C), 120.9, 121.2, 128.6, 
128.9, 134.7, 135.4, 149.2 (2C), 149.9, 150.1, 162.2, 168.5; IR (film) vmax 2995, 2953, 2932, 
2916, 2835, 1643, 1599, 1583, 1512, 1504, 1462, 1427, 1416, 1265, 1225, 1159, 1140, 1024, 
964cm
-1
; HRMS (ES
+
) m/z: [M + H] calcd for C23H23NO5 394.1655; found 394.1649. 
 
Ethyl 3-(3,5-bis(4-hydroxy-3-methoxystyryl)isoxazol-4-yl)propanoate (49). Compound 49 
was prepared following the same procedure used in the preparation of compound 47. The residue 
was purified by flash chromatography (SiO2, 2:3:5 (CH2Cl2, EtOAc, hexanes)) to afford 49 (60.7 
mg, 76%) as a yellow amorphous solid: 
1
H NMR (CDCl3, 500 MHz) δ 1.23 (t, J = 7.2 Hz, 3H), 
2.60 (t, J = 7.6 Hz, 2H), 2.97 (t, J = 7.6 Hz, 2H), 3.96 (s, 6H), 4.13 (q, J = 7.2 Hz, 2H), 5.90 (bs, 
2H), 6.79 (d, J = 16.5 Hz, 1H), 6.80 (d, J = 16.3 Hz, 1H), 6.94 (d, J = 8.1 Hz, 1H), 6.94 (d, J = 
8.2 Hz, 1H), 7.05 (d, J = 1.8 Hz, 1H), 7.06 (d, J = 1.7 Hz, 1H), 7.08 (dd, J1 = 8.3 Hz, J2 = 1.8 Hz, 
1H), 7.11 (dd, J1 = 8.3 Hz, J2 = 1.8 Hz, 1H), 7.31 (d, J = 16.3 Hz, 1H), 7.37 (d, J = 16.5 Hz, 1H) 
178 
13
C NMR (CDCl3, 125 MHz) δ 14.2, 17.9, 34.6, 56.0 (2C), 60.9, 108.7, 108.9, 109.4, 112.1, 
112.3, 114.7, 114.8 (2C), 121.3, 128.5, 128.8, 133.9, 135.2, 146.7, 146.8, 146.8 (2C), 160.0, 
164.7, 172.5; IR(Film) νmax 3499, 3416, 3049, 2962, 2935, 2872, 2853, 2758, 2748, 2644, 2590, 
2548, 2311, 2060, 1728, 1634, 1593, 1514, 1450, 1439, 1373, 1275, 1236, 1207, 1184, 1159, 
1122, 1095, 1063, 1032, 964, 939 cm
-1
, HRMS (ES
+
) m/z: [M + H] calcd for C26H27NO7 
466.1866; found 466.1860. 
 
Ethyl 3-(3,5-bis(3,4-dimethoxystyryl)isoxazol-4-yl)propanoate (50).  Compound 50 was 
prepared following the same procedure used in the preparation of compound 47. The residue was 
purified by flash chromatography (SiO2, 2:3:5 (CH2Cl2, EtOAc, hexanes)) to afford 50 (64.4 mg, 
61%) as a dark yellow amorphous solid: 
1
H NMR (CDCl3, 500 MHz) δ 1.15 (t, J = 7.2 Hz, 3H), 
2.52 (t, 7.5 Hz, 2H), 2.91 (t, J = 7.5 Hz, 2H), 3.86 (m, 12H), 4.05 (q, J = 7.15 Hz, 2H), 6.73 (d, J 
= 4.15 Hz, 1H), 6.75 (d, J = 4.0 Hz, 1H), 6.79-6.82 (m, 2H), 7.01-7.06 (m, 4H), 7.21 (d, J = 19.0 
Hz, 1H), 7.31 (d, J = 16Hz, 1H); 
13
C NMR (CDCl3, 125MHz) δ 14.2, 17.9, 34.6, 56.0, 60.8, 
109.0, 109.1, 109.7, 111.1, 111.2, 112.4, 112.5, 120.9, 121.0, 129.0, 133.8, 135.1, 149.2 (2C), 
149.9, 150.0, 160.0, 164.7, 172.5; IR (Film) νmax 3541, 3435, 3053, 2959, 2930, 2853, 2839, 
2598, 2033, 1728, 1674, 1634, 1591, 1514, 1454, 1443, 1421, 1375, 1339, 1263, 1236, 1159, 
1140, 1094, 1063, 1024, 966 cm
-1
; HRMS (ES
+
) m/z: [M + H] calcd for C28H31NO7 494.2179; 
found 494.2163. 
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3,5-Bis(3,4-dimethoxystyryl)-4-methylisoxazole (51). Compound 51 was prepared following 
the same procedure used in the preparation of compound 47. The residue was purified by flash 
chromatography (SiO2, 2:3:5 (CH2Cl2, EtOAc, hexanes)) to afford 51 (59.2 mg, 59%) as a 
yellow-orange amorphous solid: 
1
H NMR (CDCl3, 500 MHz) 2.18 (s, 3H), 3.85 (s, 3H), 3.85 (s, 
3H), 3.88 (s, 3H), 3.89 (s, 3H), 6.70 (d, J = 16.3Hz, 1H), 6.79-6.83 (3H), 6.99-7.05 (4H), 7.22 (d, 
J = 16.4Hz, 1H), 7.26 (d, J = 16.7Hz, 1H); 
13
C NMR (CDCl3, 125 MHz)δ 29.7, 55.9 (2C), 56.0 
(2C), 108.8, 109.0, 109.2, 110.0, 111.1, 111.2, 113.5, 120.8, 129.1, 129.3, 133.2, 134.9, 149.2 
(2C), 149.8, 149.9, 160.5, 164.2; IR(Film) νmax 3541, 3445, 3194, 3051, 2999, 2959, 2930, 2853, 
2837, 2600, 2361, 2322, 2280, 2033, 1682, 1645, 1634, 1593, 1514, 1506, 1454, 1441, 1421, 
1387, 1339, 1312, 1263, 1236, 1196, 1159, 1138, 1092, 1024, 964 cm
-1
; HRMS (ES
+
) m/z: [M + 
H] calcd for C24H25NO5 408.1811; found 408.1797. 
 
Benzyl Mercaptan Addition Studies. In a 1 dram vial, 15.0 mg curcumin (27) (0.041 mmol) 
was dissolved in 0.60 mL d-DMSO. 4.7 µL of benzyl mercaptan (0.041 mmol) was then added, 
marking time zero. The contents of the vial were transferred to an NMR tube and 
1
H NMR 
spectra were recorded at set intervals (10 min, 1 h, 5 h, 14 h, and 24 h) to monitor the progress of 
the reaction. The presence of the benzyl mercaptan-curcumin conjugate was confirmed by 
HRMS (ES+) m/z: single addition product: [M + H] calcd for C28H28O6S 493.1685; found 
493.1664; double addition product: [M + Na] 639.1851; found 639.1835. 
1
H NMR (d6-DMSO, 
400 MHz) As a mixture of curcumin, benzyl mercaptan and conjugated product: 2.84 (t, J = 7.7, 
1H), 2.96 (d, J = 7.7Hz, 2H), 3.58 (m, 2H), 3.73 (d, J = 8Hz, 2H), 3.81 (s, 3H), 3.85 (s, 3H), 3.85 
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(s, 6H), 4.17 (t, 7.8, 1H), 5.78 (s, 1H), 6.07 (s, 1H), 6.59 (d, J = 15.9Hz, 1H), 6.74 (d, J = 
11.2Hz, 2H), 6.77 (d, J = 15.8Hz, 2H), 6.83 (d, J = 8.2Hz, 2H), 7.11 (dd, J1 = 1.9, J2 = 8.3, 2H), 
7.16 (dd, J1 = 1.9Hz, J2 = 8.3 Hz, 2H), 7.23 (m, 3H), 7.30 (d, J = 8Hz, 2H), 7.32 (m, 5H), 7.46 (d, 
J = 15.8Hz, 1H), 7.56 (d, J = 16Hz, 2H), 8.97 (s, 1H) 9.68 (s, 2H) 10.07 (s, 1H); 
13
C NMR (d6-
DMSO, 500 MHz)  34.8, 34.8, 34.8, 43.1, 43.1, 44.0, 48.8, 55.5, 55.6, 79.1, 101.2 101.3, 111.1, 
111.5, 111.6, 115.1, 115.6, 119.4, 120.0, 120.1, 120.1, 126.8, 128.3, 128.8, 131.6, 131.7, 131.9, 
138.1, 140.5, 145.6, 145.6, 145.7, 147.4, 147.5, 149.3, 156.3, 156.4, 177.5, 190.7, 196.7, 202.1; 
IR (Film) max 3028, 2959, 2930, 2916, 1601, 1574, 1556, 1514, 1494, 1452, 1429, 1367, 1360, 
1269, 1236, 1209, 1177, 1153, 1121, 1070, 1032, 916 cm
-1
. Similar experiments were carried out 
with the pyrazole and isoxazole derivatives of curcumin, compounds 38 and 47, respectively: 
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1
H NMR spectra for the addition of benzyl mercaptan to compound 38 after (1) 10 min, (2) 1.5 h, 
(3) 4.5 h, (4) 7.5 h, (5) 24 h, and (6) 48 h. 
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1
H NMR spectra for the addition of benzyl mercaptan to compound 38 after (1) 10 min, (2) 1.5 h, 
(3) 4.5 h, (4) 7.5 h, (5) 24 h, and (6) 48 h. 
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1
H NMR spectra for the addition of benzyl mercaptan to compound 47 after (1) 10 min, (2) 1.5 h, 
(3) 4.5 h, (4) 7.5 h, (5) 24 h, and (6) 48 h. 
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1
H NMR spectra for the addition of benzyl mercaptan to compound 47 after (1) 10 min, (2) 1.5 h, 
(3) 4.5 h, (4) 7.5 h, (5) 24 h, and (6) 48 h. 
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Anti-Proliferation Assays.  MCF-7 and SKBr3 cells were maintained in a 1:1 mixture of 
Advanced DMEM/F12 (Gibco) supplemented with non-essential amino acids, L-glutamine (2 
mM), streptomycin (500 g/mL), penicillin (100 units/mL), and 10% FBS. Cells were grown to 
confluence in a humidified atmosphere (37 C, 5% CO2), seeded (2000/well, 100 L) in 96-well 
plates, and allowed to attach overnight. Compound or geldanamycin at varying concentrations in 
DMSO (1% DMSO final concentration) was added, and cells were returned to the incubator for 
72 h.  At 72 h, the number of viable cells was determined using an MTS/PMS cell proliferation 
kit (Promega) per the manufacturer’s instructions. Cells incubated in 1% DMSO were used as 
100% proliferation, and values were adjusted accordingly. IC50 values were calculated from 
separate experiments performed in triplicate using GraphPad Prism. 
Western Blot Analysis. MCF-7 cells were grown to confluence as described above, seeded in 10 
cm culture dishes (1x10
6 
cells/dish) and allowed to attach overnight. Compound was added at 
varying concentrations in DMSO (1% DMSO final concentration) and the cells were incubated 
with drug for 24 h. Cells were harvested in cold PBS and lysed in mammalian protein extraction 
reagent (MPER, Pierce) lysis buffer containing protease inhibitors (Roche) on ice for 1 h. 
Lysates were clarified at 14,000g for 10 min at 4° C. Protein concentrations were determined 
using the Pierce BCA protein assay kit per the manufacturer’s instructions. Equal amounts of 
protein (2.5-10 μg) were electrophoresed under reducing conditions (10% acrylamide gel), 
transferred to a polyvinylidene fluoride membrane (PVDF), and immunoblotted with the 
corresponding specific antibodies. Membranes were incubated with an appropriate horseradish 
peroxidase-labeled secondary antibody, developed with a chemiluminescent substrate, and 
visualized. 
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